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Transmissible spongiform encephalopathies (TSEs), such as scrapie and variant 
Creutzfeldt-Jakob disease are infectious, fatal, neurodegenerative diseases.  Following 
peripheral infection TSE agents usually accumulate in lymhoid tissues before 
spreading to the central nervous system. In mice, follicular dendritic cells (FDCs) 
expressing the host prion protein (PrPC) are essential for scrapie agent accumulation 
in lymphoid tissues.  The accumulation of the scrapie agent on FDCs is critical for the 
efficient spread of infection to the brain.  However, it is unknown whether FDCs 
themselves actively replicate the scrapie agent, or simply accumulate it following 
production by other cells types such as neurones, lymphocytes or other stromal cell 
populations. To definitively address this issue a transgenic mouse model was created 
in which PrPC is switched on or off exclusively on FDCs.   
 
Expression of cre-recombinase (Cre) under the action of cell-specific gene promoters 
can be used to induce or delete the expression of a target gene in specific cell 
populations.  In this model, Cre expression is driven by the complement receptor type 
2 gene (Cr2/CD21) which is expressed by FDCs and mature B lymphocytes.  
Characterisation of the CD21-cre mouse line was achieved by crossing with a 
ROSA26 reporter strain. The CD21-cre mouse line was subsequently crossed with 
floxed-PrP mouse lines to produce compound transgenic mouse lines in which PrPC 
expression was switched on or off, only in FDCs.  Cre expression by B lymphocytes 
was eliminated by γ-irradiation and grafting recipient mice with Cre-deficient bone 
marrow.  Immunohistochemical analysis confirmed the expression PrPC had been 
switched on or off exclusively on FDCs.  Subsequently, the mice were challenged 
with scrapie by intra-peritoneal injection to determine the precise role of FDCs in the 
accumulation of scrapie in lymphoid tissues.   
 
Switching off PrPC expression exclusively on FDCs prevented the accumulation of 
TSE agent specific disease-associated PrPSc in the spleen after i.p inoculation. 
Conversely, in mice in which PrPC was expressed only on FDC, successful replication 
of the agent occurred on the FDC network in the spleen.  Taken together, these data 
show PrPC-expressing FDCs alone are sufficient to support the accumulation of the 
scrapie agent within lymphoid tissues.  Furthermore, these data suggest FDC replicate 
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1.1 The transmissible spongiform encephalopathies (TSEs) 
 
1.1.1 TSE diseases 
 
The Transmissible spongiform encephalopathies (TSEs) are fatal diseases of the 
central nervous system (CNS) which affect various mammalian species, including 
humans (Table 1.1).  These include Creutzfeldt-Jakob disease (CJD) and kuru in 
humans, scrapie in sheep and goats, and bovine spongiform encephalopathy (BSE) in 
cattle.  TSE diseases have a varied aetiology and can be sporadic, familial or acquired.  
These diseases are characterised by typical pathology in the CNS including 
spongiform change or vacuolation (Dickinson, Meikle et al. 1968),  activation of glial 
cells, and abnormal accumulation of a host protein, in the brains of TSE-affected 
animals (Bolton, McKinley et al. 1982; Bruce, McBride et al. 1989).  TSE diseases are 
difficult to study as various factors can impact on pathogenesis including host 
genotype (Dickinson, Meikle et al. 1968; Bruce, McConnell et al. 1991), route of 
inoculation (Eklund, Kennedy et al. 1967; Kimberlin and Walker 1979) and the strain 
of TSE used (Bruce and Fraser 1991).  Additionally, in experimental studies the 
pathogenesis of TSE disease can exceed the lifespan of the infected animal which can 
complicate interpretation of incubation period data (Dickinson, Fraser et al. 1975).  
These barriers contribute to the many unknowns still present in TSE research 






Scrapie is the earliest known TSE and affects sheep and goats and most of the 
knowledge we have of TSE disease has come from experimental transmission of 
scrapie into mice.  In sheep, the disease is characterised by scratching and nibbling at 
skin leading to severe wool loss and skin damage, unco -ordination and recumbancy 
and results in severe weight loss and inevitably death.    Scrapie is a centuries old 
disease, with the first traceable mention of the disease in a German publication from 
1750 (Leopoldt 1750; Brown and Bradley 1998; Schneider, Fangerau et al. 2008a).  
Scrapie has so far been found in twelve EU member states including Britain, France 
and Germany, 3 candidate member states and Canada, US, Brazil and Japan.  
However two of the largest sheep producing countries of the world- Australia and 
New Zealand- remain scrapie-free. 
 
Scrapie has been known to be infectious since its earliest traceable publication 
however the mechanisms of transmission and the nature of the infectious agent are 
still not fully understood to this day (Leopoldt 1750; Brown and Bradley 1998; 
Schneider, Fangerau et al. 2008a).    The first definitive experiments to show scrapie 
transmission were carried out by Cuillé and Chelle in 1936. Animals were observed 
for 18 months to ensure they were scrapie-free before intraocular, subcutaneous, 
epidural or intracranial (ic) inoculation with brain and spinal cord homogenates from 
affected animals.  They successfully transmitted scrapie to some, but not all of the 
animals inoculated, with incubation times between one and two years depending on 
the route of inoculation (Cuillé and Chelle 1936; Cuillé and Chelle 1938; Brown and 
Bradley 1998; Schneider, Fangerau et al. 2008a).  Some infected homogenates were 
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passed through a bacterial exclusion filter prior to inoculation. These innocula 
successfully transmitted disease showing that the agent was not microbial (Cuillé and 
Chelle 1938; Brown and Bradley 1998; Schneider, Fangerau et al. 2008a).  These 
experiments demonstrated for the first time that scrapie was transmissible by various 
routes, the disease has a long incubation period and showed differences in 
susceptibility between sheep. Transmission between species was also achieved by 
experimental inoculation of goats with sheep brain and spinal cord homogenates 
(Cuillé and Chelle 1939; Brown and Bradley 1998; Schneider, Fangerau et al. 2008a). 
Furthermore, accidental transmission of scrapie occurred via a new louping-ill 
vaccine prepared from brain, spinal cord and spleen homogenates of virus- infected 
sheep, attenuated with 0.35% formalin.  This accidental transmission demonstrated 
that the spleen was also a source of scrapie-infected material and that the scrapie 
agent was resistant to treatment with formalin (Gordon 1946).   The route of 
transmission of natural scrapie is still not fully understood. However it is known that 
disease can occur via both horizontal transmission, i.e. from sheep to sheep 
(Brotherston, Renwick et al. 1968), and lateral transmission, i.e. from ewe to lamb 
(Foster, Hunter et al. 1996; Foster, McKenzie et al. 2006). 
 
Resistance to scrapie was known to be hereditary by the end of the 18th (Comber 
1772) and beginning of the 19th (Thaer 1821; von Richthofen 1827; Schneider, 
Fangerau et al. 2008a) centuries, however effective genetic breeding selection 
methods in sheep were only applied recently by the European Commission when the 
genetics of scrapie were understood more fully (regulation 2001; regulation 2004; 
regulation 2007).  In the 1960’s, studies by Dickinson et al looking at ME7 scrapie 
incubation times in inbred mouse strains led to the discovery of the involvement of 
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the scrapie incubation period or “Sinc” gene in scrapie pathogenesis (Dickinson and 
Mackay 1964; Dickinson, Meikle et al. 1968). This group were also carrying out 
studies using the scrapie isolate SSBP/1 in sheep and concluded that the resistance of 
some sheep to SSBP/1 scrapie must be due to a single gene with a fully dominant 
allele for susceptibility (Dickinson, Stamp et al. 1968).   In the 1980’s, a 33-35 KDa 
protein, named the prion protein or PrP, was discovered to be the main component of 
scrapie-associated fibrils (SAF; (Oesch, Westaway et al. 1985; Hope, Morton et al. 
1986).  Subsequently, it was discovered that the Sinc gene encoded the prion protein 
(PrP) and confirmed the involvement of the normal cellular host prion protein (PrPC) 
in TSE pathogenesis (Hunter, Hope et al. 1987).  This discovery led to many studies 
of PrP sequence polymorphisms and their relevance to scrapie incubation time as well 
as much research into the role of PrPC in health and disease. 
 
1.1.3 Bovine spongiform encephalopathy 
 
Bovine spongiform encephalopathy (BSE) is hypothesised to have emerged after 
cattle were fed on a diet containing mammalian meat and bone meal (MBM) derived 
from the rendered carcasses of scrapie-infected sheep (Wilesmith, Ryan et al. 1991; 
Anderson, Donnelly et al. 1996) .  Cattle were not considered to be natural hosts of 
TSE disease however,  the first outbreak of BSE was discovered in the 1980’s (Wells, 
Scott et al. 1987). The development of BSE in cattle led to many subsequent cross 
species transmissions of TSE disease.  Many animal feed products were contaminated 
with cattle-derived products containing infective material, which led to the 
development of feline spongiform encephalopathy (FSE) in domestic and exotic cats 
(Wells, Scott et al. 1987; Wyatt, Pearson et al. 1991), and novel TSE disease in other 
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exotic animals including nyala, kudu and oryx (Wells, Scott et al. 1987; Jeffrey and 
Wells 1988; Kirkwood, Wells et al. 1990) . This led to the mass culls of many 
infected cattle and the enforcement of new laws preventing the inclusion of MBM in 
cattle feed, the prevention of specified risk material (SRM) entering the food chain, 
the ban of mechanically recovered meat and meat from cattle over 30 months of age 
entering the food chain (regulation 2001; regulation 2004; regulation 2007). 
 
1.1.4 Creutzfeldt-Jakob disease (CJD) and human TSEs 
 
Human TSEs can be inherited, sporadic or iatrogenic. Genetic TSEs account for 
around 10% of human prion diseases. These include Gerstmann Sträussler-Scheinker 
disease (GSS), familial Creutzfeldt-Jakob disease (fCJD) and fatal familial insomnia 
(FFI) which are all associated with inherited mutations in the prion protein gene 
PRNP (Creutzfeldt 1920; Jakob 1921a; Jakob 1921b; Gerstmann, Straussler et al. 
1936; Hsiao, Baker et al. 1989; Kretzschmar, Honold et al. 1991; Goldfarb, Petersen 
et al. 1992; Medori, Tritschler et al. 1992). 
 
 Sporadic CJD accounts for at least 85% of all human TSEs and occurs by as of yet 
unknown mechanisms, which lead to abnormal conformations of the normal host 
protein PrPC.  Possible hypotheses for the onset of sporadic TSE include acquired 
mutations of the PRNP gene or abnormal cellular metabolism of PrPC which 
subsequently leads to conversion to the disease associated conformation  (Westaway, 
DeArmond et al. 1994). 
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Iatrogenic, or peripherally acquired, human TSE diseases include kuru and variant 
CJD (vCJD).  Kuru was discovered in 1957 and was transmitted during cannibalistic 
rituals of the natives of the Eastern Highlands of Papa-New Guniea (Zigas and 
Gadusek 1957).  Kuru was restricted to this geographical location and was all but 
eradicated by raising awareness to prevent disease transmission.  vCJD was first 
identified shortly after the BSE outbreak and most likely occurred via the 
consumption of BSE contaminated meat (Will, Ironside et al. 1996; Bruce, Will et al. 
1997). As of the 9th March 2011, 171 deaths from vCJD have been reported in the 
U.K. with 4 patients currently living with probable vCJD 
(http//:www.cjd.ed.ac.uk/figures.htm). Furthermore, the more recent discovery of 
transmission of vCJD via contaminated blood products, along with the lack of a 
reliable ante-mortem diagnostic test or cure, has determined that these peripherally 
acquired TSEs remain a current public health issue (Llewelyn, Hewitt et al. 2004; 
Peden, Head et al. 2004; Wroe, Pal et al. 2006).   
 
1.2 The TSE agent and TSE pathogenesis 
 
1.2.1 The nature of the TSE agent 
 
The exact nature of the TSE agent is yet to be determined and has been a source of 
controversy and debate.  TSE diseases were originally thought to be caused by a virus 
due to the transmission of disease and the occurrence of multiple strains of each TSE.  
Due to their long incubation periods TSEs were considered to be a slow-virus, 
reproducing much more slowly than typical virus strains.  However, a TSE-associated 
virus could not be detected by electron microscopy.  Supporters of the virus 
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hypothesis suggested it may be extremely small, similar to some very small plant 
viruses such as Tobacco mosaic virus (Diringer, Gelderblom et al. 1983; Van 
Everbroeck, Pals et al. 2002).   
 
This belief developed into the virino hypothesis, which stated that a very small 
nucleic acid, or some other information encoding molecule, is a component of the 
TSE agent (Dickinson and Outram 1988; Farquhar, Somerville et al. 1998). In support 
of this theory, a recently published paper claims to have found a 25 nm virion as the 
cause of TSE diseases (Manuelidis 2007) with the presence of tubovesicular 
structures found in TSE-affected brains subsequently associated with the presence of 
this virion (Liberski, Sikorska et al. 2008). As of yet, TSE disease specific nucleic 
acids have not been identified (Alper, Haig et al. 1966; Brown, Rohwer et al. 1986; 
Taylor 1993; Somerville, Birkett et al. 1997).  However the existence of defined 
strains of TSE agents which are reproducible over multiple passages in mice has yet 
to be fully explained (Bruce and Fraser 1991; Bruce 1993). 
 
In 1982, Stanley Prusiner published a paper stating that the TSE agent that caused 
scrapie contained no genetic material and consisted entirely of protein (Prusiner 
1982).  This conclusion was reached as the scrapie agent appeared to be resistant to 
inactivation by treatments that destroy nucleic acids such as ultra-violet light, ionising 
radiation, dry heat and nucleases (Alper, Haig et al. 1966; Prusiner 1982; Fraser 1987; 
Taylor 1993; Somerville, Birkett et al. 1997; Taylor, Fernie et al. 1998). Instead, 
proteinases, which destroy proteins, could either abolish or reduce infectious 
properties of scrapie (Prusiner 1982).  Prusiner suggested that the infectious agent was 
the proteinaceous infectious particle, or prion, a novel type of protein-only pathogen 
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that lacks nucleic acid (Prusiner 1982).  Fractions of scrapie-infected hamster brain 
were purified leading to the identification of a protein, termed PrP (Prion Protein), 
that was directly proportional to the titre of infectivity and was resistant to digestion 
by proteinase K (PK; (Bolton 1982; McKinley, Bolton et al. 1983). By testing for 
mRNA to PrP, it was found that PrP was a normal host protein (PrPC; (Chesebro, 
Race et al. 1985) and that an abnormal form of this protein, PrPSc conferred disease 
(Meyer, McKinley et al. 1986).  It was hypothesised that in prion pathogenesis, 
abnormal PrPSc can act as a template for converting normal PrPC to the pathological 
variant (Rogers, Yehiely et al. 1993).  Additionally, the recent de novo creation of 
infectious PrPSc in vitro seems to conclusively show that the TSE infectious agent is 
composed solely of protein (Legname, Baskakov et al. 2004; Barria, Mukherjee et al. 
2009).  The prion hypothesis can account for why no disease specific genetic material 
has thus far been identified and why viral inactivation treatments do not affect disease 
pathogenesis.  The presence of TSE strains is a major factor in favour of the virino 
hypothesis, however it was proposed that TSE strain variation could be due to 
different conformations of PrPSc or differences in glycosylation of either the host PrPC 
or the infecting PrPSc (Prusiner 1991; Ermonval, Mouillet-Richard et al. 2003).  
However, TSE infectivity has been shown in some models without the presence of 
PrPSc (Lasmézas, Deslys et al. 1997; Barron and Manson 2003; Barron, Campbell et 
al. 2007). Therefore, although there is compelling evidence for the prion hypothesis, 
clarification is required for some remaining phenomena of TSE pathogenesis. 
 
1.2.2 The prion protein 
 
Although the exact nature of the TSE agent is still controversial, PrPC plays an 
important role in disease pathogenesis as PrP-/- mice are resistant to TSE disease 
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(Büeler, Aguzzi et al. 1993; Manson, Clarke et al. 1994b).  PrPC is a host encoded 
sialoglycoprotein expressed predominantly on neurons but also on many other cell 
types, including cells of the immune system (Kretzschmar, Prusiner et al. 1986; 
Caughey 1988).  PrPC is encoded by a single gene in rodents (Prnp), ruminants (PrP 
or Prnp) and man (PRNP) (Oesch, Westaway et al. 1985; Westaway and Prusiner 
1986).  The mouse gene has three exons and two introns, with exon 3 containing the 
entire protein coding region (Prusiner, Scott et al. 1998).  The primary translation 
product in mouse has 254 amino acid (aa) residues, during posttranslational 
maturation the protein is processed to a length of approx. 210 aa (Hegde, Mastrianni 
et al. 1998a; Hegde, Voigt et al. 1998b) forming a flexible, unstructured N-terminal 
domain and a globular, highly structured C-terminal domain (Fig1.1). 
 
After transcription and translation, the NH2-terminal signal peptide targets the protein 
to the endoplasmic recticulum (ER).  This signal peptide is subsequently cleaved into 
the ER lumen (Hegde, Mastrianni et al. 1998a; Hegde, Voigt et al. 1998b).  After the 
attachment of a glycosylphosphatidylinisotol (GPI) anchor, PrPC protein is further 
modified through complex carbohydrates as it is transported along the ER-Golgi 
towards the plasma membrane at the cell surface.  The PrPC protein matures as it is 
transported along the ER-Golgi plasma membrane pathway from an immature form, 
which is sensitive to endoglycosidase H, to a mature form which is resistant to 
endoglycosidase H (Sarnataro, Campana et al. 2004).  PrPC becomes associated with 
lipid rafts in the ER and studies have shown that this is essential for the correct 
folding and glycosylation of PrPC.  Furthermore, association with rafts allows PrPC to 
be exported from the ER to the Golgi. (Sarnataro, Campana et al. 2004; Campana, 
Sarnataro et al. 2005).   
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Figure 1.1 Structure of the mouse Prnp gene and PrPC protein 
a. Outline of the structure of the mouse Prnp gene. Prnp contains three exons and two 
introns.  Exon 3 contains the open reading frame (ORF) which codes for the entire 
PrPC protein. 
b. Outline of the structure of PrPC protein adapted from (Linden, Martins et al. 2008).  
The protein consists of a number of domains with specific functional attributes.  It 
contains and N-terminal signalling peptide (SP) from aa 1-22 which targets the 
protein to the endoplasmic reticulum.  The octapeptide repeat region (OR) is between 
aa 51-91 and is thought to have a role in copper binding (Hornshaw, McDermott et al. 
1995; Jackson, Murray et al. 2001; Cerpa, Varela-Nallar et al. 2005). PrPC contains 
both a charged cluster (CC) and a hydrophobic core (HC).  PrPC has two asparginine 
residues which are modified by N-linked glycans (CHO) at positions 180 and 196 and 
and this results in un-, mono- and di-glycosylated isoforms (Stimson, Hope et al. 
1999). PrPC also has a glycosyl phosphatidylinositol (GPI) anchor signalling peptide 




 PrPC has a short half-life and is recycled via endosomes or degraded in lysosomes. As 
part of normal processing, PrPC can be proteolytically cleaved into to fragments, with 
the N-terminal fragment secreted and the C-terminal fragment membrane-bound. 
 
 Expression levels of Prnp from microarray data from various mouse tissues and cell 
lines can be seen in Fig 1.2.  The normal cellular function of PrPC is uncertain and 
three distinct lines of PrP-/- mice show normal development and have no overt 
neurological phenotype (Bueler, Fischer et al. 1992; Manson, Clarke et al. 1994a; 
Prusiner, Scott et al. 1998; Lasmézas 2003).  This suggests that either PrPC is not an 
essential protein or that the genetic loss of PrPC expression can be compensated for by 
other factors.  Some proposed functions of PrPC  include the maintenance of circadian 
rhythm (Tobler, Gaus et al. 1996), synaptic transmission (Collinge, Whittington et al. 
1994; Colling, Collinge et al. 1996; Mallucci, Ratte et al. 2002) anxiety modulation 
(Nico, de-Paris et al. 2005), cognition (Coitinho, Roesler et al. 2003) and seizure 
thresholds (Walz, Amaral et al. 1999) as small changes in these functions have been 
observed in the PrP-/- lines.  
 
 PrPC has the ability to bind copper molecules through its sequence of octapeptide 
repeats and has therefore also been implicated in copper metabolism (Hornshaw, 
McDermott et al. 1995; Jackson, Murray et al. 2001; Lasmézas 2003; Cerpa, Varela-
Nallar et al. 2005).  More recent work claims that binding of copper ions may 
promote protein aggregation and consequently may be involved in pathogenesis 
(Shiraishi 2006).  Additionally, PrPC  has been named as a signal transduction protein 
(Mouillet-Richard, Ermonval et al. 2000; Spielhaupter and Schätzl 2001), and has 
been suggested to have roles in both pro-apoptotic signalling via an associated 
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increase in caspase 3 activity (Paitel, Alves da Costa et al. 2002) and anti-apoptotic 
via binding to the anti-apoptotic molecule Bcl-2 (Kurschner and Morgan 1995; 
Kuwahara, Takeuchi et al. 1999; Bounhar, Zhang et al. 2001; Chiarini, Freitas et al. 
2002; Paitel, Alves da Costa et al. 2002). The hypothesised functions of PrPC are 
varied and as of yet it has proved difficult to distinguish its exact role within the CNS. 
 
PrPC is also expressed on many cells of the immune system including B and T 
lymphocytes, natural killer cells, platelets, monocytes, dendritic cells, mast cells and 
FDCs (Cashman, Loertscher et al. 1990; Barclay, Hope et al. 1999; Brown, Stewart et 
al. 1999; Holada and Vostal 2000; Li, Liu et al. 2001; Thielen, Antoine et al. 2001; 
Haddon, Hughes et al. 2009). Many of the putative functions of PrPC in the CNS 
would not be required in cells of the immune system, however animal and human 
models have reported up- and down-regulation of PrPC in certain immune conditions 
and differences in immune cell function when PrP is ablated. Maturation of DCs and 
monocytes has been reported to up-regulate PrPC expression (Dürig, Giese et al. 2000; 
Burthem, Urban et al. 2001; Ballerini, Gourdain et al. 2006), whereas down-
regulation has been reported upon activation of B and T lymphocytes in mice 
(Kubosaki, Yusa et al. 2001; Liu, Li et al. 2001). PrPC is up-regulated in some 
functionally differentiated lymphocytes including a population of regulatory T 
lymphocytes (Huehn, Siegmund et al. 2004)  and in memory CD8 T lymphocytes (Li, 
Liu et al. 2001; Goldrath, Luckey et al. 2004).  PrPC has also been linked to fixation 
of complement component within the immune system (Mitchell, Kirby et al. 2007). 
Furthermore, PrPC is released in response to mast cell-mediated allergic inflammation 
(Haddon, Hughes et al. 2009).  PrPC appears to have an active functional role within 
cells of the immune system, however PrPC deficiency has no impact on expression 
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levels of both MHC Class I and II, maturation of DCs, and numbers of CD4+ and 
CD8+ T lymphocytes and B lymphocytes are no different to that seen in WT 
counterparts (Bueler, Fischer et al. 1992; Kubosaki, Yusa et al. 2001; Ballerini, 
Gourdain et al. 2006; Zhang, Steele et al. 2006).  Recent studies have shown that PrPC 
deficient T lymphocytes are more susceptible to oxidative stress (Aude-Garcia, 
Villiers et al. 2011) which is in agreement with previous publications demonstrating a 
neuroprotective role against oxidative stress for PrPC expression by neurones 
(Mitteregger, Vosko et al. 2007). This suggests PrPC expression may have protective 
role in cells of both the CNS and immune system. 
 
1.2.3 Distinguishing PrPC from PrPSc 
 
In TSE diseases, the conformational change of PrPC to PrPSc has been shown to be a 
post-translational event, which involves changes in the content of α-helices and β-
sheets (Rogers, Yehiely et al. 1993).  Normal PrPC has a structure consisting of 
around 40% α-helix and around 3% β-sheet.  However, after its conformational 
change, PrPSc contains only 30% α-helix and around 45% β-sheet (Pan, Baldwin et al. 
1993; Rogers, Yehiely et al. 1993). This increase in β-sheet content of PrP appears to 
confer some of the disease causing properties of PrPSc.  For example, increased β-
sheet content has been linked to protease resistance, insolubility in detergent and a 
propensity of the protein to aggregate (Meyer, McKinley et al. 1986; Somerville, 
Merz et al. 1986; Caughey, Dong et al. 1991) .   
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Figure 1.2 BioGPS expression profiles of Prnp in the mouse 
Expression profiles of Prnp from BioGPS database (http://biogps.gnf.org), which 
stores microarray data of steady state mRNA expression in various murine tissues and 
cell lines.  In agreement with published data, Prnp is ubiquitously expressed at low 
levels, however higher levels of expression are found within the CNS.  
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This latter characteristic is seen as fibrils of PrPSc forming in the brains of diseased 
animals (Meyer, McKinley et al. 1986; Pan, Baldwin et al. 1993; Prusiner, Scott et al. 
1998).  The partial proteinase resistance of PrPSc is thought to be conferred by a 27-30 
KDa core which remains after treatment with proteinase (Bolton, Meyer et al. 1985). 
PrPSc deposition has been shown in numerous studies to be inseparable from 
infectivity (Bolton 1982; McKinley, Bolton et al. 1983) although  this is not true for 
all TSEs as seen in studies using the P102L strain of GSS (Barron and Manson 2003; 
Barron, Campbell et al. 2007; Piccardo, Manson et al. 2007).  Nevertheless, the 
deposition of PrPSc is widely accepted as a marker of infectivity. 
 
Current antibodies available to detect PrP cannot distinguish between the cellular 
form, PrPC, and the disease-associated form PrPSc.  New antibodies are being 
developed which bind exclusively to PrPSc but are yet to be shown to be reliable for 
research application (Korth, Stierli et al. 1997; Paramithiotis, Pinard et al. 2003; 
Moroncini, Kanu et al. 2004; Jones, Wight et al. 2009; Petsch, Muller-Schiffmann et 
al. 2011). However, the biochemical properties of PrPSc, such as protease resistance 
and in solubility in detergents, allow PrPSc to be distinguished from PrPC 
experimentally.  For the histological detection of PrPSc, tissue sections can be fixed to 
nitrocellulose membrane and treated with proteinase K (PK) in the PET blot method 
(see section 2.4.3).  PK denatures native cellular PrPC leaving the PK-resistant PrPSc 
core intact (Schulz-Schaeffer, Tschoke et al. 2000).  All PrP subsequently detected by 
immunolabelling can be confirmed to be PrPSc.  PK digestion can also be used on 
tissue homogenates before immunoblotting.  PK treatment of uninfected samples will 
result in no protein bands being detectable on a blot. Whereas, PK treatment of 
17 
infected samples results in the three PrP bands representing unglycosylated, 
monoglycosylated and diglycosylated isoforms of PrP (Oesch, Westaway et al. 1985). 
 
1.2.4 Characteristics of TSE pathogenesis in the central nervous system and TSE 
strains 
 
TSE infections are difficult to diagnose as some clinical symptoms are similar to other 
neurological diseases.  The only definitive diagnosis can be made post-mortem via 
analysis of the brain.  A TSE-infected brain shows characteristic neuropathology.  As 
mentioned previously, PrPSc deposition can be used as a marker of infectivity and is 
seen at high levels in a brain at end-stage disease.  In addition, there will be 
spongiform change, which is vacuolation in the brain tissue (Mikol 1999; Van 
Everbroeck, Pals et al. 2002).  The areas in which this vacuolation occurs vary 
between TSEs but each member of the TSE family shows a distinct lesion profile 
upon transmission to experimental mice, which can be used to determine the type of 
TSE infection.(Fraser and Dickinson 1973).  The final neuropathological 
characteristics are gliosis, which can occur due to the hypertrophy and/ or hyperplasia 
of the glial cells in the brain, and neuronal loss (Mikol 1999).  Astrocytes are glial 
cells that provide trophic, metabolic and structural support to neurones.  They 
additionally have roles in neuronal-glial communication, synaptic signalling, 
regulation of blood flow and can influence neuronal precursors or stem cells within 
the adult CNS (Seifert, Schilling et al. 2006).  Astrocytosis is a common feature of 
many CNS pathologies, including TSE disease, and is thought to be a neuroprotective 
response to CNS injury (Liedtke, Edelmann et al. 1996).  However, their exact 
involvement in the pathology/ protection of the CNS in TSE disease is currently 
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uncertain.  Astrocytosis of TSE infected brain is commonly detected via glial 
fibrillary acid protein (GFAP), an intermediate filament (IF) superfamily member 
expressed by astrocytes (Schiffer, Giordana et al. 1986).  Increased numbers of 
activated microglia are also seen within TSE-affected brains.  Microglia are 
considered the macrophages of the brain are considered the macrophages of the brain 
and also respond to many CNS pathological conditions.  Their transformation from 
the resting state to an activated state involves enlargement of cells and changes in 
morphology, up regulation of cell surface molecules and proteins, and increases in the 
numbers of membrane ruffles and projections involved in phagocytosis (Block, Zecca 
et al. 2007).  Microglia are detected via the expression of ionised calcium-binding 
adaptor molecule-1 (Iba-1), which is constitutively and specifically expressed  by 
microglia and macrophages (Ohsawa, Imai et al. 2004; Ladeby, Wirenfeldt et al. 
2005).  Detection of activated astrocytes and microglia using the previously described 
markers, in addition to spongiform change and deposition of the disease associated 
prion protein, provide useful markers to allow post-mortem diagnosis of TSE-affected 
brains.   
 
Different TSE strains can be distinguished by their neuropathological characteristics 
and disease incubation periods in lines of inbred mice.  Serially passaged strains of 
scrapie injected directly into the CNS via ic injection result in highly reproducible 
disease incubation times with all animals succumbing to clinical disease within a 
matter of days of each other and can be used to distinguish scrapie strains (Dickinson, 
Meikle et al. 1968; Dickinson and Meikle 1971).  Additionally, the pattern of 
neuropathology in specific scoring areas of the brain can be used to create a lesion 
profile.  Animals from the same inbred strain infected with the same strain of scrapie 
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give a characteristic distinctive lesion profile (Bruce, McBride et al. 1989).  These 
methods of neuropathological characterisation can be used to distinguish TSE strains 
in inbred mice.  Indeed, these methods were used to confirm that vCJD in humans 
was the same strain of TSE as that which causes BSE in cattle (Bruce, Will et al. 
1997). 
 
An additional method of characterising TSE strains is via the intensity and migration 
of PrP glycoform bands after immunoblotting.  TSE strains show differences in the 
ratios of unglycosylated, monoglycosylated and diglycosylated isoforms of PrPSc, 
which migrate at different speeds using gel electrophoresis (Parchi, Castellani et al. 
1995; Collinge, Sidle et al. 1996; Somerville, Chong et al. 1997; Somerville 1999). 
These ratios are characteristic to different strains and this method is used regularly to 
distinguish scrapie from atypical scrapie (Baron, Biacabe et al. 2007). 
 
The TSE agent strain used in this thesis is the ME7 scrapie strain. This was originally 
derived from the spleen of a Suffolk sheep with natural scrapie that was intra-
gastrically inoculated into mice.  The ME7 strain was isolated after serial passages 
through inbred mouse lines (Zlotnik and Rennie 1965).  ME7 is thought to be a 
prevalent strain of natural sheep scrapie as it is frequently isolated from pooled 
natural scrapie samples (Bruce, Boyle et al. 2002).  It has been used in many 
experiments within the Neuropathogenesis Division and therefore the incubation 
period and neuropathology are well characterised for various inbred mouse lines. The 
pathogenesis of the ME7 strain includes a stage of replication within the lymphoid 
tissues followed by centripedal spread to other lymphoid tissues, peripheral nerves 
and subsequent CNS disease.  This strain provides a useful model for peripherally 
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acquired TSE diseases which also have a stage of lymphoreticular replication prior to 
neuroinvasion and CNS disease. This is similar mechanism of pathogenesis to many 
natural scrapie infections of sheep and vCJD in humans (van Keulen, Schreuder et al. 
1996; Hill, Butterworth et al. 1999; Bruce, Brown et al. 2000; Bruce, McConnell et al. 
2001; Joiner, Linehan et al. 2002).  For these reasons, ME7 provides a useful tool to 
model these peripherally-acquired TSE diseases in the lymphoid tissues. 
 
However, other TSE diseases show extra-neural pathology but with a different 
mechanisim of pathogenesis.  Diseases such as sCJD initiate within the CNS followed 
by dissemination of the agent to peripheral nerves and extra-neural pathology 
(Kitamoto, Mohri et al. 1989; Head, Northcott et al. 2003; Zanusso, Ferrari et al. 
2003; Head, Ritchie et al. 2004).  This is known as centrifugal spread and the ME7 
scrapie strain would therefore not be a relevant model for this mechanism of 
pathogenesis. 
 
1.2.5 The host immune response to TSE disease 
 
It is considered that TSE infection does not generate a specific host immune response 
and no inflammation is seen in an infected brain.  On considering the prion 
hypothesis, this may not be surprising, as the infectious agent appears to be an 
abnormally-folded form of a normal host protein.  There is no PrPSc specific antibody 
response (Clarke and Haig 1966; Marsh, Pan et al. 1970; Porter, Porter et al. 1973) 
and deficiencies in circulating antibody or the Fc-γRI  have no effect on pathogenesis 
(Klein, Kaeser et al. 2001).  It is probable that the immune system is tolerized to the 
infectious TSE agent via its close resemblance to the normal cellular form of PrP 
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(Klein, Kaeser et al. 2001).  This would occur via deletion of PrP-specific 
lymphocytes in early development of the immune system repertoire as an immune 
response against such an agent could provoke an autoimmune response.  Furthermore, 
there is also a lack of a notable cell-mediated immune response against the TSE agent 
or PrPSc however, this is not due to any immunosuppressive effects caused by the 
agent (Kingsbury, Smeltzer et al. 1981).  
 
However, in some but not all TSE strains, the TSE agent appears to undergo a stage of 
replication in the lymphoid tissue before disease progression to the CNS. Early 
experiments infecting mice with scrapie demonstrated accumulation and replication of 
the TSE agent within the spleen before neuroinvasion (Fraser and Dickinson 1970; 
Clarke and Haig 1971). Most natural sheep scrapie strains (van Keulen, Schreuder et 
al. 1996) and vCJD (Hilton, Fathers et al. 1998; Hill, Butterworth et al. 1999; Bruce, 
McConnell et al. 2001) are thought to require this replication stage for disease 
propagation, demonstrating that this could be an important area to target for early 
intervention in these diseases.  More recent studies have shown that TSE infection has 
subtle effects on the immune system suggesting there may be consequences in 
immune function and a subtle immune response in response to infection in peripheral 
lymphoid tissues.  Changes have been reported in the morphology of infected 
follicular dendritic cells (Jeffrey, McGovern et al. 2000; McGovern, Brown et al. 
2004; McGovern and Jeffrey 2007; McGovern, Mabbott et al. 2009a).  FDCs are cells 
found in the B lymphocyte follicles of peripheral lymphoid tissue which are discussed 
in more detail in Section 1.3.3.  The FDC maturation cycle and the ability of infected 
mice to elicit an efficient germinal centre response are also reported to be affected in 
the spleens of scrapie-affected mice (Jeffrey, McGovern et al. 2000; McGovern, 
Brown et al. 2004; McGovern and Jeffrey 2007; McGovern, Mabbott et al. 2009a).  
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However it is important to remember that not all TSEs appear to require this stage of 
pathogenesis as is seen in BSE (Somerville, Birkett et al. 1997) and atypical or Nor98 
scrapie (Buschmann, Biacabe et al. 2004; Vidal, Tortosa et al. 2008).   
 
1.3 Lymphoreticular pathogenesis of the TSE agent 
 
1.3.1 TSEs and the immune system 
 
In many cases of TSE infection after peripheral exposure to the TSE agent, PrPSc 
deposition is seen in the gut-associated lymphoid tissue (GALT), including the 
Peyer’s patches and mesenteric lymph nodes long before the deposition in the CNS 
(Kimberlin and Walker 1979; Andreoletti, Berthon et al. 2000).  Early experiments 
using splenectomy of mice prior to scrapie inoculation were shown to prolong disease 
incubation period, suggesting that the spleen may be an important site for agent 
replication (Fraser and Dickinson 1970; Clarke and Haig 1971; Fraser 1978). 
However, splenectomy soon after inoculation had no significant effect on disease 
pathogenesis (Fraser and Dickinson 1970).  Therefore, it was proposed that a 
functionally insignificant amount of the TSE agent remains in the spleen, while the 
majority replicates in other tissues (Fraser and Dickinson 1970).   
 
Immunodeficient mice have also been used to demonstrate the necessity of 
lymphoreticular replication of certain TSE strains.  SCID (Severe- Combined 
Immunodeficient) mice have no B or T lymphocytes or FDCs and are resistant to 
scrapie infection (Fraser, Brown et al. 1996).  However, these cell types can be 
repopulated by grafting with wild type (WT) bone marrow, and doing so restores 
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susceptibility to disease (Fraser, Brown et al. 1996).  These early experiments, 
amongst others, gave the first evidence that the immune system could have an 
important role in early disease pathogenesis. 
 
1.3.2 The role of lymphocytes in TSE pathogenesis 
 
SCID mice with no B- or T-lymphocytes are refractory to scrapie infection (Fraser, 
Brown et al. 1996).  Early experiments investigating a role for B and T lymphocytes 
in TSE agent replication used immunodeficient mice.  Thymectomy of mice before or 
after scrapie inoculation had no effect on scrapie incubation time or neuroinvasion, 
suggesting T-lymphocytes were not involved in TSE pathogenesis (Fraser 1978).  
This was confirmed using T lymphocyte-deficient mice with genetic deletions of 
CD4, CD8, perforin, β2μ or TCR-α which again showed no differences in disease 
pathogenesis, confirming that T-lymphocytes have no role in TSE agent replication 
(Klein, Frigg et al. 1997).   
 
To investigate a possible role for B lymphocytes β2μ deficient mice with no B 
lymphocytes were inoculated with scrapie. These mice did not accumulate PrPSc or 
infectivity in their spleens and did not develop disease and B lymphocytes were 
suggested to replicate the TSE agent (Klein, Frigg et al. 1997).  As PrPC expression is 
essential for TSE transmission (Büeler, Aguzzi et al. 1993; Sakaguchi, Katamine et al. 
1995). Expression of PrPC exclusively by B lymphocytes was not sufficient to allow 
scrapie pathogenesis in the lymphoid tissue (Montrasio, Cozzio et al. 2001). 
Experiments using SCID mice and RAG-/- mice, which have no lymphocytes but 
express PrPC equivalent to WT mice, were reconstituted with Prnp+/+ or Prnp-/- bone 
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marrow before inoculation with scrapie.  Expression of PrPC by lymphocytes was 
shown to be irrelevant to TSE pathogenesis in this model (Klein, Frigg et al. 1998). 
This has since been confirmed with similar chimeric mouse models and with various 
strains of the TSE agent (Brown, Stewart et al. 1999; Loeuillet, Lemaire-Vielle et al. 
2010). These experiments suggested that B lymphocyte products, rather than the cells 
themselves, were essential in TSE pathogenesis; or that pathogenesis may involve 
other cells dependent on B lymphocyte-derived signals for their development and/ or 
function.  However, it is possible that B lymphocytes may assist in the spread of the 
TSE agent to other lymphoid organs.  PrPd was found associated with CD21+ B 
lymphocytes in the blood of scrapie-affected sheep.  Therefore it is possible that 
although B lymphocytes may not actively replicate the TSE agent, they may still have 
a role in pathogenesis via aiding the dissemination of the agent post-replication in 
other cells. 
 
1.3.3 The role of FDCs in TSE pathogenesis 
 
Initial studies examining TSE agent infectivity within the lymphoid tissues found that 
the stromal component of the spleen, which would have contained FDCs, contained 
more infectivity than the pulp (Clarke and Kimberlin 1984).  FDCs are long-lived and 
mitotically inactive, making them resistant to ionising radiation which identifies them 
as a candidate for TSE agent replication as irradiation of mice has no effect on TSE 
pathogenesis (Fraser 1987).   The expression of PrPC has been shown to be essential 
for TSE pathogenesis and FDCs have relatively high amounts of PrPC on their surface 
in uninfected mice (Brown, Stewart et al. 1999; Ritchie, Brown et al. 1999).  
Immunohistochemical analysis of TSE-infected lymphoid tissue in mice shows strong 
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immunolabelling of PrPSc associated with the FDCs, which can be used as a 
biochemical marker of TSE infectivity (McBride, Eikelenboom et al. 1992; Brown, 
Stewart et al. 1999; Ritchie, Brown et al. 1999; Bruce, Brown et al. 2000).  
Furthermore, labelling of the disease-associated PrPd is also found in FDCs of sheep 
with natural scrapie (van Keulen, Schreuder et al. 1996), deer and elk with chronic 
wasting disease (Sigurdson, Williams et al. 1999) and humans with vCJD (Hill, 
Zeidler et al. 1997).  Electron microscopy of infected lymphoid tissue showed high 
accumulation of PrPSc on the FDC surface and around the dendrites (Jeffrey, 
McGovern et al. 2000). 
 
Mice with genetic deficiencies in tumour necrosis factor (TNF)-α have a lack of 
terminally differentiated FDCs but do have functional and mature T and B 
lymphocytes (Pasparakis, Alexopoulou et al. 1996).  TNFα-/-mice are resistant to TSE 
infection after peripheral exposure (Mabbott, Williams et al. 2000a). The TNF-
signalling pathway can be disrupted treatment with a TNF-R1 homologue that causes 
a temporary dedifferentiation of FDCs but no disruption to lymphocyte populations.  
These TNF-depleted mice have increased disease incubation times on infection with 
ME7 scrapie, suggesting a role for FDCs in the peripheral replication of the scrapie 
agent (Mabbott, McGovern et al. 2002).  However, a few mice in this study did 
develop disease after the same incubation as the control mice raising the question of 
whether FDCs are the only cell involved in TSE agent replication (Mabbot 2002).  
TNF-α is also an important cytokine for macrophage activation, meaning that TNF 
depleted mice would show some deficiencies in this process.  It is possible that 
macrophages are involved in taking up and degrading the infective agent early after 
inoculation.  In this instance, disease may have occurred in some of the TNF depleted 
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mice due to the lack of early sequestering and degradation of the agent by 
macrophages (Mabbott, McGovern et al. 2002).  It is also possible that the agent may 
be able to replicate in unactivated macrophages as the TNF-induced degradation 
processes, such as lysosome activation and superoxide formation, will not have been 
activated.  This was demonstrated by Prinz et al who inoculated TNFR1-/- mice with 
Rocky Mountain Laboratory (RML) scrapie strain and noted prion protein 
accumulation associated with some macrophages in the absence of FDC networks 
(Prinz, Montrasio et al. 2002). 
 
Signalling through the lymphotoxin (LT) β Receptor (LTβR) on FDCs is required for 
maintenance of a mature FDC network and blocking this signalling results in their 
dedifferentiation to an immature state. These mice still retain functional lymphocytes, 
macrophages and DCs (Mackay and Browning 1998).  FDCs can be dedifferentiated 
temporarily using LTβR-Ig, which acts as a soluble decoy receptor, binding LTβ 
ligands and preventing their interaction with LTβR.  The blockade of  LTβR-
signalling before inoculation with ME7 scrapie can significantly extend the survival 
time of the mouse and reduces disease susceptibility (Mabbott, Mackay et al. 2000b).  
However, some animals eventually succumbed to clinical disease, therefore it may be 
that infectivity can persist in some other cell type until the FDC network reforms and 
the agent can begin to replicate (Mabbott, Mackay et al. 2000b).  LTβR signalling can 
also be disrupted completely using knockout mice and studies have looked at the 
differences between LTα and LTβ deficient mice.  These mice have similar 
reductions in their FDC populations, but LTα knockout mice appear to be more 
susceptible to RML scrapie than LTβ knockouts (Oldstone, Race et al. 2002).  This 
suggests the possible involvement of another, unidentified LTβ-dependent cell type 
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which may also have a role in lymphoid replication of the TSE agent.  Alternatively, 
LTβ may have additional effects on FDCs, distinct from those shared with LTα, that 
as of yet are unknown. 
 
 The CXCR5 receptor on B lymphocytes responds to stimulation via CXCL13 
secreted by FDCs and is important in organising the structure of the follicle.  A 
deficiency in CXCR5 disrupts the follicle structure, placing FDCs adjacent to the 
peripheral nerve endings found near the central arterioles of the spleen (Voigt 2000).  
These mice were inoculated with RML scrapie and the speed of neuroinvasion was 
found to be greatly increased when compared to the wild type (Prinz, Heikenwalder et 
al. 2003).  This suggested that FDCs replicate the TSE agent prior to neuroinvasion 
and the speed of neuroinvasion can be increased by manipulating distance between 
the FDCs and nerve endings.  As a control, this was repeated in CXCR5-/- mice with 
their FDCs depleted.  These mice did not develop scrapie, confirming that the 
hastened disease progression was due to the displacement of the FDCs (Prinz, 
Heikenwalder et al. 2003).   
 
These studies provided strong evidence that FDCs are responsible for replicating the 
TSE agent in the lymphoid tissues.  However, FDCs are specialised in taking up and 
retaining proteins on their surface, therefore, it is uncertain whether the FDCs are 
actively replicating the TSE agent or instead are accumulating agent after replication 
in other cells.  This question was addressed using chimeric mice which have 
mismatches in PrPC expression between their FDCs and their bone marrow-derived 
cells.  SCID mice have no FDCs due to their lack of B cells but FDC populations of 
host genotype can be restored by grafting with donor bone marrow (Humphrey, 
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Grennan et al. 1984; Kapasi, Burton et al. 1993; Brown, Stewart et al. 1999).  
Inoculating these PrPC chimeric mice with ME7 scrapie showed that scrapie 
pathogenesis was dependent on FDC expression of PrPC, regardless of expression 
status of bone marrow-derived cells .  This has been confirmed by recent studies 
which have also shown PrPC-expressing bone marrow derived cells are not 
responsible for replicating the TSE agent (Loeuillet, Lemaire-Vielle et al. 2010).  
From this it appears that FDCs themselves actively replicate the TSE agent. However, 
non-bone marrow-derived cells such as neural, epithelial and stromal cells within the 
lymphoid tissue retained expression of PrPC in this model.  Therefore, this does not 
exclude the possibility that FDCs simply acquire PrPSc from other cell types rather 
than replicating the agent themselves.  To definitively determine the role of FDCs in 
scrapie pathogenesis an FDC-specific model is required that allows the role of these 
cells to be assessed in isolation from all other cell types within the lymphoid tissue. 
 
1.3.4 The role of macrophages in TSE pathogenesis 
 
Macrophages were also investigated as a possible cellular host for TSE agent 
replication.  Tingible body macrophages (TBMs) reside in the follicles of lymph 
nodes where their main role is the clearance of proteins and apoptotic cells, many of 
which are produced in the germinal centre reaction during an immune response 
(Swartzendruber and Congdon 1963).  Electron microscopical analysis of infected 
lymphoid tissue found PrPSc within TBMs of scrapie-affected sheep and mice 
(Jeffrey, McGovern et al. 2000; Jeffrey, Martin et al. 2001; Ryder, Dexter et al. 2009) 
and was also present in TBMs of lymphoid tissues of vCJD patients (Hilton, Ghani et 
al. 2004).  Additionally, in vitro incubation of the scrapie agent with peritoneal 
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macrophages led to an association of the agent with macrophages (Carp and 
Callaghan 1981) and incubation with synthetic PrP peptide 106-126 was found to 
slightly stimulate macrophages causing up-regulation of PrPC and TNFα production 
(Zhou, Xu et al. 2008).  However incubating ME7 scrapie with macrophages prior to 
inoculation, led to an increased incubation period in mice in comparison to non-
macrophage incubated ME7 (Carp and Callaghan 1982).  This indicated that some of 
the scrapie had been inactivated or degraded by the macrophages and therefore 
macrophages would not be an adequate host cell for agent replication. Additionally, 
PrPSc detected in macrophages was usually associated with lysosomes suggesting 
macrophages were degrading the scrapie agent (Jeffrey, Martin et al. 2003; McGovern 
and Jeffrey 2007; McGovern, Mabbott et al. 2009a).  To further confirm these 
findings, depletion of splenic macrophages using clodronate just before or after 
inoculation with scrapie leads to decreased incubation period and accelerated disease 
progression.  Immunolabelling of PrPSc within TBMs using a panel of antibodies that 
bind different epitopes of PrP determined that PrPSc found within TBMs was 
truncated with a loss of 23-90 aa from the N-terminus (Jeffrey, Martin et al. 2003; 
McGovern, Mabbott et al. 2009a).  Evidence suggests that macrophages do take up 
the TSE agent but degrade and destroy it and therefore macrophages would not be an 
adequate host cell for replication to occur in. 
 
1.3.5 The role of dendritic cells in TSE pathogenesis 
 
Dendritic cells (DCs) are bone marrow-derived cells of a distinct origin and function 
to that of FDCs.  They form the body’s immune surveillance by patrolling the 
periphery and sampling antigen in their local environment, subsequently migrating to 
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the draining lymph node and presenting it to T lymphocytes. Therefore, DCs have 
also been investigated as a candidate cell for the uptake and replication of the TSE 
agent in the lymphoid tissues. In vitro studies have shown that rat DCs are able to take 
up and retain scrapie for up to 72 hours (Huang, Farquhar et al. 2002) and PrP 
fragment 106-126 has been reported to be chemoattractant to immature DCs 
(Kaneider, Kaser et al. 2003).  DCs have been shown to take up scrapie agent from 
the gut and transport it to the lymph node (Huang, Farquhar et al. 2002). This was 
confirmed by recent studies which showed DC-like cells containing PrPSc are present 
in the villus lacteals, submucosal lymphatics and sinuses of mesenteric lymph nodes 
1.5- 24 h post oral inoculation with scrapie, further suggesting that DCs transport the 
scrapie agent to the lymphoid tissue (Jeffrey, González et al. 2006).  Selective 
depletion of CD11c+ DCs prior to oral inoculation with scrapie resulted in prolonged 
incubation periods, further supporting a role for DCs in the uptake and transport of the 
TSE agent (Raymond, Aucouturier et al. 2007). However, in this model, some 
animals eventually succumbed to disease suggesting that the TSE agent is able to 
utilise other cell types.  Evidence so far supports a role for DCs in the uptake of the 
TSE agent, which is thought to be aided by complement opsonisation of the TSE 
agent (Flores-Langarica, Sebti et al. 2009) and subsequent transportation to the 
lymphoid tissues.  However ionising radiation, which would deplete all DCs, has no 
effect on scrapie pathogenesis (Fraser and Farquhar 1987; Fraser, Farquhar et al. 
1989) and bone marrow chimeric models have shown that TSE agent pathogenesis is 
not dependent on PrPC expressing bone marrow-derived cells (Klein, Frigg et al. 
1998; Brown, Stewart et al. 1999; Loeuillet, Lemaire-Vielle et al. 2010). Therefore it 
appears that DCs do not replicate the TSE agent but may be involved in initial 
localisation of the agent to the lymphoid tissue after some routes of peripheral 
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exposure. DCs may also be involved in the dissemination of the TSE agent after 
replication on the FDC networks and subsequent neuroinvasion as CD11c+ splenic 
DCs were shown to be able to transport the TSE agent to the CNS in mouse scrapie 
139A (Aucouturier, Geissmann et al. 2001).  
 
1.3.6 The role of complement in TSE pathogenesis 
 
The complement system is a cascade of heat labile serum proteins that can interact 
with pathogens to mark them for destruction.  Complement can initiate an immune 
response by inducing inflammation, recruiting phagocytic cells, opsonising pathogens 
and forming immune complexes for clearance and lysis of certain pathogens and cells.  
An additional function of complement is its importance in the binding of antigenic 
immune complexes to the FDC surface via its CD21 and CD35 complement receptors 
(van der Berg, Yoshida et al. 1995).  It is known that C3 is essential for the follicular 
localisation of antigen in an immune response therefore, complement may also be 
important in the localisation of the TSE agent to the follicle via the binding of the 
TSE agent to the FDC network via its expression of complement receptors.   
 
The importance of complement in scrapie pathogenesis was investigated by both 
genetic deletion of C3 (Klein, Kaeser et al. 2001) and temporary removal of plasma 
C3 using cobra venom factor, which inhibits antigen localisation to the follicle 
(Mabbot 2001).  Both of these studies showed increased incubation time and delayed 
neuroinvasion with intra-peritoneal (ip) inoculation of RML and ME7 scrapie 
respectively.  However, infectivity titres in the spleen were similar to WT control 
mice, suggesting that although C3 may be involved in localising the TSE agent to the 
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lymphoid tissue it may not be important in the subsequent replication and 
neuroinvasion of the agent. Deletions of complement components associated with the 
terminal pathway, such as C5, have no effect on TSE pathogenesis, suggesting that 
this complement pathway has no role in the pathogenesis of the TSE agent (Mabbott 
2004). Furthermore, genetic deletions of complement components appear to have no 
effect on TSE-associated neuropathology, suggesting that neurodegeneration in TSE 
infection is not complement-mediated (Mabbott, Bruce et al. 2001) 
 
Immune complexes, can also bind to FDCs via their Fc receptors, however depletion 
of these receptors had no effect on RML scrapie pathogenesis (Klein, Kaeser et al. 
2001). Therefore the localisation of the TSE agent to the FDC is unlikely to be 
mediated via immunoglobulins.  The C1q complement component binds antigen 
complexes and can mediate their uptake directly via its receptor, CD35, or by 
activating C4 (Klickstein, Barbashov et al. 1997).  Recent studies have shown that 
PrPSc can directly bind C1q via covalent interactions and activate complement via the 
classical pathway (Mitchell, Kirby et al. 2007).  In addition, it is thought that FDCs 
themselves can synthesise C1q aiding immune complex formation and localisation of 
antigen to the follicle (Schwaeble, Schafer et al. 1995).  These studies suggest that 
complement components, especially C1q, have a role in the localisation of the TSE 









1.4 The origin and function of  follicular dendritic cells   
 
 
1.4.1 Function of the FDC network 
 
Follicular dendritic cells (FDCs) are currently thought to be the cells in the lymphoid 
tissue responsible for replicating the TSE agent.  Prior to initiation of an immune 
response, FDCs are found within the primary follicle of secondary lymphoid tissues 
where they form networks of long dendrites and maintain the structural integrity of 
the B lymphocyte follicle (Heinen, Bosseloir et al. 1995).  After exposure to antigen, 
primary follicles form germinal centers which contain FDCs, B lymphocytes, helper 
CD4+ T lymphocytes and TBMs. FDCs aid this process via the secretion of 
chemokines which result in the recruitment of these cells to form the germinal centre 
(Kosco, Pflugfelder et al. 1992; Kosco-Vilbois, Bonnefoy et al. 1997; Kosco-Vilbois 
2003). The structure of the germinal centre ensures the FDCs have close contact with 
large numbers of B lymphocytes, which is essential for their function.  FDCs are 
specialised to capture antigen in the form of immune complexes but are non-
phagocytic and have no class II MHC expression (Gray and Skarvall 1988; Kosco, 
Pflugfelder et al. 1992; Maeda, Matsuda et al. 1995; van der Berg, Yoshida et al. 
1995).  Instead these immune complexes are retained on their surface for long periods 
of time and are thought to be important in B lymphocyte development, affinity 
maturation, antibody class switching and maintenance of B lymphocyte memory 
(Gray and Skarvall 1988; Gray, Kosco et al. 1991; Kosco, Pflugfelder et al. 1992; 
Heinen, Bosseloir et al. 1995).  This occurs via positive selection of anti-apoptotic 
signals to B cells with highest antigen affinity.  To allow immune complex capture, 
FDCs express complement receptors CR2 (CD21) and CR1 (CD35) and FcγRIIb on 
34 
their surface and may additionally have complement receptor 3 (CR3) and FcεRII 
(Qin, Wu et al. 2000; Balogh, Aydar et al. 2001).  Fc receptors have high affinity for 
the Fc fragment of immunoglobulin molecules and allow FDCs to bind immune 
complexes of antigen opsonised by IgG. This is aided by the expression of the 
complement receptors. CD21 has a high affinity for the complement fragments C3dg 
and C3d, whereas CD35 binds the complement fragments C3b and C4b, allowing 
FDCs to bind antigens opsonised by these (Liu, Xu et al. 1997).  Other possible 
surface markers found on FDCs include some usually found on B cells, including 
CD20, CD22, CD24 and CD45 however, this is difficult to determine by 
immunohistochemistry due to FDC close proximity to B lymphocytes in vivo (Heinen, 
Bosseloir et al. 1995; van der Berg, Yoshida et al. 1995).  During the germinal centre 
response FDCs also up-regulate the adhesion molecules intercellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) (Kosco, 
Pflugfelder et al. 1992; Heinen, Bosseloir et al. 1995; Nielsen 2000; Videm and 
Albrigtsen 2008). 
 
FDCs produce IL-6, which is important for the organisation and maintenance of the 
germinal centre reaction (Kosco-Vilbois, Bonnefoy et al. 1997; Kopf, Herren et al. 
1998).  This IL-6 is thought to amplify production of complement component C3 by 
local TBMs, which may subsequently increase the formation of immune complexes 
and attachment of these to the FDCs (Kopf, Herren et al. 1998).  FDCs also produce 
the chemokine CXCL13, which attracts B cells to the follicle via their CXCR5 
receptor (Kosco, Pflugfelder et al. 1992; Heinen, Bosseloir et al. 1995; Kosco-Vilbois, 
Bonnefoy et al. 1997). 
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FDCs have recently been discovered to be aid the uptake of apoptotic B cells in the 
germinal centre by tingible body macrophages (TBMs).  FDC-M1 or monoclonal 
antibody (MAb) clone 4C11 is considered to be a useful marker for FDCs as its 
expression is restricted to FDCs and TBMs.  However until recently the epitope 
recognised by this MAb was unknown (Kosco, Pflugfelder et al. 1992) .  Kranich et al 
noted that milk fat globule epidermal growth factor 8 knockout (Mfge8-/-) mice had no 
FDC-M1+ FDC networks in the lymphoid tissues although the FDCs were detectable 
by CD21/35 immunolabelling.  They confirmed that MFGE-8 is the same antigen as 
the epitope recognised by MAb FDC-M1 and is secreted by the FDCs to opsonise 
apoptotic B cells in the germinal centre.  This mediates the clearance of apoptotic B 
cells by TBMs and is essential for the prevention of autoimmune disorders 
(Hanayama, Tanaka et al. 2004; Kranich, Krautler et al. 2008). Secretion of MFGE-8 
is possibly driven by signalling through the lymphotoxin β receptor (LTβR) as 
MFGE-8 levels are greatly reduced in LTβR-/- mice (Kranich, Krautler et al. 2008). 
 
1.4.2 The origin and development of the FDC network 
 
The origin of FDCs is controversial but the predominant hypothesis is that they are 
non-bone marrow-derived cells and instead are derived from stromal cell precursors.  
One reason for this opinion is that FDCs share many surface markers with fibroblasts 
and can form ectopically under chronic inflammatory conditions, for example in the 
inflamed synovium of rheumatoid arthritis patients (Heinen, Bosseloir et al. 1995; 
Maeda, Matsuda et al. 1995).  Initial experiments showed that animals which were 
irradiated and reconstituted with bone marrow consistently had FDCs of host origin 
(Humphrey, Grennan et al. 1984).  This was confirmed in later studies using SCID 
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mice which have no FDCs. Grafting these mice with donor bone marrow can 
indirectly restore FDC networks via B-lymphocyte-derived signals. Work by Kapasi 
et al showed that newly generated FDCs in SCID mice were consistently of host 
genotype and not that of donor bone marrow (Kapasi, Burton et al. 1993). This 
procedure was subsequently used to create mice with mismatches in PrPC expression 
with the newly generated FDCs consistently of host PrPC expression status and not 
that of donor bone marrow, further suggesting FDCs are not bone marrow-derived 
cells (Brown, Stewart et al. 1999).  Another experiment used transplantations of 
human cord blood into RAG-2-/- mice, which also have no B or T lymphocytes or 
FDCs.  This resulted in the generation of murine, and not human, FDCs even though 
animal was repopulated with human blood cells (Traggiai, Chicha et al. 2004).  FDC-
derived cell lines have been shown to express many surface proteins relating them to 
bone marrow stromal cell progenitors and the expression of α-smooth muscle actin on 
FDC cell lines specifically related them to myofibroblasts (Munoz-Fernandez, Blanco 
et al. 2006).   
 
In contrast, some studies argue that the FDC precursor is derived from the bone 
marrow and not the stromal cell population (Mebius, van Tuijl et al. 1998).  Various 
authors have suggested bone marrow-derived cells such as CD5+ B-1B lymphocytes 
or antigen transporting cells such as DCs can act as inducer cells for the formation of 
the FDC networks (Szakal and Tew 1992; Wen, Shinton et al. 2005).  Kapasi et al 
reconstituted SCID mice with donor bone marrow and found cells expressing donor 
antigens and the FDC marker FDC-M1 in the newly formed lymphoid tissues 
(Kapasi, Qin et al. 1998).  However, FDCs are known to be able to acquire proteins 
on their surface that they themselves do not express, therefore it is possible that FDCs 
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acquired these antigens from donor B lymphocytes, rather than the FDC networks 
developing from donor bone marrow precursors (Gray, Kosco et al. 1991; Denzer, 
van Eijk et al. 2000). 
 
A recent study by Murakami et al proposed to have found a cell type that induces the 
formation of FDC networks. CD19-CD11c-CD35+B220+ inducer cells were separated 
from splenocytes, and injected intradermally along with stromal like CD45-CD35+ 
cells to successfully induce the formation of lymphoid tissue-like structures.  
Furthermore, GFP-tagged inducer cells demonstrated that these inducer cells gain 
expression of the FDC marker FDC-M1 in the newly formed follicles.  This was 
confirmed by adoptive transfer of GFP-tagged inducer cells into naïve C57BL/6J-Jcl 
mice resulting in GFP+ FDCs in the reticulum of the spleen (Murakami, Chen et al. 
2007).  The inducer cells were able to retain immune complexes on their surface both 
in-vitro and in-vivo, a major distinguishing feature of FDCs.  These data strongly 
suggest a role for these CD19-CD11c-CD35+B220+ inducer cells in the formation of 
the FDC network.   The development of the FDC network is also dependent on B cell-
derived lymphotoxins (Chaplin and Fu 1998), especially the membrane-bound LT. 
LTα-/- or LTβ-/- mice, have defects in the formation of lymph nodes and no Peyer’s 
patches (Chaplin and Fu 1998).  TNF-/- mice also had a similar phenotype, suggesting 
this is also involved in FDC development (Chaplin and Fu 1998).  It has since been 
confirmed that signalling through the p55 TNFR on FDC is essential for formation of 
the FDC network and maintenance of FDC function (Victoratos, Lagnel et al. 2006).  
Furthermore, these signals are not just required for initial FDC development, 
continual signalling via LTα1β2 secreted from B cells is also required for 
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maintenance of the FDC network structure as blocking this signal using a soluble LTβ 
receptor causes the networks to dedifferentiate (Mackay and Browning 1998).  
 
1.4.3 FDC-independent TSE agent replication  
 
From the work mentioned previously, it seems certain that FDCs have a role in TSE 
pathogenesis, however some conflicting results have shown that they may not always 
be required.  Some naturally occurring TSE diseases appear to be restricted to the 
CNS, with no PrPSc deposition or infectivity found in the extraneural tissues.  For 
example, no extraneural disease was detected in sCJD patients (Hill, Butterworth et 
al. 1999) until a method of concentrating PrPSc to increase the sensitivity for western 
blot was used and PrPSc was subsequently detected in some of the samples tested 
(Glatzel, Abela et al. 2003).  This is in contrast to vCJD where infectivity and PrPSc 
deposition have been reported in various tissues including the spleen and tonsils (Hill, 
Butterworth et al. 1999).  Additionally, disease appears to be restricted to the CNS in 
cattle naturally infected with BSE (Somerville, Birkett et al. 1997).  In contrast, PrPSc 
has been detected in the PP of the distal ileum in cattle experimentally infected with 
disease (Terry, Marsh et al. 2003) and experimental inoculation of BSE into sheep has 
also resulted in PrPSc deposition in the lymphoid tissues (Lemzi, Ronzon et al. 2006).   
Atypical forms of BSE and scrapie have recently been described and there also 
appears to be no involvement of the lymphoid tissues with these TSE strains 
(Buschmann, Biacabe et al. 2004; Benestad, Arsac et al. 2008). A case of atypical 
scrapie with a concurrent, non-related inflammation in the brain was recently 
described.  This animal was detected as having atypical scrapie by active surveillance 
and also had virus induced, non-purulent encephalitis which had led to the formation 
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of ectopic lymphoid follicles in the brain tissue.  Examination tissues from this animal 
showed that there was no association of PrPSc with any draining lymph nodes or 
ectopic follicles found in the brain tissue (Vidal, Tortosa et al. 2008). This lack of 
PrPSc accumulation on ectopic follicles in the brain further demonstrate the lack of 
lymphoreticular involvement of the atypical scrapie strain as inflammatory conditions 
in various organs which cause the formation of FDC-containing ectopic follicles, have 
previously shown to be a favourable environment for PrPSc accumulation 
(Heikenwalder, Zeller et al. 2005).  Furthermore, PrPSc accumulation in inflamed 
excretory organs such as the kidney or mammary glands is thought to aid spread of 
scrapie through shedding of the TSE agent in urine or milk respectively 
(Heikenwalder, Zeller et al. 2005; Ligios, Sigurdson et al. 2005; Ligios, Cancedda et 
al. 2007; Konold, Moore et al. 2008).  These studies suggest that there may be 
variations in TSE strain cellular targeting.  
 
Recent evidence has suggested that the FDCs themselves might not be essential for 
PrPSc replication but that any stromal cell with some FDC-like functions could 
theoretically support prion replication.  Heikenwalder et al created a model in which 
TSE agent replication occurred in complete Freunds adjuvant (CFA) -induced 
granulomas in the skin following ip inoculation.  Analysis of the granuloma showed a 
complete lack of commonly used FDC markers and FDC-specific, Mfge8 mRNA but 
relatively high levels of PrPC.  However, administration of the LTβR-Fc, which has 
been shown to dedifferentiate FDCs, reduced TSE agent accumulation in the 
granulomas (Mackay and Browning 1998; Heikenwalder, Kurrer et al. 2008).  
Furthermore, these stromal cells expressed high levels of PrPC and organised 
lymphocytes within the granuloma into follicle-like structures.  Analysis of this model 
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led to the conclusion that that scrapie replication was occurring on a radio-resistant 
fibroblastic cell which did not express any FDC-specific markers and that this 
occurred in a LTβ-dependent manner (Heikenwalder, Kurrer et al. 2008).  This is in 
accordance with the finding that unaltered, mouse derived fibroblast cell lines can be 
infected with RML scrapie in vitro and are sufficient to sustain PrPSc replication 
(Vorberg, Raines et al. 2004).  Muscle cell lines have also been shown to support 
prion replication with finding of PrPSc in the muscle tissue of a sporadic CJD patient 
confirming this (Kovacs, Lindeck-Pozza et al. 2004; Dlakic, Grigg et al. 2007). 
Therefore it may be possible that any stromal cell with an FDC-like function has the 
capacity to support TSE agent replication. 
 
Natural and experimental strains of TSE disease show variation in pathogenesis 
thought to be due to genetic or strain properties, but there are also reported differences 
between groups using the same agent strain. For example, Klein et al inoculated 
TNFR1-/- mice, which have no mature FDCs with RML scrapie and observed no 
difference in disease pathogenesis between the TNF deficient mice and their wild type 
counterparts, suggesting that FDCs are not involved in scrapie pathogenesis (Klein, 
Frigg et al. 1997). This was further confirmed by Prinz et al who also found that TNF-
/- mice developed scrapie at the same time as their WT counterparts.  Furthermore, 
although PrPSc was absent in the spleen, they found high accumulation in the lymph 
nodes of these animals (Prinz, Montrasio et al. 2002).  However, they also discovered 
PrPSc accumulation in macrophages in the lymph nodes of these mice, suggesting that 
unactivated macrophages may act as a replication site in the absence of FDCs (Prinz, 
Montrasio et al. 2002). Studies by Oldstone et al using the RML scrapie strain in LTα-
/- and LTβ-/- mice analysed the role of FDCs after oral and i.p. scrapie inoculation. In 
41 
these studies, all of the LTα-/- mice developed disease, whereas the lack of FDCs led 
to impaired scrapie pathogenesis in the LTβ-/- mice.  It was suggested that scrapie 
replication may be dependent on some other unknown cell type dependent on LTβ 
(Oldstone, Race et al. 2002).  However, it should be mentioned that high doses of 
RML Scrapie were used for inoculation in these studies, so it may be that the need for 
an amplification stage in the spleen in unnecessary for neuroinvasion to proceed after 
high dose of infection. The discrepancies between various experiments using same 
strains have been put down to various factors such as TSE agent load and route of 
inoculation, however the reasons behind these differences will not be fully understood 
until the true nature of the TSE agent is discovered. 
 
1.6 Thesis aims 
 
From studies published so far, it has been determined that PrPC expressing FDCs are 
required for the successful pathogenesis of many TSE agent strains within the 
lymphoid tissue (McBride, Eikelenboom et al. 1992; Brown, Stewart et al. 1999; 
Mabbott, McGovern et al. 2002; Prinz, Montrasio et al. 2002; Mabbott, Young et al. 
2003).  However in the models used so far, it is possible that FDCs acquire 
accumulation of PrPSc on their surface after scrapie agent replication on other 
neuronal, stromal or endothelial cells within the lymphoid tissue.  To definitively 
determine the role of FDCs in scrapie pathogenesis, a model is required where PrPC 
expression can be manipulated exclusively on the FDC network. 
 
The aims of this thesis were to create and characterise transgenic mouse models that 
allow the manipulation of PrPC expression specifically on FDCs and subsequently to 
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infect these animals with scrapie to determine the specific role of the FDCs in TSE 
pathogenesis within the lymphoid tissue. The hypothesis was explored that if FDCs 
are simply accumulating the TSE agent on their surface after replication on another 
cell type, the accumulation of the TSE agent will occur on PrPC deficient FDCs when 
all other cell types within the lymphoid tissue retain PrPC expression.  If however, the 
FDCs actively replicate the TSE agent in the lymphoid tissue, accumulation of PrPd 
will not occur on the PrPC deficient FDCs. Additionally, if FDCs are responsible for 
replicating the TSE agent within the lymphoid tissue, then PrPC expression 
exclusively on FDCs should be sufficient to allow replication of the TSE agent within 
the lymphoid tissue. 
 
1.7 Transgenic mouse lines used in this thesis 
 
 
1.7.1 Cre-LoxP Model 
 
To create a model which allows manipulation of PrPC specifically on FDCs, the Cre-
LoxP sytem of targeted gene deletion was used.  The Cre-LoxP system is a model that 
can be used to generate transgenic animals in which gene expression is tissue- or cell- 
type specific.  This occurs through the use of the Cre-recombinase enzyme that cuts 
out or inverts any DNA that is flanked by LoxP sites i.e. “floxed” DNA.  In non-Cre 
expressing cells the target DNA remains unchanged.  This system can be made 
specific by inserting the Cre-recombinase after a tissue- or cell type- specific 
promoter (Kos 2004).  LoxP is short for Locus of crossover P and these sites are 34bp 
DNA sequences that are used to flank the target DNA.  They contain an 8bp core that 
determines the “directionality” of the target DNA and this is flanked by 13bp 
pallindromic sequences.  Cre-recombinase is a 38 KDa cyclisation recombination 
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recombinase enzyme that creates the recombination of the DNA between LoxP sites.  
It is a member of the integrase family of recombinases and is coded for by 
bacteriophage P1 (Kos 2004). When Cre is activated, it creates a transient DNA-
protein covalent linkage to bring the two LoxP sites together and catalyses a site-
specific recombination event.  Depending on the orientation of the two LoxP sites, the 
DNA will either be inverted or excised.  If the LoxP sites are inverted, i.e. are in 
opposite directions, the DNA segment between undergoes inversion and the two LoxP 
sites remain in their position in the DNA.  However if the two LoxP sites are in the 
same direction, Cre excises the target DNA segment and a single LoxP site remains 
(Kos 2004). 
 
1.7.2 The CD21-Cre mouse line 
 
The CD21-cre mouse line was chosen to create a model which allows manipulation of 
PrPC expression exclusively on FDCs.  CD21 is also known as complement receptor 2 
(CR2) and was thought to be expressed solely on FDCs and mature B lymphocytes 
(Reynes, Aubert et al. 1985; Liu, Xu et al. 1997; Takahashi, Kozono et al. 1997). 
There are two types of CD21- a long and a short isoform- which are expressed on 
FDCs and B cells respectively.  CD21 has a high affinity for the complement 
fragments C3dg and C3d and on FDCs, will bind antigens opsonised by these (Liu, 
Xu et al. 1997).  On B lymphocytes, CD21 acts as a co-receptor for the B cell receptor 
(BCR), where the binding of specific antigen opsonised by complement components 
decreases the threshold level for signalling through the BCR.  However, in humans, 
expression of CD21 has also been reported on a subpopulation of immature 
thymocytes (Tsoukas and Lambris 1988; Wagner and Hansch 2006), peripheral T 
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lymphocytes (Morgan, Marchbank et al. 2005) and on cervical epithelium (Sixbey, 
Lemon et al. 1986).  Within the mouse, expression has also been reported on a small 
population of CD4+ T lymphocytes within the MLN, activated granulocytes and mast 
cells (Gray and Skarvall 1988; Gray, Kosco et al. 1991; Andrasfalvy, Prechl et al. 
2002; Heggebo, Gonzalez et al. 2003; Llewelyn, Hewitt et al. 2004).  The expression 
of CD21 appears to more widespread than initially reported, however all non-FDC 
expression of CD21 is found on bone marrow derived cells. This is confirmed using 
data from the BioGPS database which stores microarray data of gene expression 
profiles from various mouse and human tissues.  Analysis of CD21 (Cr2) expression 
using the BioGPS database confirms there is no non-lymphoid expression of CD21 
reported (Fig 1.3). To restrict Cre expression in the CD21-cre mouse exclusively to 










Figure 1.3 BioGPS expression profiles of Cr2 in the mouse 
Expression profiles of Cr2 from BioGPS database (http://biogps.gnf.org) which stores 
microarray data from various murine tissues and cell lines.  In agreement with 
publication data, Cr2 expression is restricted to the lymphoid tissues on FDCs and 
bone marrow-derived cells.  
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2. Materials and methods 
 
2.1 Production of mouse lines 
 
2.1.1 CD21-cre mice 
 
CD21-cre mice were kindly provided by Klaus Rajewski (CBR Institute for 
Biomedical Research) and were created by targeted insertion of CD21/35 bacterial 
artificial chromosome (BAC) clone containing a Cre expression cassette.  
Homologous recombination of Cre into the BAC was confirmed by Southern Blot and 
used for microinjection into fertilized oocytes (Kraus, Alimzhanov et al. 2004).  
CD21-cre mice are on a C57BL/6 background. 
 
2.1.2. CD21-creROSA26 mice  
  
The CD21-creROSA26 reporter strain was created at the Roslin Institute by crossing 
the CD21-cre mice with a ROSA26 reporter strain (a kind gift from Yuko Fujiwara 
and Stuart H. Orkin, Howard Hughes Medical Institute, Harvard Med School, 
Massachusetts, USA).  The ROSA26 mice have a floxed 1.3-kb BglII–EcoRI 
‘‘stopper’’ fragment from plasmid cAct-XstopXnZ (Fig 2.1), followed by the LacZ 
gene, a β-galactosidase coding sequence, inserted into the ROSA26 locus. The 
ROSA26 locus is ubiquitously expressed during embryonic development and in adult 
cells. Cell-specific expression of Cre causes removal of the floxed stop cassette and β-
galactosidase expression is switched on in that cell type. (Mao, Fujiwara et al. 1999).  
The progeny of this cross were genotyped and selected for Cre and LacZ (ROSA26) 
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expression by PCR analysis of genomic DNA from tail snips.  Age matched, Cre-





LacZ  Cr2 Cre X 
 
Fig 2.1 CD21-creROSA26 mice 
Cre is expressed under the Cr2 promoter region.  Expression of Cre causes excision of 
a floxed stop cassette, switching on expression of the LacZ gene which is a β-
galactosidase coding region. 
 
2.1.3 CD21-crePrPfl/fl mice 
 
The CD21-crePrPfl/fl mouse strain was created by crossing the CD21-cre mice with 
mice which has the Prnp ORF flanked by loxP sites i.e. “floxed” (termed PrP fl/fl) 
(Tuzi, Clarke et al. 2004). The ORF of the murine Prnp gene is contained within exon 
3. The PrPfl/fl mice are on a 129/Ola background and have loxP sites flanking Prnp 
exon 3 created by homologous recombination with a PrPfl/fl targeting vector.  Cell-
specific Cre activation removes exon 3 of Prnp thus switching off PrPC expression. 
The progeny mice were genotyped and selected for Cre and Prnpfl expression.  
 
3 1 2 LoxP LoxP 
 Cr2 Cre X 
 
Figure 2.2 CD21-crePrPfl/fl mice 
Cre is expressed under the Cr2 promoter region. Expression of Cre causes excision of 
the floxed exon 3 of the Prnp gene, which contains the protein coding region. 




2.1.4 CD21-crePrPfl/- mice 
 
Non promoter-specific recombination of the floxed Prnp ORF was detected in the 
CD21-crePrPfl/fl.  Multiple generations of the CD21-cre line crossed with the floxed 
line on a mixed genetic background may have led to the Cr2 promoter losing control 
of Cre expression.  As a consequence, these mice were not used for subsequent 
scrapie experiments. To compensate for this, the CD21-cre mice were bred onto a 
Prnp null background by crossing with a PrP-/- mouse (Manson, Clarke, et al 1994).  
This PrP-/- mouse is on a 129/Ola background and was created by gene targeting a PrP 
DNA fragment construct containing a neomycin resistance gene into exon 3 of the 
Prnp gene, disrupting the protein coding region for PrPC.  These CD21-crePrP-/- mice 
were then crossed with the PrPfl/fl line.  Animals were selected by genotyping for Cre, 
Prnpnull and Prnpfl and the resulting CD21-crePrPfl/- mice produced were used in 
subsequent scrapie experiments.  Age matched Cre-negative littermates were used as 
controls and bone marrow donors in experiments, where indicated. 
 
2.1.5 CD21-crePrPstop/- mice 
 
The CD21-crePrPstop/- strain was created by crossing CD21-crePrP-/- mice with 
PrPstop/- mice (Tuzi, Clarke et al. 2004).  The PrPstop mice contain a floxed β-geo 
cassette inserted into intron 2 of the Prnp gene, upstream of the coding region.  
Insertion of this β-geo cassette prevents the expression of PrPC, however site specific 
expression of Cre removes the cassette, switching on PrPC expression. The PrP stop/- 
mice are also on a 129/Ola background. Animals were selected by genotyping for Cre, 
Prnpnull and Prnpstop and the resulting CD21-crePrPstop/- mice were used in subsequent 
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scrapie experiments. Age-matched Cre-negative littermates were used as controls and 
bone marrow donors in experiments, where indicated.  
 
 
 LoxP 3 
stop
LoxP 1 2 
 
 
Cr2 Cre X 
Figure 2.3 CD21-crePrPstop/- mice 
Cre is expressed under the Cr2 promoter region. Expression of Cre causes excision of 
a floxed stop cassette inserted before exon 3 of the Prnp gene, which contains the 
protein coding region. Consequently, PrPC expression is switched on in Cre-
expressing cells.   
 
 
2.1.6 Genotyping animals 
 
Tail snips of CD21-creROSA26 mice were lysed in 800μl of proteinase K (PK)-
containing buffer (0.3 M sodium acetate, 0.1% SDS, 0.1M Tris pH8, 1 mM EDTA, 
7mg/ml PK) and cleaned by addition of 600μl phenol chloroform followed by 
centrifugation.  The supernatants were removed and added to 600μl of isopropanol 
and 20ul of 3M sodium acetate to pellet DNA.  DNA pellets were then cleaned by 
centrifugation with 70% ethanol and resuspended in 100μl distilled water.  Resulting 
DNA samples were analysed for Cre and LacZ expression using the primers in the 
table below (Table 2.1).  PCR products were viewed by running on a 1% agarose gel, 
containing 0.001% ethidium bromide (Sigma).   
 
For CD21-crePrPfl/fl, CD21-crePrP-/-, CD21-cre PrPfl/- , CD21-crePrPstop/- strains, 
DNA was prepared from tailsnips, earpunches, blood, tail or spleen using a DNeasy 
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blood and tissue kit (Qiagen, Crawley, UK) according to the manufacturer’s 
instructions.   
CD21-cre PrPfl/fl DNA samples were genotyped for Cre and Prnpfl using primers 
listed in Table 2.1.  PCR product for Cre samples were viewed by running on a 1% 
agarose gel containing 0.001% ethidium bromide producing a band of 786 base pairs 
(bp).  
Prnp fl product was run on a 2% agarose gel containing 0.001% ethidium bromide 
resulting in a band of 210 bp.  PrnpWT could also be detected as a band of 167 bp 
which demonstrated whether the sample was homozygous or heterozygous for Prnpfl.  
Animals were subsequently genotyped for Prnpfl with or without recombination of the 
floxed exon 3 (Prnpfl(R)).  To do this, the Prnpfl primers were used with the addition of 
an extra primer, vitro Cre B, to detect any recombination of the floxed exon.  Full 
recombination resulted in one band of 344 bp whereas partial recombination resulted 
in both the recombined band of 344 bp and the Prnpfl band at 210 bp.  PrnpWT was 
also detected in as a band of 167 bp as in the Prnpfl PCR. 
 
CD21-cre PrP-/- DNA samples were genotyped for Cre as previously described. 
Samples were also genotyped for Prnpnull and PrnpWT using primers listed in Table 
2.1.  PCR product was run on a 1% agarose gel containing 0.002% gelred (Biotium, 




CD21-cre PrPfl/- DNA samples were genotyped for Cre, PrnpWT and Prnpnull as above 
and also Prnpfl(R) as in the genotyping of CD21-crePrPfl/fl DNA samples with primers 
listed in Table 2.1.   
 
CD21-cre PrPstop/- DNA samples were genotyped for Cre, PrnpWT and Prnpnull as 
previously described.  In addition, these samples were genotyped for Prnpstop to detect 
the floxed STOP cassette and any recombination of the floxed STOP DNA using the 
primers listed in Table 2.1. This produced a band of 1 Kbp for the floxed stop cassette 
(Prnpstop) and a band of 840bp for recombined Prnpstop (Prnpstop(R)).  
 
2.1.7 Production of bone marrow chimeras 
 
Where indicated, mice were lethally γ-irradiated with 950 rads from a Caesium137 
source (Gravatom Engineering Systems Ltd, UK).  Mice were reconstituted with bone 
marrow from age and sex matched animals 24 h post-irradiation.  Bone marrow 
preparations were made as single cell suspensions in Hank’s balanced salt solution 
(HBSS; GIBCO Life Technologies, Paisley, UK) from the femurs and tibias of 
selected donor mice. Bone marrow suspensions contained between 3x 107- 4x 107 
viable cells per 1ml. Mice were reconstituted by injection of 0.1ml of bone marrow 
suspension into the tail vein.  Animals were left for 100 days before experimental 
analysis to allow removal of long-lived B lymphocyte populations and replacement 





2.1.8 Animal Housing 
 
All protocols using experimental mice were approved by the Neuropathogenesis 
Unit’s Protocols and Ethics Committee and conducted according to the regulations of 
the Home Office.  Experimental work was carried out under project license number 
60/3983 held by Dr. Karen Brown to investigate immune system influences on TSE 
pathogenesis. All mouse strains used were kept in a conventional animal housing unit 
under specific pathogen free conditions.  Bone marrow chimeric mice were housed in 
individually ventilated cages. 
 
 
2.2 Characterisation of  CD21-creROSA26 animals 
 
2.2.1 Detection of β-galactosidase 
 
Tissues from CD21-creROSA26 animals were dissected into ice cold phosphate 
buffered saline pH 7.4 (PBS) and fixed for one hour in LacZ fixative 
[paraformaldehyde-gluteraldehyde (2% paraformaldehyde, 0.2% gluteraldehyde, 
PBS), 0.02% Nonidet P40, 0.01% sodium deoxycholate, 5mM EGTA, 2mM MgCl2].    
Tissues were then given three 20 minute washes in LacZ wash buffer (0.02% Nonidet 
P40, 0.01% Sodium deoxycholate, 2mM MgCl2, 1X PBS pH 7.4).  After washing, 
tissues were incubated in 15% sucrose in PBS overnight followed by a further 
overnight incubation in 30% sucrose in PBS.  Tissues were subsequently embedded in 
Tissue-Tek® O.C.T. CompoundTM (Bayer PLC, Newbury, UK) and frozen using 
isopentane at the temperature of liquid nitrogen.  Serial sections of 8µm were cut on a 
cryostat and processed further for X-gal staining and immunohistochemistry. 
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To detect β-galactosidase, sections were incubated in LacZ staining solution [1X PBS 
pH 7.4 1mg/ml X-gal (Glycosynth, Warrington, UK), 0.02% Nonidet P40, 0.01% 
sodium deoxycholate, 2mM MgCl2, 5mM potassium ferricyanide, 5mM potassium 
ferrocyanide] at 37°C overnight and protected from light.  Staining reaction was 
stopped by washing for 5 min in LacZ wash buffer followed by distilled water for  
1 min.  Sections were counterstained with nuclear fast red (Vector Laboratories, 
Peterborough, UK), dehydrated and mounted in Pertex (CellPath, Powys, UK). 
 
2.2.2 Immunohistochemistry (IHC) of frozen tissues 
 
Sections (thickness 8μm) were cut from tissues fixed for β-galactosidase detection 
(Section 2.2.1) using a cryostat.  Sections were fixed in acetone for 10 minutes before 
addition of a species specific normal serum block followed by primary antibodies as 
listed in Table 2.2.  For light microscopy, a species specific biotin-conjugated 
secondary antibody was added.  This was detected by alkaline phosphatase (AP) 
coupled to the avidin–biotin complex (Vector Laboratories) using Vector Red as a 
substrate (Vector Laboratories) and counterstained with haematoxylin.  Light 
microscopy was carried out on a Nikon Eclipse E800 microscope (Nikon U.K. Ltd, 
Surrey, U.K.)  For fluorescent microscopy, species specific secondary antibodies 
conjugated to alexa-fluor 488, 594 or 647 were added and detected by confocal 
microscopy.  All fluorescent microscopy was carried out on a Zeiss LSM5 confocal 






PCR Forward Primer(s) Reverse Primer(s) Product Size 
























Prnpfl 210 bp 
PrnpWT167 bp 
Prnpfl(R) Vitro CreB 
AATGGTTAAACTTTC
GTTAAGGAT 
3’orfR1 and 5’orfR1 
As previous 
Prnpfl(R) 344 bp 
Prnpfl 210 bp 
PrnpWT167 bp 





























Prnpstop(R) 840 bp 
PrnpWT 750Kbp 
 
Table 2.1 Primers used in PCR genotyping of animals 
Details of oligonucleotide primers used for PCRs to genotype transgenic animals 
during breeding to produce mouse lines detailed in section 2.1.  
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2.2.3 Characterisation of spleen and blood cells from CD21-creROSA26 animals by 
flow cytometry 
 
Single cell suspensions of spleens were prepared by passing cells through a cell 
strainer in 1ml of fluorescence- activated cell sorting (FACS) buffer [GIBCO 1xPBS 
pH 7.4 (Invitrogen, Paisley, UK) 2% Foetal calf serum (Sigma, Dorset, UK)].  Blood 
was collected into heparinised tubes to prevent clotting and added to FACS buffer.  
Cell suspension were spun at 2000 rpm for 10 min at 4°C and resulting cell pellets 
were re-suspended in red blood cell lysis buffer (Sigma) for 5 minutes. Viable cells 
were counted in a 1:10 dilution in trypan blue (GIBCO) and adjusted to 1 X 106 
viable cells per 50 μl.  Samples of 1x106 cells were blocked using 1μl Seroblock FcR 
rat anti-mouse CD16/32 (AbD Serotech, Oxford, UK) and incubated for 30 minutes 
with an appropriate dilution of primary antibody (Table 2.3) at 4˚C.  
 
Samples labelled with directly conjugated primary antibodies were transferred to 
FACS tubes for analysis.  Samples labelled with biotin-conjugated primary antibodies 
were incubated for 30 min in a 1:200 dilution of streptavidin-conjugated alexa 594 or 
488.  Samples labelled with unconjugated primary antibodies were incubated with a  
1:200 dilution of the species specific secondary antibody conjugated to a 
fluorochrome.  To detect intracellular antigens, such as β-galactosidase, samples were 
permeabilised using a BD fixation/ Permeabilisation kit (BD bioscience, Oxford, 
UK).  After labelling cell surface antigens, cells were added to BD Fixation/ 
Permeabilisation solution.  Cells were incubated in the primary antibody for 30 
minutes according to the manufacturer’s instructions.  Species specific, isotype 
controls were used in all experiments to detect any background fluorescence.  A 
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FACS Scan flow cytometer (Becton Dickinson, Oxford, UK) was used to analyse 
cells with the lymphoid cells gated for by forward and side scatter. 
 




2.3.1 PCR analysis of bone marrow chimeric mice 
 
Blood, tail and spleen samples were taken from transgenic mouse lines and snap 
frozen until DNA extraction was performed.  DNA was extracted using a DNeasy 
blood and tissue kit (Qiagen, Crawley, UK) according to the manufacturer’s 
instructions. Samples were genotyped for Cre, Prnpnull, Prnpfl(R) and Prnpstop as 
described previously (2.1.5).  Differences in gene expression between blood and 
spleen/ tail were used to demonstrate the chimera status of animals and confirm 
whether specific Cre-mediated DNA recombination was occurring in stromal, 
haematopoietic or both compartments.  
 
2.3.2 Immunohistochemistry of frozen tissues 
 
 
Tissues were snap frozen in liquid nitrogen, embedded in Tissue-Tek® O.C.T. 
CompoundTM (Bayer PLC, Newbury, UK) and 8µm sections were cut using a 
cryostat. IHC analysis was carried out for light and fluorescent microscopy as 
previously described (2.2.2) using the antibodies listed in Table 2.2.  Light and 






2.3.3 ImageJ analysis of confocal images 
 
Confocal images were analysed and converted to data using the program ImageJ 
(http://rsbweb.nih.gov/ij/index.html). This program processes images in Java to create 
data that were used to analyse the total area of specific immunostaining and the co-
localisation of proteins.  The accuracy of analysing images in this way was previously 
validated by comparing manual counts to automated computer generated data (Inman, 
Rees et al. 2005). This method of analysis has considerable advantages because it 
ensures consistency over analysis of images and is faster and more accurate than 
observational analysis. Furthermore, it allows statistical analysis and data to be 
extracted from images to prove true co-localisation of proteins as opposed to co-
localisation due to the random association of fluorochromes on an image. 
 
ImageJ was used to determine and compare the area occupied by FDC networks in 
spleen sections from each of the transgenic mouse lines when compared to wild type 
mice. To do this spleen sections were stained using the rat-anti-mouse CD35 antibody 
clone 8C12 as described previously (2.3.2).  Five areas of each spleen were imaged 
using the Zeiss confocal microscope at x200 magnification. ImageJ was used to 
convert images to grayscale and measure the number of pixels positively labelled with 
the CD35 antibody. This enabled calculation of the average area of FDC per image. 
 
Co-localisation of proteins was also assessed using ImageJ.  Firstly, the multiple 
colour backgrounds macro (Appendix I) was used over 2 images from each of the 
animals.  A line is drawn through the image and the macro measures the intensity of 
the colour over that line. This enables a threshold for background staining to be 
determined for each colour in the image. The multiple colour analysis macro 
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(Appendix II) is then used to measure the number of black and coloured pixels in the 
image, using the previously estimated threshold to eliminate the count of any 
background.  These values were then used to work out the total area of staining for 
each antibody used and determine the amount of co-localisation 
 
2.3.4 Fluorescence-activated cell sorting (FACS) analysis 
 
Flow cytometry was used to determine PrPC expression status of CD21+ lymphocytes.  
Cells were extracted from both spleen and blood to demonstrate the chimera status of 
animals.  Single cell suspensions from spleen and blood were prepared as described 
previously (2.2.3) and labelled with 1B3 and CD21/35 (Table 2.3).  CD21+ B 
lymphocytes were gated and assessed for PrPC expression status using a FACS Scan 
flow cytometer (Becton and Dickinson). 
 
2.3.5 In-vivo analysis of immune complex trapping by FDCs 
 
Animals were given intra-peritoneal injections of 100 μl of preformed rabbit 
peroxidise-anti-peroxidase (PAP) immune complex (Sigma) and culled 48 h later.  
Spleens were snap frozen and 8μm sections were cut on a cryostat. Sections were 
blocked with normal goat serum and incubated with a goat-anti-rabbit antibody 
conjugated to alexa-fluor 555.  After washing, sections were blocked with normal 
mouse serum and then incubated with biotin-conjugated rat-anti-CD35. 
Immunolabelling was detected using a streptavidin-alexa 488 conjugate. Images were 
taken on the Zeiss confocal microscope and were analysed for co-localisation using 
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Table 2.3 Detection antibodies used for flow cytometric analysis 
Details of antibodies used for immunolabelling of lymphocytes isolated from spleen 
and blood for detection by flow cytometry 
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2.4 Experimental analysis of scrapie infected animals 
 
2.4.1 Inoculation with the scrapie agent 
 
All animals were injected with the ME7 strain of the scrapie agent either intra-
peritoneally (ip) or intra-cranially (ic).  This strain was originally isolated from a 
spleen of a Suffolk sheep with natural scrapie and was passaged into Moredun 
random-bred mice via intra-gastric inoculation followed by passage via ic inoculation 
in Moredun random bred mice (Zlotnik and Rennie 1963). This was subsequently 
passaged nine times via ic inoculation in C57BL/Dk mice at the Neuropathogenesis 
Unit in Edinburgh. This strain has been extensively used as a mouse model of TSE 
disease and pathogenesis has been thoroughly characterised in inbred mouse lines 
(Bruce, Boyle et al. 2002).  For ic inoculation, mice were anaesthetised with 3% 
fluorine gas in oxygen.  Mice were injected in the right mid temporal cortex with 20 
μl of 1% (wt/vol) scrapie-infected brain homogenate in physiological saline. For i.p. 
inoculation, 20μl of 1% (wt/vol) scrapie-infected brain homogenate was injected into 
the peritoneal cavity. 
 
2.4.2 Immunohistochemical analysis of paraffin-embedded tissues 
 
Spleens and brains from scrapie-infected mice were fixed in 2% periodate-lysine-
paraformaldehyde (PLP) (0.1M sodium periodate, 0.075M D-L lysine, 2% 
paraformaldehyde in 0.05M PBS) and embedded in paraffin wax.  Sections of 6μm in 
thickness were cut on a microtome.  For detection of PrP in brains and spleens, 
sections were deparaffinised and autoclaved at 121˚C for 15 minutes.  Sections were 
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immersed in 98% formic acid for 10 minutes followed by incubation with primary 
antibodies 1B3or 6H4 (Table 2.4) overnight at room temperature. Biotin-conjugated, 
species specific, secondary antibodies were incubated for one hour.  PrP in the spleen 
was detected using avidin-biotin complex conjugated to AP (Vector Labs) and 
visualised using Vector Red.  PrP in the brain was detected using avidin-biotin 
complex conjugated to horseradish peroxidise (HRP, Vector Labs) which was 
visualised using 3,3’-diaminobenzadine (DAB, Sigma).  Spleens were also labelled 
for FDCs and B lymphocytes using antibodies listed in Table 2.4 and visualised using 
AP-Vector red. Brains were also labelled for activated astrocytes and microglia and 
visualised using AP-Vector red (Table 2.4). 
 
2.4.3 Paraffin-embedded tissue (PET) blots 
 
Antibodies used to detect PrPSc are polyclonal and can detect both PrPC and PrPSc. To 
ensure labelling in infected spleens was the disease-associated PrPSc, paraffin-
embedded tissue blots were used.  During this procedure, treatment with PK destroys 
any cellular PrPC, leaving only the pK-resistant PrPSc if present.  Section of 6μm 
thickness were cut onto nitrocellulose membrane Trans-blot transfer medium (Bio-
Rad Laboratories, Hertfordshire, U.K.) and dried overnight at 55˚C. Sections were 
deparaffinised and incubated overnight in 20 μg/ml pK (Sigma) in PK digest buffer 
(10 mM/0.01 M Tris pH 7.8, 100 mM/0.01 M Sodium Chloride, 0.1% Brij).  Protein 
was denatured in 3mol/L guanidine isothiocyanate (GndSCN) for 10 minutes at room 
temperature followed by a block with 2% Casein western blotting reagent (Roch, 
Welwyn Garden City, U.K.) in Tris-buffered saline-Tween (TBS-tween; 10 mM/0.01 
M Tris pH 7.8, 100 mM/0.01 M NaCl2, 0.5% Tween 20). Primary polyclonal rabbit-
65 
anti PrP, antiserum 1B3 (Neuropathogenesis Unit, Edinburgh) was added in a 1/4000 
dilution in blocking buffer and incubated for 2 hours at room temperature. Bound 1B3 
was detected using goat anti-rabbit conjugated to AP (Jacksons Laboratories) and 
visualised using Nitro-blue tetrazolium chloride- 5-bromo, 4-chloro, 3’-
indolyphosphate P-toluidine salt (NBT/BCIP) tablets (Sigma) dissolved in distilled 
water.  Sections were imaged using a Lecia WLD MZ8 stereo light microscope 
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Table 2.4 Detection antibodies used for immunohistochemical analysis of 
paraffin-embedded sections 
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Follicular dendritic cells (FDCs) are considered to be important sites of scrapie agent 
accumulation in lymphoid tissues after peripheral exposure.  However, models used 
so far have not been able to distinguish the role of the FDCs from that of all other 
stromal and lymphoid cells found within the lymphoid tissue.  The Cr2 gene encodes 
complement receptor 2 (CR2) also known as CD21, is reported to be expressed only 
on FDCs and mature B lymphocytes.  In this chapter, the CD21-cre mouse was 
investigated as a possible tool for creating an FDC-specific transgenic mouse model.  
This was achieved by crossing the CD21-cre mouse line with the ROSA26 reporter 
line, resulting in β-galactosidase expression in cells where Cre is activated.  To 
restrict Cre expression exclusively to FDCs, animals were lethally γ-irradiated and 
reconstituted with non-transgenic WT bone marrow.  Cellular localisation of Cre 
expression in tissues was determined by the histological detection of β-galactosidase 
expression.  Cre was successfully activated in FDCs and B lymphocytes in the CD21-
creROSA26 mouse line.  Irradiation and reconstitution of CD21-creROSA26 mice 
with WT bone marrow successfully restricted Cre expression to the FDCs in 
lymphoid tissues.  Data from the CD21-creROSA26 model suggests that the CD21-cre 
mice reconstituted with WT bone marrow are a useful tool to manipulate gene 






After peripheral infection, for example oral or ip exposure, many TSE agents undergo 
a stage of intense replication in the spleen and lymph nodes accompanied by high 
deposition of PrPSc (Fraser and Dickinson 1970; Clarke and Haig 1971; van Keulen, 
Schreuder et al. 1996).  FDCs reside in the B cell follicles of peripheral lymphoid 
tissue and express relatively high amounts of PrPC on their surface, expression of 
which is essential for scrapie pathogenesis (Klein, Frigg et al. 1998; Brown, Stewart 
et al. 1999). In the lymphoid tissue of scrapie affected mice strong immunolabelling 
for PrPSc is associated with FDCs (McBride, Eikelenboom et al. 1992; Bruce, Brown 
et al. 2000).  To confirm this finding, analysis of infected lymphoid tissue at the ultra-
structural level showed high accumulation of PrPSc on the FDC surface and around 
the dendrites (Jeffrey, McGovern et al. 2000).  Studies using mice depleted of FDCs 
have shown significant increases in incubation time, delayed pathogenesis and 
reduced susceptibility (Mabbot 2000; Montrasio 2000; Mabbot 2002; Oldstone 2002; 
Mabbott, Young et al. 2003).  However, in the models used so far, there has been no 
way to dissociate PrPC expression on FDCs from stromal, neural and lymphoid cells 
within the lymphoid tissue.  Therefore it is possible that FDCs themselves do not 
actively replicate the TSE agent, but instead accumulate it on their surface after 
replication on another cell type.  Thus, to definitively determine the role of the FDCs 
in peripheral TSE pathogenesis, a model is required where manipulation of PrPC 
expression is exclusively restricted to the FDC network. 
 
The Cre-loxP system can be used to generate transgenic animals in which gene 
expression is tissue- or cell type-specific. This occurs through the use of a Cre-
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recombinase (Cre) that cuts out or inverts any DNA that is flanked by loxP sites i.e. 
“floxed” DNA.  Whereas, in non-Cre expressing cells the target DNA remains 
unchanged.  This system can be made specific by inserting Cre after a tissue- or cell 
type- specific promoter (Kos 2004).  In this chapter, the CD21-cre mouse (Kraus, 
Alimzhanov et al. 2004) is tested as a possible method of manipulating gene 
expression exclusively on FDCs.  In this strain, Cre is inserted after the Cr2 promoter, 
which encodes CD21.  CD21 is considered to be restricted to FDCs and mature B 
lymphocytes. (Reynes 1985; Liu 1997; Takahashi, Kozono et al. 1997; Heggebo, 
Press et al. 2002).  However, in humans, expression of CD21 has also been reported 
on a subpopulation of immature thymocytes (Tsoukas and Lambris 1988; Wagner and 
Hansch 2006), peripheral T lymphocytes (Fox, Jewell et al. 2006) and on human 
cervical epithelium (Sixbey, Lemon et al. 1986) .  Expression has also been reported 
within the mouse on a population of CD4+ T lymphocytes found within the 
mesenteric lymph node, activated granulocytes and mucosal mast cells (Gray and 
Skarvall 1988; Gray and Matzinger 1991; Andrasfalvy, Prechl et al. 2002; Heggebo, 
Gonzalez et al. 2003). In this study, to overcome expression of Cre in lymphocytes, 
the mice will be exposed to lethal γ-irradiation, which will deplete host bone marrow-
derived cells, and subsequently reconstituted with donor, non-Cre-expressing, bone 
marrow. As a consequence, all Cre-expressing host-derived lymphocytes are depleted 
and replaced with the non-transgenic WT donor lymphocytes restricting Cre-
expression to the FDCs. 
 
Next, to determine the cellular localisation of Cre activation in CD21-cre mice, this 
line was crossed with a Rosa reporter strain.  The ROSA26 line contains a floxed 
STOP cassette in front of the LacZ gene, which contains a β-galactosidase coding 
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region (Mao, Fujiwara et al. 1999).  In cells which activate Cre, the STOP cassette is 
removed by the activity of Cre and β-galactosidase expression is switched on.  
Expression of β-galactosidase can be detected using X-gal, a substrate of β-
galactosidae. Digestion of X-gal by β-galactosidase produces a blue product which 
can be used to histologically locate where β-galactosidase is expressed.  Lymphoid 
and a large variety of non-lymphoid tissues from both the CD21-creROSA26 line and 
CD21-creROSA26 animals that were lethally γ-irradiated and reconstituted with non 
transgenic bone marrow from WT mice were then assessed to determine the cellular 
sites of Cre expression.  This analysis confirmed that Cre is activated in the FDCs and 
mature B lymphocytes in CD21-cre mice and this expression is restricted to the FDC 
network after irradiation and reconstitution with WT bone marrow.  Therefore it was 
concluded that CD21-cre mice will be a useful tool to manipulate gene expression 




3.3.1 Production of CD21-creROSA26 mice 
 
To determine the cellular localisation of Cre expression in the CD21-cre mouse line, 
CD21-cre mice were first crossed with the ROSA26 reporter line which induces the 
expression of β-galactosidase in cells which activate Cre.  Animals were genotyped 
by PCR and chosen based on expression of the Cre and Rosa (LacZ) transgenes.  To 
restrict Cre expression to FDCs, animals were given whole body, lethal, ionising 
radiation to remove all host lymphocytes and were subsequently reconstituted with 
non-transgenic, WT bone marrow (termed WT →CD21-creROSA26 mice).  Cellular 
expression of Cre driven by the Cr2 promoter was assessed in animals with and 
without bone marrow reconstitution (Fig. 3.1).    In the CD21-creROSA26 animals, 
expression of Cre induces production of the bacterial enzyme β-galactosidase in Cre 
expressing cells.  An X-gal stain for β-galactosidase expression is used to locate β-
galactosidase and assess Cre activity.  Animals expressing only the ROSA26 transgene 
were used to control for any background β-galactosidase staining that may be present. 
 
 
3.3.2 Irradiation of CD21-creROSA26 mice followed by reconstitution with WT bone 
marrow successfully removes Cre expression in CD21+ B-lymphocytes  
 
Cellular sites of Cre expression in tissues from CD21-creROSA26 mice was assessed 
using an X-gal stain to detect β-galactosidase expression. X-gal (5-bromo, 4-chloro, 









               
786 bp 
300 bp 
 1      2       3       4      5      6       7       8      9      10     11    12     13    14 
CD21-creROSA26 
CD21-creROSA26 ROSA26 WT →CD21-creROSA26 
ROSA26 WT →CD21-creROSA26 







Figure 3.1 Confirmation of genotype of CD21-creROSA26 mice  
DNA was extracted from the tails of CD21-creROSA26, ROSA26 and WT →CD21-
creROSA26 mice.  A PCR analysis was used to confirm the presence of Cre and LacZ 
transgenes.  This analysis confirmed that CD21-creROSA26 (lanes 1-6) and WT 
→CD21-creROSA26 (lanes 9-14) mice contained both the Cre and LacZ transgenes.  







were immersed in X-gal solution which in Cre-expressing cells is catalysed by β-
galactosidase to form a blue product that can be visualised using light microscopy. 
 
B-lymphocytes and FDCs are closely compacted within the B lymphocyte follicle of 
lymphoid tissues. For this reason, it is difficult to distinguish β-galactosidase labelling 
of B lymphocytes in the follicle from that of FDC networks.  However, labelling in 
the follicles of CD21-creROSA26 mice which received irradiation and reconstitution 
with WT bone marrow was greatly reduced in comparison to labelling in follicles of 
untreated CD21-creROSA26 animals (Fig 3.2).  Therefore it can be concluded that 
irradiation and reconstitution with WT bone marrow successfully removes Cre-
expressing CD21+ B lymphocytes and restricts Cre expression to the FDC networks in 
the lymphoid tissues. 
 
 Single cell labelling of β-galactosidase was detected in the villi and isolated 
lymphoid follicles (ILFs) of the large and small intestine in tissues from CD21-
creROSA26 mice which did not receive any pre-treatment (Fig 3.5).  This labelling 
was presumed to be intra-epithelial B lymphocytes and B lymphocytes in the 
capillaries, lymphatics and follicles of the intestine. However monoclonal antibodies 
against B lymphocyte markers were not sensitive enough to detect single cells after an 
X-gal stain. This type of single cell labelling was also demonstrated in the thymus and 
lung and was thought to be circulating lymphocytes in the capillaries of these organs.  
In CD21-creROSA26 mice which received the irradiation and bone marrow 
reconstitution, labelling of single cells within these tissues was no longer detected. 
Therefore it can be concluded that irradiation and reconstitution with WT bone 
marrow successfully removes Cre-expressing CD21+ circulating B lymphocytes. 
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Figure 3.2 Irradiation of CD21-creROSA26 mice and reconstitution with wild 
type bone marrow successfully removes Cre expressing B lymphocytes 
Sections of lymphoid tissues from CD21-creROSA26 and CD21-creROSA26 given 
irradiation and WT bone marrow (WT → CD21-creROSA26)  to remove all the 
transgenic CD21+ B lymphocytes were stained for β-galactosidase (blue) expression 
using an X-gal staining solution and were counterstained with nuclear fast red (pink).  
Lymphoid tissues from Rosa mice containing the LacZ reporter gene insert but no Cre 
transgene were stained as negative controls.  In all lymphoid tissues from Cre 
expressing animals, staining of β-galactosidase is found in the B-lymphocyte follicles 
which contain both FDCs and CD21+ B lymphocytes.  The levels of staining in 
lymphoid tissues from animals which received the irradiation and bone marrow graft 
is greatly reduced in comparison to those that did not receive this pre-treatment.  This 
suggests that β-galactosidase, and therefore Cre expression, has been removed from 
CD21+ B lymphocytes in the lymphoid tissue.  This implies that WT →CD21-






3.3.3 Cre is activated by the Cr2 promoter in FDCs and CD21+ B lymphocytes 
   
The cellular localisation of Cre expression was assessed in the lymphoid tissues, 
including the spleen, mesenteric, axillary and inguinal lymph nodes, thymus, Peyers 
patches and isolated ILFs of the gut.  CD21 expression was initially reported to be 
restricted to CD21+ mature B lymphocytes and FDCs however, expression has since 
been reported in other bone marrow-derived cells in mice, including T lymphocytes, 
activated granulocytes and mast cells, however this expression was postulated to be 
removed by the irradiation and bone marrow reconstitution (Gray and Skarvall 1988; 
Gray and Matzinger 1991; Andrasfalvy, Prechl et al. 2002; Llewelyn, Hewitt et al. 
2004).  To determine whether Cre-mediated DNA recombination occurred in other 
cell types, various non-lymphoid tissues were also analysed. These included the heart, 
lung, liver, kidney, large intestine, small intestine, pancreas, tongue, epithelium (ear), 
muscle, sciatic nerve, spinal cord and brain. Results describing the detection of β-
galactosidase activity in all tissues is summarised in Table 3.1 
 
β-galactosidase activity was detected on FDC networks within the B lymphocyte 
follicles of all lymphoid tissues in CD21-creROSA26 mice, both with and without 
pre-treatment of lethal irradiation and reconstitution with WT bone marrow (Fig 3.2).  
Subsequently, an X-gal stain followed by immunolabelling of B lymphocytes and/or 
FDCs was used to determine cellular location of the β-galactosidase.  The β-
galactosidase labelling was found in areas of the follicle which also showed positive 
immunolabelling for FDC and FDC/B lymphocyte markers demonstrating that Cre 
recombinase is effectively activated under the Cr2 promoter in FDCs and CD21+ B 





































Figure 3.3 Cre is expressed within B lymphocyte follicles and FDC networks in 
CD21-creROSA26 mice 
Spleen sections from CD21-creROSA26, WT →CD21-creROSA26 and ROSA26 
mice, were stained for β-galactosidase (blue) and B lymphocytes (red) or FDCs (red). 
Immunohistochemical detection of B lymphocytes using anti-B220 monoclonal 
antibodies and FDCs using anti CD35 monoclonal antibodies occurs in the same area 
of the follicle as β-galactosidase detected by an X-gal stain.  This demonstrates that 
Cre is successfully expressed under the CD21 promoter in FDCs and CD21-


















Tissue β-galactosidase Notes 
  staining   
 
Spleen present On FDCs and B-lymphocytes.  Background on capsule 
Inguinal 
Lymph Node present On FDCs and B-lymphocytes.  Background on capsule 
Axillary 
Lymph Node present On FDCs and B-lymphocytes.  Background on capsule 
Mesenteric 
Lymph Node present On FDCs and B-lymphocytes.  Background on capsule 
Peyers 
Patches present On FDCs and B-lymphocytes.  Background on capsule 




On B lymphocytes and cells of plexi . Background in 




On B lymphocytes and cells of plexi . Background in 
crypts and contaminating intestinal bacteria 
 
Ileum present 
On B lymphocytes and cells of plexi . Background in 
crypts and contaminating intestinal bacteria 
 
Colon present 
On B lymphocytes and cells of plexi . Background in 
crypts and contaminating intestinal bacteria 
Heart absent Background only 
Lung 
present 
On B lymphocytes  and background on mucosal 
surfaces 
Liver absent No staining 
Kidney absent Background only 
Pancreas absent No staining 
Ear absent No staining 
Tongue absent No staining 
Muscle absent No staining 
Ovary, uterus,  absent Background only 
Testes,bladder absent Background only 
Sciatic Nerve absent No staining 
Brain present Staining of a population of cells in brain 
Spinal Cord absent No staining 
 
 
Table 3.1 Expression patterns of β-galactosidase in CD21-creROSA26 mice 
Summary of β-galactosidase staining found in tissues from 6 untreated CD21-
creROSA26 and 6 WT →CD21-creROSA26 mice. Staining was concluded to be B-
lymphocyte staining if it was present in the untreated group but absent in the group 
which received the irradiation and bone marrow.  Staining was concluded to be 
background if it was also present in the same regions in tissues from ROSA26 mice.  
Examples of this can be seen in Figure 3.5   
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3.3.4 Insertion and expression of the Cre transgene under the Cr2 promoter has no 
toxic effect on CD21 expressing cells 
 
Cre toxicity is a reported phenomenon that can occur in some Cre transgenic lines.  In 
these cases, Cre recombinase targets sequences of DNA that are similar to its 24 bp 
target LoxP sites causing mis-recombination, DNA damage and death of the Cre-
expressing cells (Schmidt-Supprian and Rajewsky 2007).  Immunohistochemistry and 
flow cytometry was used to determine whether insertion of the Cre transgene has any 
adverse effects on CD21-expressing cells.  Sections of spleen from CD21-creROSA26 
and WT →CD21-creROSA26 mice were labelled with antibodies against FDCs and B 
lymphocytes and compared to spleen sections from WT and ROSA26 controls. 
Immunohistochemical analysis showed no differences in FDC or B lymphocyte 
labelling between the transgenic animals and their WT counterparts (Fig. 3.4).  In 
addition, CD21+ B lymphocytes were isolated from spleen and counted by FACS 
analysis. FACS analysis of spleens from each mouse group showed no differences in 
either the number of CD21+ or CD19+ B lymphocytes (Fig. 3.5). 
 
3.3.5 Detection of β-galactosidase expression in non-lymphoid tissues 
 
Unexpectedly, β-galactosidase expression was detected in a population of cells in the 
ganglia of the myenteric and submucosal plexi of the large and small intestine. This 
staining only occurred in a small number of ganglia per section, however it was 
observed consistently in all of the animals (Fig 3.7).  Practical difficulties were 
encountered in determining the precise nuclei with which the X-gal staining was 
associated with, possibly due to differential cellular packaging of β-galactosidase.  
Therefore, it could not be determined from the X-gal staining, whether this Cre- 
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 WT → 
CD21-creROSA26 ROSA26 WT CD21-creROSA26  
























Figure 3.4 Expression of Cre under the Cr2 promoter has no effect on FDCs and 
CD21+ B lymphocyte numbers 
Immunohistochemical detection of B lymphocytes (B220, CD19, CD1d, red) and 
FDCs (CD35, C4, red) in spleens from double transgenic mice, with and without 
irradiation and reconstitution with WT bone marrow, ROSA26 and C57BL/6 lines.  
There is no observed difference in immunolabelling of B lymphocytes and FDCs of 
transgenic mice in comparison to C57BL/6 WT control line using a panel of anti-B 
lymphocyte and anti-FDC monoclonal antibodies. Scale bar 100 μm.  Sections 








Figure 3.5 Expression of Cre under the Cr2 promoter has no effect on CD21+ B 
lymphocyte numbers 
Detection of CD21 and CD19 on splenic lymphocytes from CD21-creROSA26 and 
C57BL/6 mice. No difference was observed in the numbers of CD19+ splenic B 
lymphocytes in CD21-creROSA26 mice (B) in comparison to WT controls (A). There 
is also no difference in CD21 expression between the transgenic line (D) and WT 
control (C).  These data suggest that insertion and expression of Cre under the Cr2 
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Fig 3.6 β-galactosidase detection in cells other than FDCs 
Sections from various tissues of CD21-creROSA26, WT →CD21-creROSA26 and 
ROSA26 transgenic animals were stained for β-galactosidase (blue) and 
counterstained with nuclear fast red (pink). 
a. Background β-galactosidase staining was found in some tissues from Rosa animals 
containing no Cre transgene.  These included the capsule of the spleen (A), the 
tubules and glomeruli of the kidney (B), paneth cells in the crypts of the intestines 
(C), the thymus (D), the brush borders of the bronchiole of the lung (E) and villi of 
large intestine (F), Brunner’s glands in the duodenum and the uro-genital tract of both 
male and female animals (eppididymus pictured H)  Original magnification D x100 
A, E, F, G, H x200 B, C x400 
b. Single cell β-galactosidase staining was detected in the lung (A), villi of intestine 
(B) and thymus (C) of CD21-creROSA26 mice but not in WT →CD21-creROSA26 
mice. These were concluded to be circulating CD21+ Cre-expressing B lymphocytes 
which were removed after irradiation and replaced with non-Cre-expressing WT bone 









expression was in neuronal or glial cell populations within the ganglia.  To clarify 
this, immunohistochemistry was attempted using an anti-β-galactosidase antibody 
along with an antibody against a pan-neuronal marker which recognises a neuronal 
protein named protein gene product 9.5 (PGP 9.5), to examine whether expression of 
these proteins were co-localised.  Unfortunately, anti-β-galactosidase immunostaining 
using this antibody was not achieved even on positive control spleen and lymph node 
sections tested.  An alternative method using an X-gal stain followed by 
immunohistochemistry for PGP 9.5 was tried instead (Fig 3.7).  Although both 
staining of PGP 9.5 and X-gal occurred within the ganglia, it did not provide any 
further information on the cellular location of the X-gal staining. 
 
The sciatic nerve and spinal cord did not show any activation of Cre.  However β-
galactosidase staining occurred in a population of large cells in the brain (Fig 3.7.).  
As with the co-localisation analysis on the plexi of the intestine, immunolabelling 
with anti-β-galactosidase antibodies was unsuccessful, therefore it is uncertain 
whether this staining is occurring within neuronal or glial cell populations.   However, 
as irradiation and reconstitution with WT bone marrow did not remove this staining 
from both the intestine and the brain, it is likely that the Cre activation was within 
host-derived neurones rather than glial cells. 
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Fig 3.7 β-galactosidase labelling occurs in a population of cells in the plexi of 
intestine and the brain 
A population of cells in the ganglia of both the submucosal (A) and myenteric (B) 
plexi of the intestine were found to express β-galactosidase (blue).  This only 
occurred in a few ganglia per section of intestine, however it appeared consistently in 
each of the 12 animals analysed.  Co-localisation analysis using anti-β-galactosidase 
antibodies and neuronal antibodies was unsuccessful (data not shown).  Staining for 
β-galactosidase using an X-gal staining solution followed by immunolabelling of 
nerves using the monoclonal antibody PGP 9.5 (Red) (C) was not accurate enough to 
determine if this β-galactosidase was expressed in a neuronal or glial cell population 
within the ganglia. 
Transverse (D) and longitudinal (E) sections of spinal cord were both clear of β-
galactosidase labelling, as was the sciatic nerve (F). 
However a population of cells in the brain which appeared in the optic tract (G), 
hippocampus, (H) and corpus collosum (I) also expressed β-galactosidase. 
Sections are counterstained with nuclear fast red (pink).  Original magnification A, C 













In this chapter, the CD21-cre mouse was investigated as a possible model for 
restricting gene expression to FDCs.  This was achieved by crossing the CD21-cre 
mouse with a ROSA26 reporter strain which allows the detection of Cre activity via 
the production of β-galactosidase. The characterisation studies undertaken on this 
mouse line indicate that the CD21-cre model will be a useful tool to manipulate PrPC 
expression specifically on FDCs and to study the role of the FDC network in TSE 
pathogenesis.  Cre-expression under the Cr2 promoter did not appear to affect 
lymphoid tissue structure as determined by immunolabelling of B lymphocytes and 
FDCs using a panel of monoclonal antibodies against various cell-specific markers.  
This is in accordance with Kraus et al (2004), who reported that insertion and 
expression of Cre under the Cr2 promoter does not interfere with B lymphocyte 
development or numbers (Kraus, Alimzhanov et al. 2004). 
 
The detection of β-galactosidase expression using the ROSA26 reporter strain has 
shown that Cre-mediated DNA recombination is occurring efficiently on both FDCs 
and B lymphocytes.  Although DNA recombination on B lymphocyte subsets was not 
examined, previous studies suggest that mature B lymphocytes express the highest 
levels of CD21, while immature and pro- and pre- B lymphocytes express low levels 
or none, respectively (Takahashi, Kozono et al. 1997).  Studies on the CD21-cre line 
by Victoratos et al indicate that efficiency of this DNA recombination is 75% on B 
lymphocytes and 96% in FDCs (Victoratos, Lagnel et al. 2006). This was reflected in 
this characterisation study as all CD21-creROSA26 animals showed efficient 
expression of β-galactosidase in the FDCs and B lymphocytes in a variety of 
lymphoid tissues tested. 
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Irradiation and reconstitution with WT bone marrow successfully restricted Cre 
expression to the FDC networks within the lymphoid tissue.  The animals were 
lethally γ-irradiated (950 rads) and reconstituted with age and sex matched bone 
marrow 24 h later.  Animals were maintained for 100 days post bone marrow transfer 
before analysis of tissues.  Previous studies have shown that a minimum of 28 days is 
required for efficient re-differentiation of the FDC networks and repopulation of 
lymphocytes from donor bone marrow (Brown, Stewart et al. 1999).  However, 
populations of long-lived B lymphocytes have also been reported, therefore animals 
were left for 100 days post irradiation and bone marrow transfer to ensure removal of 
the majority of host derived lymphocytes (Miller and Cole 1967). 
 
Unfortunately FACS analysis of B lymphocytes using anti-β-galactosidase 
monoclonal antibodies was attempted for both cell surface and intracellular β-
galactosidase but was unsuccessful.  Fluorescent immunolabelling of tissue sections 
using the same antibodies also did not work.  This is possibly because all tissues taken 
were fixed specifically for staining with X-gal in fixative which included detergents to 
permeabilise tissues.  However when comparing levels of X-gal staining between 
CD21-creROSA26 animals with CD21-creROSA26 animals which were irradiated and 
given bone marrow, staining was greatly reduced in the irradiated animals suggesting 
that expression of β-galactosidase by B lymphocytes had been removed. 
 
Staining of β-galactosidase in non-lymphoid tissues was also detected, for example in 
the kidney, lung, and intestine (Table 3.1).  This is thought to be Cre-activation on 
circulating B lymphocytes as this staining was absent in CD21-creROSA26 animals 
which were irradiated and re-grafted with WT bone marrow.  In agreement with this,  
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Kraus et al performed analysis of Cre-mediated DNA recombination on B lymphocyte 
populations isolated from various tissues and found intermediate levels of 
recombination in the kidney and gut samples, confirming the presence of Cre-
mediated DNA recombination in CD21+ B lymphocytes found in non-lymphoid 
tissues (Kraus, Alimzhanov et al. 2004).  As the irradiation and reconstitution with 
WT bone marrow removes all Cre expressing lymphocytes, CD21-expressing cells 
within these tissues should have no impact on the specificity of the model.  
Expression of CD21 has also been reported on activated granulocytes and mast cells 
in mice, however again, any Cre expression in these cell types will be eliminated by 
the irradiation and bone marrow reconstitution pre-treatment (Gray and Matzinger 
1991; Ahmed and Gray 1996). 
 
β-galactosidase expression on a small subset of cells in the thymus was also 
consistently detected.  A population of immature human thymocytes has been 
reported to express CD21 and additionally in the mouse, CD21 expressing activated T 
lymphocytes have been reported (Gray and Skarvall 1988; Tsoukas and Lambris 
1988; Llewelyn, Hewitt et al. 2004) .  However, a study analysing CD21 expression in 
the mouse found that CD21 expressing cells in the thymus always co-localised with B 
lymphocyte markers, and suggested that these were the rare thymic B lymphocyte 
pool (Takahashi, Kozono et al. 1997).  Again, this labelling was eliminated after 
irradiation and reconstitution with WT bone marrow.    
 
Expression of β-galactosidase was detected in a population of neuronal or glial cells 
in the brain.  β-galactosidase labelling was detected in large cells of the hippocampus, 
corpus collosum, dentate gyrus, coroid plexus and occurs diffusely throughout the 
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cortex.  As monoclonal antibodies against β-galactosidase did not work on these 
tissues, it was not possible to do double immunolabelling and co-localisation analyses 
to determine which subset of cells were expressing Cre.  This Cre-mediated DNA 
recombination was still present in animals which received irradiation and bone 
marrow reconstitution.  The manipulation of gene expression in these cells in CD21-
cre mice should have no impact in the early stages of TSE agent accumulation in the 
spleen as the agent does not reach the brain until the late stages of the incubation 
period.  However, this may need to be taken into account for any animals that are left 
to progress to CNS disease as manipulation of PrP expression in these neurones may 
affect disease outcome. 
 
Expression of β-galactosidase was also found in a population of cells within the 
ganglia of the myenteric and submucosal plexi of both the large and small intestine.  
For reasons stated previously, it was not possible to determine whether this staining 
occurred in a neuronal or glial cell population.  These cells are reasonably close to the 
sites of initial prion accumulation in oral inoculation.  Expression of β-galactosidase 
was only found in a few ganglia of these plexi per section of intestine but was 
expression was consistent in most of the animals.  Sciatic nerve and spinal cord did 
not show any labelling for β-galactosidase. 
 
 A study by Gonzalez et al investigated the role of the enteric nervous system in oral 
inoculations with the murine BSE strain 301V.  They observed strong labelling for 
PrP on both the myenteric and submucosal plexus of the inoculated mice, however, 
much of this was removed after PK treatment indicating that it was mainly the cellular 
PrPC that was being detected (Gonzalez, Terry et al. 2005).   Due to the detection of 
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Cre-mediated DNA recombination within the intestine, the ip route was chosen as the 
route of TSE agent exposure in future studies to avoid possible effects of Cre-
mediated DNA recombination in enteric ganglia. 
 
In conclusion, these data show the CD21-cre model will be a useful tool to 
manipulate Prnp expression exclusively on FDCs to determine the role of FDCs in 
scrapie pathogenesis after ip inoculation. Cre-mediated DNA recombination occurred 
efficiently on the FDC networks and mature B lymphocytes.  Furthermore, irradiation 
and repopulation with non-Cre-expressing bone marrow successfully eliminated the 
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Data from the CD21-creRosa26 model (Chapter 3) suggests that CD21-cre mice 
reconstituted with WT bone marrow are a useful tool to manipulate gene expression 
exclusively on FDCs.  PrPC expressing FDCs are considered to be important sites of 
scrapie agent accumulation in lymphoid tissues after peripheral exposure.  However, 
models used so far have not been able to definitively distinguish the role of the FDCs 
from that of all other stromal, lymphoid and neural cells found within the lymphoid 
tissue.  For this reason, it is possible that rather than actively replicating the scrapie 
agent, FDCs may simply accumulate the agent after replication on another cell type.  
To generate a model which may be used to determine the specific role of FDCs in 
peripheral scrapie pathogenesis the CD21-cre mouse line was crossed with a line 
where the coding region of PrPC is flanked by loxP sites (PrPfl/fl) allowing PrPC to be 
switched off under control of the Cr2 promoter.  The progeny CD21-crePrPfl mice 
were fully characterised to determine within which cells PrPC was switched off and 
ensure that the transgenes had no additional effects on the lymphoid tissues that could 
have an impact on scrapie pathogenesis.  Characterisation of the CD21-crePrPfl 
mouse demonstrated that PrPC was efficiently and exclusively switched off on Cre-
expressing FDCs.  Furthermore, insertion and expression of the transgenes had no 
adverse effects on the microarchitecture of the lymphoid tissue or the number, area or 
functionality of FDCs. These data suggest that the CD21-crePrPfl mouse will be a 






Expression of the cellular prion protein, PrPC, is essential for efficient scrapie 
pathogenesis to occur (Bueler, Fischer et al. 1992; Büeler, Aguzzi et al. 1993; Blattler, 
Brandner et al. 1997; Klein, Frigg et al. 1998; Brown, Stewart et al. 1999; Wroe, Pal 
et al. 2006).  In the lymphoid tissue of scrapie affected mice strong immunolabelling 
for PrPSc is associated with FDCs (McBride 1992; Bruce, Brown et al. 2000; Jeffrey, 
McGovern et al. 2000).  Previous studies have shown that expression of PrPC on 
FDCs is essential for scrapie pathogenesis to occur after peripheral exposure (Brown, 
Stewart et al. 1999).  Previous data suggests that FDCs are responsible for replicating 
the scrapie agent within the lymphoid tissue prior to neuroinvasion and CNS disease.  
However in the models used so far, there has been no way to dissociate PrPC 
expression on FDCs from all other stromal, neural and lymphoid cells within the 
lymphoid tissue.  Therefore it is possible that FDCs themselves do not actively 
replicate the TSE agent, but instead accumulate it on their surface after replication on 
another cell type.  Data in this thesis (Chapter 3) shows that the CD21-creROSA26 
mouse efficiently activated Cre-mediated DNA recombination in the FDCs and this 
could be made specific by lethal γ-irradiation and reconstitution with non-Cre 
expressing bone marrow. Therefore this model was crossed with a transgenic floxed 
PrP line to allow PrPC to be switched off exclusively on FDCs. 
 
The coding region for PrPC is contained within exon 3 of the Prnp gene.  In PrPfl/fl 
mice, exon 3 of Prnp is flanked by loxP sites i.e. “floxed” exon 3 (Tuzi, Clarke et al. 
2004). This mouse strain was crossed with the CD21-cre mouse to allow PrPC to be 
switched off under control of the Cr2 promoter.  Based on data from the CD21-
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creROSA26 model, the CD21-crePrPfl mouse together with lethal γ-irradiation and 
reconstitution with non-Cre-expressing bone marrow, should allow PrPC to be 
switched off exclusively on FDCs.  In this chapter, the CD21-crePrPfl line was 
characterised to determine if PrPC was successfully switched off on the FDC networks 
and that the transgenes had no additional affects on the lymphoid tissue.  Analysis of 
the CD21-crePrPfl line showed that PrPC was efficiently switched off on Cre- 
expressing FDCs however expression remained present on other non-CD21-
expressing cells in the lymphoid tissues such as the nerves.  Furthermore, there were 
no differences in the michroarchitecture and the number, area and function of FDCs in 
the spleen.  From these data, it can be concluded that the CD21-cre PrPfl line will be a 





4.3.1 Production of CD21-cre PrPfl/fl mouse line  
 
 To switch of PrPC in FDCs the CD21-cre line was crossed with the PrPfl/fl line, and 
progeny selected by screening for expression of Cre and Prnpfl by PCR.  Progeny 
mice were then bred together, further selecting for Cre and Prnpfl expression until 
sufficient CD21-crePrPfl/fl mice were obtained for use in characterisation studies.  
During this process, the results of the genotyping indicated there was a problem and 
DNA was extracted from a number of tissues to assess where Prnpfl DNA was being 
recombined in the animals.  In CD21-crePrPfl/fl animals, the PCR results should show 
partial recombination of Prnpfl DNA in the lymphoid tissues due to the presence of 
CD21+ B lymphocytes and FDCs, and also a band for un-recombined Prnpfl due to the 
presence of non-CD21-expressing cells in the tissues.  This is termed “partial 
recombination” of Prnpfl DNA.  In the first mouse analysed, partial recombination of 
Prnpfl DNA was found in the spleen, mesenteric lymph node (MLN) and inguinal 
lymph node (ILN) as expected.  However partial recombination was also detected in 
the liver, kidney, brain and ear but not in the heart or lung (Figure 4.1).  This 
suggested that Cre-mediated DNA recombination was not occurring under control of 
the Cr2 promoter.  Tissues analysed from animals taken from subsequent rounds of 
breeding showed full recombination of the Prnpfl DNA with no un-recombined Prnpfl 
present (Figure 4.1).  This spontaneous recombination of the Prnpfl DNA resulted in a 
Prnp deficient mouse as all Prnpfl DNA was recombined to remove exon 3 of the 
Prnp gene, switching off PrPC expression in all cell types.  As a consequence, this line 
could no longer be used in subsequent scrapie experiments. 
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4.3.2 Production of CD21-crePrP fl/null mouse line  
 
 
To compensate for the spontaneous recombination occurring in the PrPfl/fl 
homozygous mice, the CD21-cre line was subsequently bred as Prnpfloxed 
heterozygotes on a PrP-/- background. To achieve this, the CD21-cre line was first 
crossed with a PrP-/-   line.  The resulting CD21-creXPrP-/- mice were then crossed 
with the PrPfl/fl line and CD21-crePrPfl/- progeny were used in subsequent 
experiments. 
 
To switch off PrPC exclusively in FDCs, CD21-crePrPfl/- animals were lethally γ-
irradiated and given bone marrow from age- and sex-matched Cre negative littermates 
(termed Cre-ve →CD21-crePrPfl/-). Experimental control groups were also produced. 
These included, CD21-crePrPfl/- mice given bone marrow from Cre+ve littermates, 
(termed Cre+ve →CD21-crePrPfl/-), in which PrPC will be switched off in both FDCs 
and CD21+ B lymphocytes.  Also, PrPfl/- mice were given bone marrow from CD21-
cre PrPfl/- mice, (termed Cre+ve → PrPfl/-), in which PrPC is switched off on CD21+ B 
lymphocytes only.  The final control group was PrPWT/- mice given PrPWT/- bone 
marrow. The copy number of the Prnp gene has been shown to have a strong 
influence in scrapie incubation period, with PrPWT/- heterozygous mice having almost 
double the incubation time of PrPWT/WT homozygotes (Manson, Clarke et al. 1994b)  
Therefore, this control group was included due to the CD21-crePrPfl/- experimental 
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Figure 4.1 Spontaneous recombination of Prnpfl DNA in CD21-crePrPfl/fl mice 
DNA was extracted from a variety of tissues from CD21-crePrPfl/ fl mice and 
genotyped by PCR to determine in which tissues Prnpfl DNA was recombined.  
Tissues analysed included liver (1), kidney (2), heart (3), lung (4), spleen (5), ILN (6), 
MLN (7), brain (8), ear (9) and gut (10).  PCR results show a band of 167 bp for 
PrnpWT (c), a band of 210 bp for Prnpfl (a), and a band of 344 bp for Prnpfl(R) 
recombined DNA.  Heterozygous PrPfl/WT or PrP fl/- animals have bands at 167 bp and 
210 bp (b).  Homozygous PrPfl/fl animals with partial recombination of the Prnpfl 
DNA show bands at 210bp and 344 bp (d) whereas heterozygous PrPfl/WT or PrP fl/- 
animals with partial recombination of the Prnpfl DNA show all three bands (e). 
 
Tissues from the first animal assessed, CD21-crePrPfl/fl 1, showed partial 
recombination of Prnpfl DNA in the spleen and lymph nodes as expected, but also in 
the liver and kidney.  Tissues from an animal taken after subsequent rounds of 
breeding, CD21-crePrPfl/fl 2, showed full recombination of Prnpfl DNA in all tissues. 
This demonstrates that the Cr2 promoter has lost control of Cre-mediated 
recombination of Prnpfl DNA.  These animals are now PrP-/- as all Prnpfl DNA has 




















Bone marrow chimera status of experimental animal groups was confirmed by PCR 
analysis (Fig 4.2).  DNA was extracted from blood, tail and spleen and was genotyped 
for both Cre and Prnpfl with or without Cre-mediated recombination of the Prnpfl 
DNA.  This analysis confirmed that the host/ donor genotypes were as expected and 
also that Prnpfl DNA was only recombined in tissues where both the Cre transgene 
and CD21-expressing cells were present. 
 
4.3.3 Insertion and expression of transgenes and bone marrow reconstitution have no 
effect on lymphoid tissue michroarcitecture 
 
In addition to confirming that Cre-mediated recombination was restricted to CD21-
expressing cells and was occurring efficiently, it was also essential to ensure that there 
were no other changes to the lymphoid tissue that could mediate an effect on scrapie 
pathogenesis.  Spleens from all four groups of experimental mice were 
immunolabelled to detect B lymphocyte subsets, T lymphocytes, FDCs and dendritic 
cells and compared tissues from WT animals (Fig 4.3).  No differences could be seen 
in intensity or location of immunolabelling for each cell type between WT and 
experimental spleens. It can be concluded that neither expression of the transgenes 
nor irradiation and bone marrow reconstitution has any significant effect on the 
michroarchitecture of the lymphoid tissues.  Furthermore, spleen sections taken from 
CD21-crePrPfl/-, Cre-ve PrPfl/- and WT 129/Ola mice were immunolabelled using an 
anti-CD35 MAb to detect the FDC networks.  FDC networks in the spleen were 
manually counted and the area of FDC networks in the spleen was measured using 
ImageJ image analysis software (Inman, Rees et al. 2005).  This quantification 









                   
Cre 

























                










 Figure 4.2 Genotypes of CD21-crePrPfl/- animals used for characterisation and 
subsequent scrapie experiments 
DNA was extracted from blood (B), spleen (S), and tail (T) from 6 animals from each 
of the transgenic lines to be used in subsequent scrapie experiments. One example of 
genotype results for Cre-ve →CD21-crePrPfl/-, Cre+ve →CD21-crePrPfl/- and Cre+ve 
→PrPfl/- lines is shown on the above gels. 
 
a. The Cre transgene was present in the spleen and tail of CD21-crePrPfl/- mice but 
was only present in the blood if Cre+ve donor bone marrow had been given. PrPfl/- 
mice had no Cre transgene detected in tail DNA, however Cre was present in the 
spleen and blood due to Cre+ve bone marrow given. 
 
b. Tissues from all animals contained Prnpfl and Prnp- bands.  However, recombined 
Prnpfl(R) DNA was only detected in tissues where both the Cre transgene and CD21-








networks or differences in the number or area of FDC networks between transgenic 
mice and WT controls with P=0.221 and 0.091 respectively using a one-way ANOVA 
test (Fig 4.4). Taken together, these results show that insertion of the Cre transgene 
under the Cr2 promoter has no adverse effects on the number and size of the FDC 
networks, or the general michroarchitecture of the surrounding lymphoid tissue.   
 
4.3.4 PrPC immunolabelling is removed on Cre-expressing FDCs 
 
Spleens from all experimental and control lines were immunolabelled to detect PrPC 
expression to ensure that PrPC protein was specifically removed from the FDC 
network in animals that expressed the Cre transgene.  Within the lymphoid tissues, 
PrPC can be detected on FDCs and peripheral nerves using immunolabelling. 
Therefore, to determine if removal of PrPC was specific to the FDC network, spleen 
sections were fluorescently immunolabelled for PrPC, FDCs and peripheral nerves.  
Co-localisation of fluorescent labelling was then quantified using Image J software.  
Animals which expressed Cre showed removal of PrPC specifically on the FDC 
networks but not on the peripheral nerves (Fig 4.5).  Quantification of co-localised 
pixels showed that the co-localisation detected was significant co-localisation (P=5.4 
x 10-30 * and 6.5 x10-22**, Fig 4.6) and not background due to random association of 
pixels.  Animals with PrPC switched off on FDCs had statistically significantly lower 
levels of PrPC staining in comparison to non-Cre expressing spleens (P< 1.0 x 10-23 



























































Figure 4.3 Insertion and expression of the transgenes and irradiation and bone 
marrow reconstitution has no effect on the microarchitecture of peripheral 
lymphoid tissues 
Frozen spleen sections from all experimental transgenic mouse lines were 
immunolabelled for B lymphocyte subsets (CD45R and CD1d), T lymphocytes 
(CD3), FDCs (C4 and CD21/35), classical DCs (CD11c) and marginal zone cells 
(MADCAM-1 and CD1d).  Comparison of sections from transgenic animals with WT 
controls showed no differences in the number or location of cell subsets within the 
spleen.  Scale bar on flourescent images 100 μm.  Scale bar on light microscopy 
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Fig 4.4 Expression of transgenes has no effect on the number or area of FDC 
networks in the spleen 
Frozen spleen sections from WT, PrPfl/- and CD21-crePrPfl/- animals were 
immunolabelled for FDCs using an anti CD35 monoclonal antibody.  For each mouse 
line, 4 spleen sections 50 μm apart were immunolabelled and 4 images of 900.47μ2 
were taken per section. 
a.  FDC networks were manually counted for each image and the average number of 
FDC networks per image was calculated.  No significant difference was observed in 
the number of FDC networks per 900.47μm2 of spleen in transgenic animals in 
comparison to WT controls using a one-way anova (p=0.221) 
b.  The area of FDC networks per image was determined using ImageJ. This uses the 
total number of positive immunolabelled pixels per image to calculate a percentage 
area of a 900.47μm2 of spleen positive for FDC network immunolabelling. No 
significant difference was observed in the percentage area of FDC immunolabelling in 
transgenic spleens in comparison to WT controls using a one-way anova (p=0.091)     
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4.3.5 Insertion and expression of transgenes and irradiation and bone marrow 
reconstitution have no effect on the distance between FDC networks and peripheral 
nerves in the spleen 
 
Previous studies have shown that the distance between peripheral nerves and FDC 
networks can influence scrapie incubation period after peripheral inoculation (Glatzel, 
Heppner et al. 2001; Prinz, Heikenwalder et al. 2003).  Therefore immunolabelling 
was used to further characterise the microarchitecture of lymphoid tissues of 
transgenic mice by measuring the distance between peripheral nerves and FDCs in the 
spleen.  Frozen sections were immunolabelled for FDCs and peripheral nerves and 
LSM image browser software was used to measure the distance between them (Fig 
4.7). Comparison of the average distance between FDCs and the nearest peripheral 
nerve showed there was no statistically significant difference in the distance between 
FDCs and peripheral nerves between transgenic spleens in comparison to WT 
counterparts (P=0.765, Fig4.7). 
 
4.3.6 Insertion and expression of transgenes has no effect on immune complex 
trapping function of FDCs 
 
 
A major function of FDCs in the immune system is to trap and retain antigen-
containing immune complexes.  In scrapie infection, removal of complement 
components C3 or C1q can significantly delay incubation period, suggesting that 
complement-mediated binding of scrapie agent to FDC networks is one possible 
method of scrapie agent localisation to the follicle (Cardone and Pocchiari 2001; 
Klein, Kaeser et al. 2001; Mabbott, Bruce et al. 2001; Mabbott 2004; Sim, Kishore et 
al. 2007).  To ensure that FDCs in transgenic animals were not functionally 
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Fig 4.5 PrPC expression is removed specifically on FDC networks in animals 
which express Cre  
Immunolabelling of PrPC (blue) on FDC networks     (CD35/red) and peripheral  
nerves      (Tyrosine hydroxylase/green) in spleen sections from transgenic mouse 
lines. Animals were lethally γ-irradiated, received donor bone marrow 24 h later and 
were culled 100 days post reconstitution to allow replacement of all host-derived 
lymphocytes.  Spleen sections from 6 animals from each line were labelled and 
analysed.  CD21-crePrPfl/- animals which received Cre–ve (A) or Cre+ve (B) bone 
marrow had no PrPC labelling on their FDC networks however PrPC labelling was 
detected on the peripheral nerves. These data demonstrate that expression of PrPC has 
been removed specifically on the Cre-expressing FDCs.   
PrPfl/- animals which received Cre+ve  bone marrow (C) and PrPWT/- animals which 
received PrPWT/- bone marrow (D) show PrPC labelling on both FDC networks and 




       
 
 
                
 





















































Fig 4.6 Expressionof Cre in FDCs under the Cr2 promoter specifically removes 
PrPC immunolabelling on FDC networks 
Frozen spleen sections were immunolabelled for PrPC, FDC and peripheral nerves.  
For each mouse line, spleens were taken from 6 animals.  Two sections, 50μm apart, 
were immunolabelled for each spleen  and  4 images per section were taken.  This 
resulted in the analysis of 48 images for each mouse line using ImageJ image analysis 
software.  For each image the number of pixels of each colour were counted using the 
multiple colour analysis macro allowing values to be obtained for total number of red 
(FDC) blue (PrPC) and magenta (PrPC co-localised with FDC) pixels per image.  
These values allowed the calculation of the average percentage of FDC area co-
localised with PrPC.  In CD21-crePrPfl/- animals, which have Cre-expressing FDCs 
this value is almost 0 and is significantly lower than PrPfl/- or PrPWT/- animals which 
do not have Cre-expressing FDCs.  These data show that PrPC has been switched off 















   
 












          b.  Distance between peripheral nerves and FDCs in the spleen 
 






















Fig 4.7 Insertion and expression of the transgenes has no effect on the distance 
between peripheral nerves and FDCs in the spleen 
a.  Frozen spleen sections from transgenic and WT lines were immunolabelled for 
FDC networks (CD35/red) and peripheral nerves (Tyrosine hydroxylase/green). For 
each mouse line, spleens were taken from 6 animals.  Two sections, 50 μm apart, 
were immunolabelled for each spleen  and  4 images per section were taken.  This 
esulted in 48 images analysed for each mouse line. Scale bar 50 μm. 
b.  The distance between the FDC networks and peripheral nerves was measured 
using LSM image browser software (Zeiss). The average distance between nerves and 
FDCs was calculated for each mouse line.  Analysis using a one-way anova test 
determined there was no significant difference in the distance between the FDC 




impaired, immune complex trapping was assessed and compared with that of WT 
animals.  Transgenic and WT control lines were injected with pre-formed rabbit PAP 
immune complexes.  Animals were culled 24 hours later and spleens were harvested 
for analysis.  Frozen sections were stained for rabbit immunoglobulin (Ig) and co-
localisation of rabbit Ig on FDC networks was measured using ImageJ software as 
described previously.  There were no observed differences in levels of immune 
complex trapping by FDCs between transgenic animals and WT controls (P=0.085, 
Fig 4.8). Uninjected control animals showed no immunolabelling of rabbit Igs on the 
FDC networks.  These data show that insertion and expression of Cre under the Cr2 
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Figure 4.8 Insertion and expression of transgenes has no effect on immune 
complex trapping by FDCs 
Transgenic and WT mice were injected with preformed rabbit peroxidise-anti-
peroxidase (PAP) immune complexes (n=4).  Spleens were harvested 24 h later for 
analysis.  Uninjected controls for each line (n=2) were also collected. 
a. Frozen sections were immunolabelled for FDCs (CD35/green) and rabbit Ig (red) 
to detect co-localisation of PAP on FDC networks. Original magnification x 200. 
b. Images were analysed for co-localisation using an ImageJ macro described 
previously (Fig 4.6).  For each animal, two spleen sections 50 μm apart were 
immunolabelled and 5 images were taken per section.  A total of 40 images per mouse 
line for PAP-injected, and 20 images per mouse line for uninjected controls, were 
analysed for co-localisation.  There is no significant difference in the percentage area 
of FDC co-localised with PAP between WT and transgenic lines.  From this data, it 
can be concluded that insertion and expression of the transgenes has no functional 






The CD21-cre line was crossed with a PrPfl/fl line to create a model where PrPC could 
be switched off exclusively on FDCs.  In this chapter the CD21-crePrPfl line was 
extensively characterised to determine if it would be an efficient tool to study the role 
of FDCs after peripheral scrapie exposure.  The characterisation studies carried out on 
this line indicate that PrPC was switched off specifically on Cre-expressing FDCs and 
remained present on other non-Cre-expressing cells within the lymphoid tissue such 
as the nerves.  Furthermore, insertion and expression of the transgenes had no 
additional effects on the lymphoid tissue that could influence scrapie pathogenesis.   
 
The first breeding strategy used to create this line with homozygous PrPfl/fl resulted in 
the Cr2 promoter losing control of Cre expression and all floxed Prnp DNA within 
the animal was recombined, resulting in a PrP deficient animal.  As multiple 
generations of mice were produced containing both the Cre and the floxed Prnp 
transgenes, it is possible that Cre was expressed in the germline cells.  If this occurs 
and both the Cre and loxP transgenes are inherited from one parent, this can result in 
Cre being expressed in all tissues and complete recombination of the floxed DNA 
throughout the animal (Schmidt-Supprian and Rajewsky 2007).  To compensate for 
this, the CD21-cre line was crossed with a PrP-/- line and resulting CD21-crePrP-/- 
progeny were crossed in one generation with the PrPfl/fl line to create CD21-crePrPfl/- 
line.  By eliminating generations of mice which had both the Cre and loxP transgenes 
present, the problem of Cre-mediated DNA recombination in the entire animal was 
also eliminated.  Therefore the CD21-crePrPfl/- line was used in subsequent 
characterisation and scrapie infection experiments. 
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PrPC expression was successfully switched off in the FDCs of Cre-expressing 
animals.  PCR analysis of DNA extracted from spleens confirmed the presence of the 
Cre transgene and recombination of the Prnpfl transgenes.  Immunolabelling of spleen 
sections confirmed that PrPC was removed on FDCs but present on non-CD21 
expressing cells such as peripheral nerves, leaving little/no PrPC detectable by 
immunolabelling. This is in agreement with previous studies using the CD21-cre line, 
which measured 96% of floxed DNA was recombined in CD21-cre mouse line 
crosses (Victoratos, Lagnel et al. 2006).   
 
Characterisation of the lymphoid tissues of transgenic experimental lines was 
essential to ensure that any differences in scrapie pathogenesis were due to removal of 
PrPC on the FDC and not due to changes in the lymphoid tissues caused by the 
insertion of the transgenes.  Depletion of CD11c+ cells and B lymphocytes has been 
shown to delay the onset of peripherally acquired scrapie (Klein, Frigg et al. 1997; 
Raymond, Aucouturier et al. 2007).  Therefore, various cell subsets were 
immunolabelled on spleen sections from transgenic experimental and WT lines to 
determine if there were any differences in michroarchitecture caused by insertion and 
expression of the transgenes.  No observable difference could be seen in the number 
or location of B lymphocytes, T lymphocytes, dendritic cells or marginal zone cells in 
the spleen. 
 
The presence of mature FDC networks in the spleen is also essential for efficient 
scrapie pathogenesis and changes in the number or cellular location of FDCs can alter 
scrapie pathogenesis (Brown, Stewart et al. 1999; Mabbott, Williams et al. 2000a; 
Mabbott, McGovern et al. 2002; Mabbott, Young et al. 2003; Prinz, Heikenwalder et 
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al. 2003).  Analysis of FDC networks in the spleens of transgenic mice showed there 
were no differences in the number and area of FDC networks in comparison to WT 
controls. The function of the FDC networks in transgenic mice was also analysed by 
measuring their ability to trap pre-formed immune complexes.  No measureable 
differences in the level of immune complex trapping on FDCs of transgenic lines in 
comparison to WT controls was detected indicating that insertion and expression of 
the transgenes had no effect on FDC function. The distance between peripheral nerves 
and FDC networks can also influence scrapie incubation period (Glatzel, Heppner et 
al. 2001; Prinz, Heikenwalder et al. 2003).  This was measured in spleen sections 
from transgenic experimental lines and WT controls and no significant difference was 
measured in the distance between the FDC networks and nerves.   
 
Taken together, these data show that the insertion and expression of the transgenes in 
experimental mice has no effects on the microarchitecture of the spleen or the number 
or distribution of various cell subsets found within. These data confirm previous 
studies using the CD21-cre mice which did not report any toxic effects caused by the 
Cre transgene and showed no differences in FDC and B lymphocyte numbers or 
location in the spleen (Kraus, Alimzhanov et al. 2004; Victoratos, Lagnel et al. 2006; 
Schenten, Kracker et al. 2009).  Additionally, characterisation of the PrP-/-  line has 
shown no overt phenotype even though PrPC is ubiquitously expressed (Manson, 
Clarke et al. 1994a). 
 
Characterisation of the CD21-crePrPfl/- mouse line has shown that PrPC is efficiently 
removed in Cre-expressing FDCs but remains present on other cell types within the 
lymphoid tissues.  Furthermore, insertion and expression of the transgenes have no 
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additional effects on the cellular composition or structure of the lymphoid tissue. 
Therefore the CD21-crePrPfl/- mouse line is an effective model to study the role of 
FDCs after peripheral exposure to scrapie. This line will be used to determine if PrPC 
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After peripheral exposure to TSE agents, PrPSc and infectivity usually accumulates on 
FDCs in the lymphoid tissues.  Models used so far have not been able to definitively 
distinguish the role of the FDCs from that of all other stromal, lymphoid and neural 
cells found within the lymphoid tissue.  For this reason, it is possible that rather than 
actively replicating the scrapie agent, FDCs may simply accumulate the agent after 
replication on another cell type within the lymphoid tissue. Characterisation of the 
CD21-crePrPfl/- model (Chapter 4) confirmed that CD21-crePrPfl/- mice reconstituted 
with WT bone marrow switch off PrPC expression exclusively on FDCs.   These mice 
were inoculated ip with the ME7 scrapie agent to determine if FDCs simply acquire 
the TSE agent on their surface.   
 
After initial localisation of the scrapie agent to the FDC network, animals with Cre-
expressing, PrPC deficient FDCs were unable to replicate the scrapie agent in the 
lymphoid tissue when inoculatied ip with ME7 scrapie.  In the absence of replication, 
PrPSc was scavenged from the FDC network by TBMs and possibly degraded.  
Furthermore, animals with Cre-expressing, PrPC deficient FDCs inoculated ic with 
ME7 scrapie were susceptible to scrapie infection and had positive neuropathology 
and PrPSc deposition in their brains.  However, spleens from these animals remained 
free from PrPSc accumulation.  In conclusion, these data show that PrPC-expressing 
FDCs actively replicate the TSE agent in the periphery prior to neuroinvasion and do 








PrPC expression by FDCs is considered essential for effective scrapie pathogenesis 
after peripheral exposure.  Furthermore, heavy accumulations of TSE-agent-specific 
disease-associated PrPSc occur upon the FDC networks in lymphoid tissues of scrapie-
affected mice (McBride, Eikelenboom et al. 1992; Brown, Stewart et al. 1999; 
Jeffrey, McGovern et al. 2000).  Previous data suggest that FDCs have a role in 
replicating the scrapie agent within the lymphoid tissue, however as of yet, there has 
not been a suitable model which has been able to exclusively address this issue 
(Brown, Stewart et al. 1999; Montrasio 2000; Mabbott, Williams et al. 2000a; 
Mabbott, Mackay et al. 2000b; Mabbott, Young et al. 2003; Mohan, Bruce et al. 
2005).  As the main function of FDCs within the B lymphocyte follicles is to pick up 
and retain antigen-containing immune complexes on their surfaces, the possibility 
remains that FDCs are simply acquiring the scrapie agent after replication on another 
lymphoid, stromal or neural cell types within the lymphoid tissues.  Furthermore, 
FDCs have been shown to acquire expression of proteins that they themselves do not 
express, such as class II MHC, via exosomes (Gray, Kosco et al. 1991; Thery, 
Regnault et al. 1999; Denzer, van Eijk et al. 2000). 
 
To definitively determine the role of FDCs in scrapie pathogenesis, the CD21-cre 
mouse line was crossed with the Prnpfl mouse line to create a model in which PrPC 
expression was switched off exclusively on CD21-expressing cells. These animals 
were subsequently irradiated and reconstituted with non-Cre-expressing bone marrow 
to restrict the removal of PrPC expression exclusively to the FDC network.  
Characterisation of this compound transgenic model (Chapter 4) showed that PrPC 
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expression was efficiently and specifically removed only on the FDC networks of 
CD21-crePrPfl/- mice.  Furthermore, no adverse effects on the status or function of 
FDC networks, or in the general michroarcitecture of the lymphoid tissue were 
observed.  These data confirmed that the CD21-crePrPfl/- model would be a useful 
tool to determine the role of PrPC-expressing FDCs in scrapie pathogenesis and 
elucidate whether FDCs simply accumulate TSE agent on their surfaces after 
replication on another cell type. As host expression of PrPC is essential for TSE agent 
pathogenesis (Büeler, Aguzzi et al. 1993; Blattler, Brandner et al. 1997), if FDCs 
themselves actively replicate the TSE agent, then efficient pathogenesis of TSE agent 
in peripheral lymphoid tissues should not be possible when PrPC expression is 
removed exclusively on the FDC network.  If however FDCs simply acquire the TSE 
agents, then in the absence of PrPC expression, heavy accumulation of PrPSc would 
still be detected. 
 
CD21-crePrPfl/- mice were inoculated ip with ME7 scrapie and culled at 35 or 70 dpi.  
Further animals were also inoculated ic with ME7 scrapie to ensure that transgenic 
lines were susceptible to TSE infection.  Spleens were harvested and detection of 
PrPSc was used to assess the pathology of scrapie.  PrPSc has been shown to co-purify 
with TSE agent infectivity and is considered by many to be the sole component of the 
TSE infectious agent (Bolton, McKinley et al. 1982).  
 
Experiments demonstrated that in animals with PrP ablation specifically in FDCs, the 
scrapie agent, as detected by PrPSc immunolabelling, initially located to the FDC 
network in the follicle.  However at later time points PrPSc was found only within the 
TBMs.  This is in contrast to control animals which retained Prmp+/- FDCs, where 
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PrPSc located to the FDC network in the follicle and accumulation increased over time 
suggesting replication of the scrapie agent.  These data confirm that PrPC-expressing 
FDCs actively replicate the TSE agent.  When PrPC is ablated specifically on FDCs, 
no accumulation of PrPSc occurs on the FDC surface, demonstrating that FDCs do not 
acquire the scrapie agent after replication on another cell type.  Instead, TBMs in the 




5.3.1 Experimental design  
 
To determine the role of FDCs in TSE agent replication, the CD21-crePrPfl/- mouse 
line which has PrPC switched off specifically on FDCs was inoculated ip with ME7 
scrapie.  Animals were aged to 8 weeks, lethally γ-irradiated and given donor bone 
marrow 24 h later. To restrict the PrP ablation specifically to FDCs, CD21-crePrPfl/- 
mice were given bone marrow from Cre-negative littermates.  However other 
transgenic host/bone marrow combinations were also produced as control lines and 
these are summarised in Table 5.1.  Animals were used in subsequent experiments at 
100 d post bone-marrow reconstitution to allow for efficient replacement of host 
bone-marrow derived cells with donor counterparts.  Mice from each group were 
inoculated with 20 μl of a 1% (wt/vol) scrapie brain homogenate.  Animals were then 
culled at 35 and 70 days post-inoculation (dpi) and tissues were collected to assess the 
cellular sites of PrPSc accumulation in the spleen.  A summary of experimental design 
can be found in Figure 5.1.  
 
Cellular sites of PrPSc accumulation in the spleen were determined by 
immunolabelling of PrP.  Current antibodies used to detect PrP cannot distinguish 
between the normal cellular isoform of the prion protein, PrPC, and the scrapie-
associated, relatively PK-resistant isoform, PrPSc.  For this reason, the disease-specific 
PrP detected by immunohistochemistry in spleens of infected animals is termed PrPd.  
All immunohistochemistry was carried out using the rabbit anti-PrP polyclonal 
antibody (PAb) 1B3 and confirmed using the mouse anti-PrP monoclonal (MAb) 
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Host Genotype Donor Genotype PrPC switched off Nomenclature 
 
CD21-crePrPfl/- PrPfl/- FDCs only Cre-ve  → 
CD21-crePrPfl/- 
CD21-crePrPfl/- CD21-crePrPfl/- FDCs and B 
lymphocytes 
Cre+ve  → 
CD21-crePrPfl/- 
PrPfl/- CD21-crePrPfl/- B lymphocytes only Cre+ve  → PrPfl/- 
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or ic 
 

















Figure 5.1 Summary of experimental design  
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antibody 6H4. As both antibodies gave similar results, only immunohistochemistry 
images from 1B3 labelling are shown. 
 
 Treatment with PK digests the cellular PrPC leaving PK-resistant core of PrPSc intact 
(Manson, Clarke et al. 1994b).  PrPC and PrPSc can be distinguished on histological 
sections using the PET blot method.  This method uses PK treatment of tissue sections 
on nitrocellulose membrane prior to immunolabelling with anti-PrP antibodies, to 
destroy PrPC. Therefore any PrP detected by this method can be confirmed as the 
scrapie-associated PrPSc.  Detection of PrPd and PrPSc have been confirmed by many 
studies to be reliable markers of TSE disease and in most cases correlate closely with 
presence of TSE agent infectivity (Bolton, McKinley et al. 1982; McBride, 
Eikelenboom et al. 1992; Brown, Stewart et al. 1999; Mabbott, Mackay et al. 2000b; 
Mabbott, Young et al. 2003; Glaysher and Mabbott 2007; Raymond, Aucouturier et 
al. 2007; Brown, Wathne et al. 2009). 
 
5.3.2 Effect of FDC-restricted PrP ablation on TSE agent accumulation in the spleen 
at 35 days post-exposure  
 
Animals were culled at 35 dpi with the ME7 scrapie agent and spleens were harvested 
for analysis of the cellular sites of PrPSc accumulation.  In all spleens with Cre-
deficient, PrPC expressing FDCs, accumulation of the abnormal, disease-associated 
PrPd occurred in the germinal centres of the spleen (Figs 5.2).  This PrPd was located 
to the FDC network as shown by immunolabelling of serial sections for PrPd, FDCs 
and B lymphocytes (Fig 5.3).  However, as animals are only expressing half copy 
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Figure 5.2 PrPd immunolabelling in the spleen at 35 dpi with the ME7 scrapie 
agent 
Four animals from each experimental line were culled at 35 dpi with ME7 scrapie and 
spleens were immunolabelled to detect PrPd (using PAb 1B3, red). 
All spleens with Cre-deficient, PrPC-expressing FDCs (I-P) show PrPd 
immunolabelling at low levels on the FDC networks (   ) and tingible body 
macrophages (TBMs, *) in the follicles.  Spleens from some animals with Cre-
expressing, Prnp-/- FDCs (A-H) also show immunolabelling on the FDC network, 
however this is detected at a lower frequency with only 2/8 animals (C, H) with 
positive PrPd immunolabelling in the FDC networks.  Some of these animals instead 
show PrPd labelling located only within the TBMs of the follicle (A). Scale bar on 
main figure100 μm.  Scale bar on x 1000 images 20μm.  Sections counterstained with 
haematoxylin, blue. 
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Fig 5.3 Immunohistochemical analysis of PrP, FDC and B lymphocytes in spleens 
of mice taken at 35 dpi after exposure to the ME7 scrapie agent 
 
Serial sections from spleens were immunolabelled for PrP (PAb 1B3, red), FDCs and 
CD21+ B lymphocytes (MAb 7G6, red) and B lymphocytes (MAb CD45R, red) to 
determine if PrPd detected co-localised to the FDC network. One animal is shown 
from each experimental transgenic line. 
 
In spleens with Cre-deficient, PrPC-expressing FDCs (G-L), PrPd (   ) is localised to 
the FDC networks (      ) as shown in serial sections.  PrPd location in spleens with 
Cre-expressing, PrPC deficient FDCs (A-F) was variable at 35 dpi.  PrPd was present 
on the FDCs of some follicles but in others was found exclusively within TBMs (*) 
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Figure 5.4 PET blot analysis of PrPSc accumulation in spleens taken at 35 dpi 
with the ME7 scrapie agent 
Paraffin-embedded sections on nitrocellulose membrane were treated with PK to 
remove any native PrPC, then immunolabelled (PAb 1B3, blue/black) to detect any 
remaining PrPSc. One representative example from each transgenic line is shown. A, 
Cre-ve→CD21-crePrPfl/-; B, Cre+ve→CD21-crePrPfl/-; C, Cre+ve→PrPfl/-; D, PrPfl/-
→PrPfl/-. Scale bar 500 μm. 
 
Due to the low levels of PrPd detected in infected tissue at this stage by 
immunohistochemistry (Fig 5.2), PrPSc is not readily detected after PK treatment in 
any of the transgenic experimental lines.  Therefore it is not confirmed that the PrPd 






number levels of Prnp and were culled early in the incubation period, the magnitude 
of PrPd accumulation was insufficient to be confirmed as PrPSc by the PET blot 
method (Fig 5.4).  Therefore it could not be confirmed that PrPd detected by 
immunohistochemistry was indeed scrapie-associated PrPSc. 
 
In animals with Cre-expressing, PrPC-deficient FDCs, spleen sections taken at 35 dpi 
showed variable deposition of PrPd in the follicles.  Only 3 out of 8 animals had 
detectable PrPd by immunohistochemistry (Figs 5.2).  This deposition was located to 
the FDCs in some animals, but only found within TBMs within the follicle in others 
(Fig 5.3).  As with animals with PrPC-expressing FDCs, levels of PrPd accumulation 
were too low to be confirmed by the PET blot method as PrPSc (Fig 5.4). 
 
 
5.3.3 Effect of FDC-restricted PrP-ablation in TSE agent accumulation in the spleen 
70 days post-exposure 
 
Animals were culled at 70 dpi with ME7 scrapie and spleens were harvested for 
analysis of the cellular sites of PrPSc accumulation.  In all spleens with Cre-deficient, 
PrPC-expressing FDCs, accumulation of the abnormal, disease-associated PrPd 
occurred in the germinal centres of the spleen at a greater intensity than that seen in 
spleens from animals culled at 35 dpi (Figs 5.5).  This PrPd was located on the FDC 
network as shown by immunolabelling of serial sections for FDCs and B lymphocytes 
(Fig 5.6).  Furthermore, the PrPd accumulation detected upon the FDCs was 
confirmed to be PK-resistant, scrapie agent-associated PrPSc using the PET blot 
method (Fig 5.7).  From these data it can be concluded that high levels of the scrapie  
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Figure 5.5 PrPd immunolabelling in the spleen at 70 dpi with the ME7 scrapie 
agent 
Four animals from each experimental line were culled at 70 dpi with ME7 scrapie and 
spleens were immunolabelled to detect PrPd (PAb 1B3, red) 
All spleens with Cre-deficient, PrPC-expressing FDCs (I-P) show PrPd 
immunolabelling on the FDC networks (   ) within the follicles at an increased level 
than that seen in spleens from animals culled at 35 dpi.  Spleens from animals with 
Cre-expressing, PrPC deficient FDCs (A-H) no longer show any labelling on the FDC 
networks as was detected in spleens from D35 animals. Instead, PrPd is detected only 
within TBMs (*) in the follicle. This suggests the scrapie agent cannot replicate on 
PrPC deficient FDCs and any PrPSc from innocula has been cleared from FDC 
networks and sequestered by TBMs in the follicle.  Scale bar on main figure100 μm.  
Scale bar on x 1000 magnification images 20μm.  Sections counterstained with 
haematoxylin, blue. 
 
















   
















   









































Fig 5.6 Immunohistochemical analysis of PrP, FDC and B lymphocytes in spleens 
of mice taken at 70 dpi with the ME7 scrapie agent 
 
Serial sections from spleens were immunolabelled for PrP (PAb 1B3, red), FDCs and 
CD21+ B lymphocytes (MAb 7G6, red) and B lymphocytes (MAb CD45R, red) to 
determine whether the PrPd detected was co-localised to the FDC network. One 
animal is shown from each experimental transgenic line. 
 
In spleens with Cre-deficient, PrPC-expressing FDCs (G-L), PrPd (   ) is localised to 
the FDC networks (      ) as shown in serial sections.  PrPd location in spleens with 
Cre-expressing, PrPC deficient FDCs (A-F) was found exclusively within TBMs (*) 
and didn’t co-localise with FDC networks in the follicle. Scale bar 100 μm.  Sections 
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Figure 5.7 PET blot analysis of PrPSc accumulation in spleens taken at 70 dpi 
with the ME7 scrapie agent 
Paraffin-embedded sections on nitrocellulose membrane were treated with PK to 
remove any native PrPC, then immunolabelled (PAb 1B3, blue/black) to detect any 
remaining PrPSc. One representative example from each transgenic line is shown A, 
Cre-ve→ CD21-crePrPfl/-; B, Cre+ve→ CD21-crePrPfl/-; C, Cre+ve→ PrPfl/- ; D, PrPfl/- 
→ PrPfl/-.  Scale bar 500 μm 
 
In spleens with Cre-deficient, PrPC-expressing FDCs (C and D), some PrP labelling  
(   ) can be detected in the follicles after treatment with PK and can therefore be 
confirmed as the disease-associated PrPSc.  In spleens with Cre-expressing, PrPC-
deficient FDCs (A and B), immunohistochemistry had shown PrPd was present only 
within the TBMs (Fig 5.5).  At the low levels of PrPd observed within the TBMs, 
PrPd is not readily detected after PK treatments.  Therefore it is not confirmed that 



















agent are able to accumulate on PrPC-expressing FDCs as expected.  In addition, as no 
significant differences are seen between levels of PrPSc in Cre+ve→ PrPfl/- spleens and 
PrPWT/-→ PrPWT/- spleens, it can be concluded that switching off PrPC specifically on 
CD21+ B lymphocytes in Cre+ve→ PrPfl/- mice has no detectable impact on TSE agent 
accumulation upon the FDCs. 
 
In animals with Cre-expressing, PrPC deficient FDCs, spleen sections at 70 dpi no 
longer showed deposition of PrPd on the FDC network. Instead if PrPd was detected 
at all, it was only found within TBMs (Figs 5.5).   Indeed, immunolabelling of serial 
sections for FDCs and B lymphocytes confirmed that the PrPd immunolabelling did 
not co-localise with FDC networks (Fig 5.6).  The, levels of PrPd observed within the 
TBMs were too low to be confirmed by the PET blot method as PrPSc (Fig 5.7).  
From these data it can be concluded that PrPC-expressing FDCs are essential for the 
scrapie agent to replicate within the lymphoid tissues.  Without active replication of 
the agent by PrPC-expressing FDCs, the scrapie agent appeared to be scavenged by 
TBMs in the follicle and possibly degraded.  This suggests that PrPC-expressing 
FDCs actively replicate the TSE agent and do not simply acquire it from other PrPC-
expressing cells present in the lymphoid tissue. 
 
5.3.4 FDC-restricted PrPC ablation has no effect on TSE disease when infection is 
established directly in the CNS 
 
Some transgenic animals with Cre-expressing, PrPC deficient FDCs were inoculated 
with the ME7 scrapie agent directly into the brain by ic injection to determine whether 
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Fig 5.8 Neuropathology within the brains of ic injected, clinically scrapie-affected 
mice             
Serial brain sections were immunolabelled to compare the characteristic 
neuropathological hallmarks of TSE disease: spongiform change (vacuolation, H+E), 
deposition of the abnormal disease associated PrPSc (PAb 6H4, brown) and 
proliferation and activation of astrocytes (GFAP+ cells, red) and microglia (IBA-1+ 
cells, red) within the brain. 
 
The levels of vacuolation, deposition of PrPSc and accumulation of activated 
astrocytes and microglia were slightly lower in the brains of transgenic animals in 
comparison to WT controls. However all characteristic hallmarks of TSE 
neuropathology are present. 
 
These data confirm that transgenic animals are equally susceptible to TSE disease as 
WT counterparts.  Therefore, any differences in TSE pathogenesis observed within 
the peripheral lymphoid tissues are due to specific removal of PrPC expression on the 
FDCs and not a general resistance to TSE disease.  Scale bars 500 μm. Sections 
counterstained with haematoxylin.
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Figure 5.9 Mean duration of incubation periods of clinically-scrapie-affected 
mice inoculated ic with the ME7 scrapie agent 
Incubation period of disease in transgenic and WT control lines after ic inoculation 
with the ME7 scrapie agent.  Each bar represents the mean +/- the standard error of 
the mean for groups of 3-5 mice. 
129/Ola and C57BL/6x129/Ola WT mouse lines which are Prnp+/+ have incubation 
periods of approximately 160 d after ic inoculation with the ME7 scrapie agent. 
Transgenic CD21-crePrPfl/- lines have an incubation period of around 280 d.  This is 
in line with the disease incubation observed in129/Ola Prnp+/- mice which also 





mice were also inoculated ic as controls.  Following infection, both WT and 
transgenic animals developed clinical TSE disease with positive spongiform 
pathology in the brain.  The classical hallmarks of TSE infection in the brain are 
deposition of disease-associated PrPSc, gliosis and spongiform pathology with 
vacuolation. Immunolabelling confirmed PrPd, microglia (IBA-1+ cells) and activated 
astrocytes (GFAP+ cells) were all present in the brains of WT and transgenic animals.  
These data confirm that CD21-crePrPfl/- transgenic mice were fully susceptible to 
TSE disease when injected directly into the brain (Fig 5.8).  However the 
neuropathology in the brains of transgenic animals appeared to be at lower than that 
found in WT controls, possibly due to the transgenic mice only expressing half copy 
number levels of Prnp or due to mouse strain differences.  Transgenic CD21-crePrPfl/- 
animals all succumbed to the clinical signs of scrapie around 280 days post-ic 
inoculation with the ME7 scrapie agent (Fig 5.9).  This is in line with previous 
transmissions of the ME7 scrapie agent into 129/Ola Prnp+/- mice undertaken at this 
instititute, which also express half copy number expression levels of Prnp (Manson, 
Clarke et al. 1994b). 
 
 These data demonstrate that the transgenic lines used are equally susceptible as WT 
mice to the ME7 scrapie agent when infection was established directly in the brain by 
ic injection. Furthermore, insertion and expression of the Cre and Prnpfl transgenes 





5.3.5 No PrPSc accumulation upon FDCs in the spleens of clinically-scrapie-affected 
mice with FDC-restricted PrPC ablation  
 
Following exposure to the ME7 scrapie agent, high levels of PrPSc are maintained on 
FDCs for the duration of the incubation period; even after ic exposure (Brown, 
Stewart et al. 1999).  The spleens from the clinically-scrapie-affected, ic injected mice 
were also assessed to determine the cellular sites of PrPSc accumulation.  As 
anticipated, spleens from PrPC-expressing WT animals showed heavy accumulation of 
PrPd in the follicles as determined by immunolabelling (Fig 5.11).  This deposition 
was confirmed to be PrPSc by the PET blot method (Fig 5.12).  However, in spleens 
with Cre-expressing, PrPC deficient FDCs, little to no PrPd could be detected. Where 
PrPd was detected it appeared to be mostly associated with TBMs rather than the FDC 
networks (Fig 5.11).  Furthermore, this pattern of immunolabelling could not be 
confirmed as PrPSc by PET blots (Fig 5.12). This suggests that although animals with 
Cre-expressing, PrPC deficient FDCs are susceptible to ME7 infection in the CNS, 
animals with terminal clinical disease are still unable to replicate the TSE agent in the 
periphery when FDCs do not express PrPC. This confirms that even at clinical disease 
without PrPC-expressing FDCs, the scrapie agent is unable to accumulate upon FDCs 
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Figure 5.11 PrPd immunolabelling in the spleens of clinically-scrapie-affected 
mice ic inoculated with the ME7 scrapie agent 
Animals were inoculated ic with ME7 scrapie and left to develop terminal disease.  
Spleens were immunolabelled to detect PrPd (PAb 1B3, red). 
Spleens from WT animals with Cre-deficient, PrPC-expressing FDCs (A-D) show 
intense PrPd immunolabelling on the FDC networks (   ) within the B lymphocyte 
follicles.  In contrast, spleens from transgenic animals with Cre-expressing, PrPC 
deficient FDCs (E-K) show no PrPd labelling on the FDC networks. Instead, the only 
PrPd detected is found within TBMs (*) in the follicle. This suggests the scrapie 
agent is unable to replicate on PrPC deficient FDCs even when animal has clinical 
TSE disease.  Scale bar 100 μm.  Sections counterstained with haematoxylin,blue. 
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Figure 5.12 PET blots analysis of PrPSc accumulation in spleens from clinically-
scrapie-affected mice ic inoculated with the ME7 scrapie agent 
Paraffin-embedded sections on  nitrocellulose membrane were treated with PK to 
remove any native PrPC, then immunolabelled (PAb, 1B3, blue/black) to detect any 
remaining PrPSc. Labelling in ic injected transgenic animals B, Cre-ve→ CD21-
crePrPfl/-; C, Cre+ve→ CD21-crePrPfl/- was compared with that of A, 129/Ola WT 
animals. Scale bar 500 μm 
 
In WT spleens with Cre-deficient, PrPC-expressing FDCs (A), intense PrPSc labelling 
(   ) can be confirmed in the B lymphocyte.  However, in transgenic spleens with 
Cre-expressing, PrPC deficient FDCs (B and C), immunohistochemistry had shown 
PrPd was present only within the TBMs (Fig 5.10).  This pattern of immunolabelling 
is not readily detected after PK treatment and therefore could not be confirmed to be 























The CD21-crePrPfl/- mouse line, with irradiation and reconstitution with non-Cre-
expressing bone marrow, was previously shown to allow the removal of PrPC 
specifically on FDCs with no other adverse effects on the lymphoid tissues (Chapter 
4).  In this chapter the CD21-crePrPfl/- mouse line was injected ip with the ME7 
scrapie agent to determine if PrPC-expressing FDCs simply acquire the scrapie agent 
after replication on another cell type within the lymphoid tissue.  As host expression 
of PrPC is essential for TSE agent pathogenesis (Büeler, Aguzzi et al. 1993; Blattler, 
Brandner et al. 1997), if FDCs themselves actively replicate the TSE agent, then PrPSc 
accumulation should not be possible when PrPC expression is removed exclusively on 
the FDC network.  In contrast, if FDCs only acquire TSE agents, high levels of PrPSc 
will accumulate upon the FDC, even in the absence of PrPC expression. 
 
Scrapie agent accumulation in lymphoid tissues was determined by immunolabelling 
for PrPd and PrPSc.  Previous studies have shown that PrPSc co-purifies with infectivity 
in tissues from scrapie-affected animals and has been confirmed in many studies to be 
a reliable marker of TSE disease in the lymphoid tissue (Bolton, McKinley et al. 
1982; McBride, Eikelenboom et al. 1992; Brown, Stewart et al. 1999; Mabbott, 
Mackay et al. 2000b; Mabbott, Young et al. 2003; Glaysher and Mabbott 2007; 
Raymond, Aucouturier et al. 2007; Brown, Wathne et al. 2009).  Abnormal, 
pathological accumulations of PrP detected by immunohistochemistry were termed 
PrPd, as the antibodies used cannot distinguish between PrPC and PrPSc.  Any PrPd 
present was subsequently verified to be PrPSc if immunolabelling was still detected 
after PK treatment using the PET blot method (Section 2.4.3).  Previous studies have 
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shown that PrPSc and infectivity accumulates in the lymphoid tissues long before 
detection in the CNS and deposition on the FDC network can be seen easily at 4 
weeks post peripheral inoculation (Brown, Stewart et al. 1999).  For this reason, 
animals were culled at 35 and 70 dpi to assess the early pathogenesis of the ME7 
scrapie agent in transgenic and control lines.  However, as animals in this study are 
expressing only half copy number levels of Prnp, less deposition of PrPSc would be 
expected on the FDC networks than seen in equivalent studies using Prnp+/+ animals. 
 
Animals with Cre-deficient, PrPC-expressing FDCs had detectable PrPd in the spleen 
at 35 dpi and this accumulation intensified by 70 dpi suggesting active replication of 
the scrapie agent upon the PrPC-expressing FDCs.  This is in agreement with previous 
studies which suggested that PrPC-expressing FDCs are essential for replicating the 
scrapie agent (McBride, Eikelenboom et al. 1992; Brown, Stewart et al. 1999; 
Mabbott, Mackay et al. 2000b; Mabbott, McGovern et al. 2002; Mabbott, Young et al. 
2003; Glaysher and Mabbott 2007; Raymond, Aucouturier et al. 2007; Brown, 
Wathne et al. 2009).  However in animals with Cre-expressing, PrPC deficient FDCs, 
deposition was only seen on occasional FDC networks at 35 dpi.  By 70 dpi PrPd 
could no longer be found on the FDC networks and is instead located within TBMs in 
the follicle.  These data suggest that the scrapie agent initially locates to the FDCs 
network independently of PrPC expression on the FDCs.  Previous data indicates that 
the scrapie agent is opsonised by complement components and is trapped on the FDC 
network as an immune complex bound by complement and Fc receptors (Klein, 
Kaeser et al. 2001; Mabbott, Bruce et al. 2001; Zabel, Heikenwalder et al. 2007).  
With no PrPC present on the FDCs, data in this chapter shows that the scrapie agent is 
unable to replicate and is cleared from the FDC network by TBMs in the surrounding 
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follicle.  Previous studies have shown that TBMs are capable of taking up immune-
complex coated portions of FDC membrane, also known as iccosomes, therefore this 
is a possible mechanism by which TBMs remove the scrapie agent from the FDC 
surface (Szakal and Tew 1992; Sandberg, Al-Doujaily et al. 2011).  As Cre-
expressing, PrPC deficient FDCs have no deposition of PrPSc on their surface, it can be 
concluded that FDCs do not accumulate the TSE agent from the other cells in the 
lymphoid tissue, such as neurones, stromal cells and lymphocytes which retain PrPC 
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The CD21-cre mouse line has been used to switch off PrPC expression specifically on 
FDCs and subsequently used to show that PrPC expressing FDCs are required for 
replication of the scrapie agent in the lymphoid tissues (Chapter 4 and 5).  To 
complement this model, the CD21-cre mouse line was subsequently crossed with a 
line which contains a floxed β-geo stop cassette inserted before the coding region of 
PrPC. This CD21-crePrPstop/- line allows PrPC expression to be switched on under 
control of the Cr2 promoter.  In the absence of Cre expression, the floxed stop 
cassette prevents transcription of the open reading frame of the Prnp gene. However 
in CD21-expressing cells, Cre-mediated recombination removes the stop cassette and 
PrPC expression is switched on. Irradiation and reconstitution of CD21-crePrPstop/- 
mice with non-Cre-expressing bone marrow allows PrPC expression to be switched on 
exclusively on CD21-expressing FDCs.  CD21-crePrPstop/- mice were fully 
characterised to determine within which cells PrPC was switched on and to ensure that 
the transgenes had no additional effects on lymphoid tissue microarchitecture that 
could have an impact on scrapie pathogenesis.  Characterisation of the CD21-
crePrPstop/- mouse demonstrated that PrPC was efficiently and exclusively expressed 
on FDCs under control of the Cr2 promoter.  Furthermore, insertion and expression of 
the transgenes had no adverse effects on the microarchitecture of the lymphoid tissue. 
These data suggest that the CD21-crePrPstop/- mouse will be a useful model to 
determine if PrPC expression exclusively on FDCs is sufficient to support replication 









Previous work in this thesis has shown that if PrPC expression is removed specifically 
on the FDCs, the scrapie agent is unable to replicate in the spleen and accumulate on 
FDC surface (Chapter 5).  In this chapter, a transgenic mouse line was created to 
allow PrPC expression to be switched on exclusively on the FDC network, which 
would subsequently be used in Chapter 7 to determine if PrPC expression on FDCs 
alone was sufficient to allow scrapie agent replication in the spleen. 
 
The coding region for PrPC is contained within exon 3 of the Prnp gene (Chapter 1, 
Fig 1.1).  In PrPstop/- mice, the coding region of Prnp is preceded by a β-geo stop 
cassette flanked by loxP sites (Tuzi, Clarke et al. 2004). The PrPstop/- mouse line was 
crossed with the CD21-cre mouse to allow PrPC to be switched on under control of 
the Cr2 promoter (Fig 2.3).  Based on data from the CD21-creROSA26 and CD21-
crePrPfl/- lines (Chapter 3 and 4, respectively) the CD21-crePrPstop/- line, together with 
lethal γ-irradiation and reconstitution with non-Cre-expressing bone marrow, should 
restrict PrPC expression exclusively to FDCs.  In this chapter, the CD21-crePrPstop/- 
line was characterised to determine if PrPC was successfully switched on specifically 
on the FDC networks and also that insertion of the transgenes had no additional 
effects on the lymphoid tissue.  Analysis of the CD21-crePrPstop/- line confirmed that 
PrPC was efficiently expressed on Cre-expressing FDCs.  Furthermore, no PrPC 
expression was detected on non-CD21-expressing cells in the lymphoid tissues such 
as the nerves.  In addition, there were no differences in the michroarchitecture of the 
lymphoid component of the spleen which could have potentially impacted on scrapie 
pathogenesis.  From these data, it can be concluded that the CD21-cre PrPfl line will 
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be a useful tool to study scrapie pathogenesis when PrPC expression has been 




6.3.1 Production of CD21-crePrPstop/- mouse line  
 
The CD21-crePrP-/- mouse line, which was created during previous work to make the 
CD21-crePrPfloxed/- mouse line (Section 2.1.3 and 4.3.2), was crossed with PrPstop/- line 
to create the CD21-cre PrPstop/- mice.  The PrPstop/- line contains a floxed stop cassette 
inserted into the Prnp gene prior to exon 3 which contains the ORF (Tuzi, Clarke et 
al. 2004).  In the absence of Cre, cells in this animal cannot express PrPC due to the 
presence of the stop cassette before the protein coding sequence in exon 3.  However 
in cells which express CD21, Cre recombinase is expressed, the stop cassette is 
removed and PrPC expression is switched on. The Prnp stop allele is lethal at 
homozygosity (Tuzi, Clarke et al. 2004), therefore, no attempts were made to create a 
homozygous CD21-crePrPstop/stop mouse line. 
 
To restrict PrPC expression exclusively to FDCs, CD21-crePrPstop/- animals were 
lethally γ-irradiated and given bone marrow from age- and sex-matched Cre negative 
littermates (termed Cre-ve →CD21-crePrPstop/-). Experimental control groups were 
also produced as in the CD21-crePrPfloxed/- experimental lines. Firstly, CD21-
crePrPstop/- mice given bone marrow from Cre+ve littermates, (termed Cre+ve →CD21-
crePrPstop/- mice), in which PrPC will be switched off in both FDCs and CD21+ B 
lymphocytes.  Also, PrPfl/- mice were given bone marrow from CD21-cre PrPstop/- 
mice, (termed Cre+ve → PrPstop/-), in which PrPC expression is switched on in CD21+ B 
lymphocytes only.  The final control group was PrPWT/- mice given PrPWT/- bone 
marrow. The copy number of the Prnp gene has been shown to have a strong 
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influence in scrapie incubation period, with PrPWT/- heterozygous mice having almost 
double the incubation time of PrPWT/WT homozygotes (Tew and Mandel 1979).  
Therefore, this control group was included due to the CD21-crePrPfl/- experimental 
line having half copy number levels of PrPC. 
 
Bone marrow chimera status of experimental animal groups was confirmed by PCR 
analysis (Fig 6.1).  DNA was extracted from blood, tail and spleen and was genotyped 
for both expression of Cre and Prnpstop with and without Cre-mediated recombination 
of the Prnpstop DNA.  This analysis confirmed that the host/ donor genotypes were as 
expected and also that recombination of the Prnpstop DNA only occurred in tissues 
which contained both Cre expression and CD21-expressing cells. 
 
6.3.2 Insertion and expression of transgenes and bone marrow reconstitution have no 
effect on lymphoid tissue michroarcitecture 
 
In addition to confirming that Cre-mediated recombination was restricted to CD21-
expressing cells and was occurring efficiently, it was also essential to ensure that there 
were no other changes to the lymphoid tissue that could mediate an effect on scrapie 
pathogenesis.  Spleens from all four groups of experimental mice were 
immunolabelled to detect B lymphocyte subsets, T lymphocytes, FDCs and classical 
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Figure 6.1 Genotypes of CD21-crePrPstop/- animals used for characterisation and 
subsequent scrapie experiments 
DNA was extracted from blood (B), spleen (S), and tail (T) from 6 animals from each 
of the transgenic lines to be used in subsequent scrapie experiments. One example of 
genotype results for Cre+ve →CD21-crePrPstop/-, Cre-ve →CD21-crePrPstop/- and Cre+ve 
→PrPstop/- lines is shown on the above gel. 
 
a. The Cre transgene was present in the spleen and tail of CD21-crePrPstop/- mice but 
was only present in the blood if Cre+ve donor bone marrow had been given. PrPstop/- 
mice had no Cre transgene detected in tail DNA, however Cre was present in the 
spleen and blood due to Cre+ve bone marrow given. 
 
b. Tissues from all animals are heterozygous for Prnpstop/- however, recombination of 
the Prnpstop DNA (Prnpstop(R)) was only present in tissues that contain both the Cre 
transgene and CD21-expressing cells. Control DNA was from PrnpWT (a), Prnpstop/- 









        
  






















































Figure 6.2 Insertion and expression of the transgenes and irradiation and bone 
marrow reconstitution has no effect on the microarchitecture of peripheral 
lymphoid tissues as determined by immunolabelling 
Frozen spleen sections from all experimental transgenic mouse lines were 
immunolabelled for B lymphocyte subsets (CD45R andCD1d), T lymphocytes (CD3), 
FDC (C4, red and CD21/35, red), DCs (CD11c) and marginal zone cells (MADCAM-
1).  Comparison of sections from transgenic animals with WT controls showed no 
differences in the number or location of cell subsets within the spleen.  Scale bars on 
fluorescent images 100 μm. Scale bars on light microscopy images 500 μm and 
sections counterstained with haematoxylin, blue. 
145 
No differences could be seen in intensity or location of immunolabelling for each cell 
type between WT and experimental spleens. It can be concluded that neither 
expression of the transgenes nor irradiation and bone marrow reconstitution has any 
significant effect on the michroarchitecture of the lymphoid tissue.   
 
6.3.3 PrPC immunolabelling is present on Cre-expressing FDCs 
 
Spleens from all experimental and control lines were immunolabelled for PrPC 
expression to determine within which cells PrPC protein expression was switched on.  
Within the lymphoid tissues, PrPC can be detected on FDCs and peripheral nerves 
using immunolabelling. Therefore, to determine if PrPC expression was switched on 
specifically on the FDC network, spleen sections were fluorescently immunolabelled 
for PrPC, FDCs via CD35 expression and tyrosine hydroxylase (TH) expressing 
peripheral nerves.  Co-localisation of fluorescent labelling was then quantified using 
ImageJ image analysis software.  Animals which expressed Cre showed PrPC 
immunolabelling present on the FDC networks but this was absent on the Cre-
deficient peripheral nerves (Fig 6.3). Quantification of co-localised pixels showed that 
the co-localisation detected was true co-localisation and not background due to 
random association of pixels (p=1.2 x 10-26*; 9.1 x10-25** and 1.3 x 10-23***, Fig 
6.4).  Animals with PrPC expression switched on specifically on FDCs had 
statistically significantly higher levels of PrPC staining in comparison to non-Cre 









                
               
C D 
A B 
                
 
Fig 6.3 PrPC is switched on specifically on FDC networks of animals which 
express Cre  
Immunolabelling of PrPC (blue) on FDC networks     (CD35/red) and peripheral 
nerves      (TH/green) in spleen sections from transgenic mouse lines. Animals were 
lethally γ-irradiated, received donor bone marrow 24 h later and were culled 100 days 
post reconstitution to allow replacement of all host-derived lymphocytes.  Spleen 
sections from 6 animals from each line were immunolabelled and analysed.  CD21-
crePrPstop/- animals which received Cre–ve (A) or Cre+ve (B) bone marrow had 
detectable PrPC labelling on the FDC networks however PrPC labelling was not 
present on the peripheral nerves. This demonstrates that expression of PrPC has been 
switched on specifically on the Cre-expressing FDCs.   
PrPstop/- animals which received Cre+ve bone marrow (C) showed no PrPC 
immunolabelling on FDCs or nerves.  B lymphocyte expression of PrPC is not 
detectable by immunolabelling.  PrPWT/- animals which received PrPWT/- bone marrow 
(D) show PrPC labelling on both FDC networks and peripheral nerves. These data 
demonstrate that PrPC has been switched on specifically on the FDCs of animals 
which express Cre under the Cr2 promoter.  Scale bar 100 μm.  
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Fig 6.4 Expression of Cre in FDCs under the CD21 promoter removes PrPC 
immunolabelling on FDC networks 
Frozen spleen sections were immunolabelled for PrPC, FDC and peripheral nerves.  
For each mouse line, spleens were taken from 6 animals.  Two sections, 50 μm apart, 
were immunolabelled for each spleen  and  4 images per section were taken.  This 
resulted in the analysis of 48 images for each mouse line using ImageJ image analysis 
software.  For each image the number of pixels of each colour were counted using the 
multiple colour analysis macro allowing values to be obtained for total number of red 
(FDC) blue (PrPC) and magenta (PrPC co-localised with FDC) pixels per image.  
These values allowed the calculation of the average percentage of FDC area co-
localised with PrPC.  In CD21-crePrPstop/- animals and PrPWT/- animals, which have 
Cre-expressing FDCs this value is significantly higher than PrPstop/- animals which do 
not have Cre-expressing FDCs.  These data show that PrPC has been switched on 











6.3.4 Insertion and expression of transgenes and irradiation and bone marrow 
reconstitution have no effect on the distance between FDC networks and peripheral 
nerves in the spleen 
 
Previous studies have shown that the distance between peripheral nerves and FDC 
networks can influence scrapie incubation period after peripheral inoculation (Glatzel, 
Heppner et al. 2001; Prinz, Heikenwalder et al. 2003).  Therefore immunolabelling 
was used to further characterise the microarchitecture of lymphoid tissues of 
transgenic mice by measuring the distance between peripheral nerves and FDCs in the 
spleen.  Frozen sections were immunolabelled for FDCs and peripheral nerves and 
LSM image browser software was used to measure the distance between them (Fig 
6.5). Comparison of the average distance between FDCs and the nearest peripheral 
nerve showed there was no statistically significant difference in the distance between 
FDCs and peripheral nerves between transgenic spleens in comparison to WT 












           
   
 




          
 
           
                     Cre-ve → 
CD21-cre 
PrPstop/- 































Fig 6.5 Insertion and expression of the transgenes has no effect on the distance 
between peripheral nerves and FDCs in the spleen 
a.  Frozen spleen sections from transgenic and WT lines were immunolabelled for 
FDC networks (CD35/red) and peripheral nerves (TH/green). For each mouse line, 
spleens were taken from 6 animals.  Two sections, 50 μm apart, were immunolabelled 
for each spleen  and  4 images per section were taken.  48 images were analysed for 
each mouse line. Scale bar 50 μm. 
b.  The distance between the FDC networks and peripheral nerves was measured 
using LSM image browser software (Zeiss). The average distance between nerves and 
FDCs was calculated for each mouse line.  Analysis using a one-way anova test 
determined there was no significant difference in the distance between the FDC 








The CD21-cre line was crossed with a PrPstop/- line to create a model where PrPC 
expression could be switched on exclusively on FDCs.  In this chapter the CD21-
crePrPstop/- line was characterised to establish if this mouse model would be an 
efficient tool to determine whether PrPC expression exclusively on FDCs is sufficient 
to allow replication of the scrapie agent within the lymphoid tissue.  The 
characterisation studies carried out on this line indicate that PrPC was switched on 
specifically on Cre-expressing FDCs and not on other non-Cre-expressing cells within 
the lymphoid tissue such as the nerves.  Furthermore, insertion and expression of the 
transgenes had no additional effects on the lymphoid tissue that could influence 
scrapie pathogenesis.   
 
Homozygous expression of the Prnpstop allele is embryonically lethal. Therefore 
CD21-crePrP-/- mice were crossed once with the PrPstop/- mice and selected CD21-
crePrPstop/- progeny were used in subsequent characterisation.  Prnp expression levels 
have previously been shown to have a crucial influence on scrapie incubation period 
(Manson, Clarke et al. 1994a).  Therefore, in subsequent scrapie infection 
experiments (Chapter 7), PrPWT/- mice will be used as a control line for the half copy 
number expression levels of PrPC present on the FDCs of the CD21-crePrPstop/- mice.   
 
Characterisation of the CD21-crePrPstop/- mice showed that PrPC expression was 
efficiently and exclusively expressed on FDCs.  PCR analysis of DNA extracted from 
spleens confirmed the presence of the Cre transgene and recombination of the Prnpstop 
transgene.  Furthermore, immunolabelling of spleen sections confirmed that PrPC was 
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expressed on FDCs but not present on non-CD21 expressing cells such as peripheral 
nerves. Previous studies using the CD21-cre line, which measured 96% of floxed 
DNA was recombined in FDCs of CD21-cre mouse line crosses (Victoratos, Lagnel et 
al. 2006).  This type of analysis was not carried out on CD21-crePrPstop/- mice, 
however PCR and immunohistochemical analysis showed efficient recombination of 
the floxed DNA. 
 
Depletion of various lymphoid cell subsets other than FDCs has been shown to delay 
the onset of peripherally acquired scrapie (Klein, Frigg et al. 1997; Raymond, 
Aucouturier et al. 2007).  Therefore, characterisation of the lymphoid tissues of 
transgenic mice was essential to ensure that the only factor affecting scrapie 
pathogenesis in CD21-crePrPstop/- mice was the expression of PrPC.  Various cell 
subsets were immunolabelled on spleen sections from transgenic experimental and 
WT lines to determine if insertion of the transgenes or irradiation had any effect on 
lymphoid tissue michroarchitecture.  No observable difference could be seen in the 
number or location of B lymphocytes, T lymphocytes or classical dendritic cells or in 
the integrity of the marginal zone in the spleen. 
 
Changes in the number and maturation status of the FDC networks in the lymphoid 
tissue has been shown to have a critical influence on peripheral scrapie pathogenesis 
(Brown, Stewart et al. 1999; Mabbott, Williams et al. 2000a; Mabbott, McGovern et 
al. 2002; Mabbott, Young et al. 2003; Prinz, Heikenwalder et al. 2003).  Analysis of 
the CD21-crePrPfl/- line (Chapter 4) showed there were no significant differences in 
the number, area and function of FDC networks of transgenic mice in comparison to 
WT controls. It was not considered to be essential to repeat these extensive studies on 
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FDCs of CD21-crePrPstop/- mice, however immunolabelling of spleen sections from 
this line showed no observable differences in the presence of various FDC markers in 
comparison to WT controls.  The positioning of FDC networks within the spleen with 
regard to their proximity to peripheral nerves can also influence the incubation period 
of peripherally acquired scrapie (Glatzel, Heppner et al. 2001; Prinz, Heikenwalder et 
al. 2003). This was measured in spleen sections from transgenic experimental lines 
and WT controls and no significant difference was measured in the distance between 
the FDC networks and nerves.   
 
These data show that neither the insertion and expression of the Cre or Prnpstop 
transgenes nor irradiation and bone marrow reconstitution in experimental mice, has 
any significant effect on the microarchitecture of the spleen or the number or 
distribution of various cell subsets found within. Previous studies using the CD21-cre 
mice also did not report any toxic effects caused by the Cre transgene and showed no 
differences in FDC and B lymphocyte numbers or location in the spleen (Kraus, 
Alimzhanov et al. 2004; Victoratos, Lagnel et al. 2006; Schenten, Kracker et al. 
2009).  Additionally, characterisation of the PrP-/-  line has shown no overt phenotype 
even though PrPC is ubiquitously expressed (Manson, Clarke et al. 1994a). 
 
FDCs have the ability to acquire proteins on their surface which they themselves do 
not express, for example Class II MHC (Gray, Kosco et al. 1991; Denzer, van Eijk et 
al. 2000).  Although PrPC has been shown to be present on the FDC surface via 
immunolabelling and electron microscopy, it is possible that FDCs acquire the 
expression of PrPC from other cell types within the lymphoid tissues.  Switching on 
Prnp expression exclusively in FDCs has determined that FDCs themselves do 
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actively express relatively high levels of PrPC and are not acquiring this expression 
from other cells.  This is in agreement with previous studies using bone marrow 
chimeric mice. Mice were lethally γ-irradiated and reconstituted with PrP-/- bone 
marrow, however host derived FDCs remained PrP+/+ suggesting that FDCs 
themselves expressed PrPC (Brown, Stewart et al. 1999). 
 
Characterisation of the CD21-crePrPstop/- mouse line has shown that PrPC is efficiently 
switched on in Cre-expressing FDCs but is not present on other cell types within the 
lymphoid tissues.  Furthermore, insertion and expression of the transgenes have no 
additional effects on the cellular composition or structure of the lymphoid tissue. 
Therefore the CD21-crePrPstop/- mouse line is an effective model to determine if PrPC 
expression exclusively by FDCs is sufficient to allow scrapie agent replication in the 
lymphoid tissues (Chapter 7). This will allow the role of the FDCs in scrapie 
pathogenesis to be fully investigated and to establish whether FDCs themselves 
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Data in this thesis (Chapter 5) has shown that PrPC deficient FDCs are unable to 
replicate the scrapie agent. Without PrPC–expressing FDCs, PrPSc appears to be 
removed from the FDCs by TBMs in the follicle and possibly degraded.  In this 
Chapter experiments are designed to determine if PrPC expression exclusively by 
FDCs in a Prnp-/- animal is sufficient to support replication of the scrapie agent in the 
lymphoid tissue. 
 
 The CD21-crePrPstop/- transgenic mouse model was extensively characterised 
(Chapter 6) and it was confirmed that in this model, PrPC expression was switched on 
exclusively and efficiently on FDCs.  Furthermore, the insertion and expression of the 
transgenes had no adverse effects on the cellular composition or microarchitecture of 
the lymphoid tissues that could potentially impact on scrapie pathogenesis.  CD21-
crePrPstop/- mice and control lines were inoculated ip with ME7 scrapie and culled at 
various time points after inoculation to assess disease progression.  By 35 dpi all 
animals with PrPC expression exclusively in FDCs, or in FDCs and CD21+ B 
lymphocytes, showed low levels of PrPd immunolabelling on the FDC network. At 
later time points, immunolabelling of PrPd was more intense and could be confirmed 
as PrPSc using the PET blot method.  These data show that PrPC expression 
exclusively on FDCs is sufficient to support replication of the scrapie agent in the 
lymphoid tissues.  Therefore it can be concluded that the FDCs themselves are 







Heavy accumulations of TSE-agent-specific disease-associated PrPSc occur upon the 
FDC networks in lymphoid tissues of scrapie-affected mice after peripheral exposure 
(McBride 1992; Brown, Stewart et al. 1999; Bruce 2000; Jeffrey, McGovern et al. 
2000).  FDCs are thought to have a role in replicating the scrapie agent within the 
lymphoid tissue, however as of yet, there has not been a suitable model which has 
been able to specifically assess the role of the FDCs in isolation from all other 
stromal, neural and lymphoid cells within the lymphoid tissue (Brown, Stewart et al. 
1999; Montrasio 2000; Mabbott, Williams et al. 2000a; Mabbott, Mackay et al. 
2000b; Mabbott, Young et al. 2003; Mohan, Bruce et al. 2005).  Previous data in this 
thesis (Chapter 5) has shown that PrPC ablation specifically on FDCs prevents the 
accumulation of the scrapie agent on the FDC surface in the lymphoid tissue.  This 
suggests that FDCs are not simply accumulating the FDCs on their surface after 
replication on another cell type within the lymphoid tissue and instead actively 
replicate the scrapie agent themselves. 
 
In this Chapter it was determined whether PrPC expression exclusively on FDCs was 
sufficient to support scrapie agent replication within the lymphoid tissue. To address 
this issue, the CD21-cre mouse line was crossed with the Prnpstop/- mouse line to 
create a model in which PrPC expression was switched on exclusively on CD21-
expressing cells. These animals were subsequently irradiated and reconstituted with 
non-Cre-expressing bone marrow to restrict PrPC expression exclusively to the FDC 
network.  Characterisation of this compound transgenic model (Chapter 6) showed 
that PrPC was efficiently and specifically expressed on the FDC networks of CD21-
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crePrPstop/- mice.  Furthermore, no adverse effects on the status of FDC networks, or 
in the general michroarcitecture of the lymphoid tissue were observed.  These data 
confirmed that the CD21-crePrPstop/- model would be a useful tool to determine the 
role of PrPC-expressing FDCs in scrapie pathogenesis and determine whether if PrPC 
expression on exclusively on FDCs is sufficient to support scrapie agent replication in 
the peripheral lymphoid tissues. As host expression of PrPC is essential for TSE agent 
pathogenesis (Büeler, Aguzzi et al. 1993; Blattler, Brandner et al. 1997), if FDCs 
themselves actively replicate the TSE agent, then PrPC expression exclusively on the 
FDC network should be sufficient to enable TSE agent replication in the lymphoid 
tissues.   
 
CD21-crePrPstop/- mice were infected ip with the ME7 scrapie agent and culled at 35, 
70 or 105 dpi.  PrPC expression in the CNS is essential for efficient transmission and 
neuropathology of the scrapie agent (Büeler, Aguzzi et al. 1993; Blattler, Brandner et 
al. 1997).  As CD21-crePrPstop/- mice have no PrPC expression in the CNS, it is not 
anticipated that these animals could develop clinical TSE disease (Tuzi, Clarke et al. 
2004). For this reason, no animals were left beyond 105 dpi. However to determine if 
this was the case, some transgenic animals were inoculated ic with the ME7 scrapie 
agent directly into the brain.  Spleens were harvested from all time points and the 
cellular sites of PrPSc accumulation were determined.  PrPSc has been shown to co-
purify with TSE agent infectivity and is considered by many to be the sole component 
of the TSE infectious agent and therefore was used as a biochemical marker of disease 
in this study (Bolton, McKinley et al. 1982).  
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In animals with PrPC expression switched on specifically in FDCs, the scrapie agent, 
as detected by PrPSc immunolabelling, located to the FDC network by 35 dpi.  The 
deposition of PrPSc on the FDC increases at later time points, suggesting that the 
scrapie agent is efficiently replicating on the FDC networks.  However, when PrPC is 
switched on only in CD21+ B lymphocytes, PrPSc is found only within the TBMs.    
These data show that PrPC expressing FDCs are responsible for replicating the scrapie 
agent within the lymphoid tissue.  Without PrPC expression on FDCs the scrape agent 




7.3.1 Experimental design  
 
To determine if PrPC expression exclusively on FDCs is sufficient to support TSE 
agent replication in the lymphoid tissues, the CD21-crePrPstop/- mouse line was 
injected ip with ME7 scrapie.  Animals were aged to 8 weeks, lethally γ-irradiated and 
given donor bone marrow 24 h later as indicated. To restrict PrPC expression 
specifically to FDCs, CD21-crePrPstop/- mice were given bone marrow from Cre-
negative littermates.  However, other transgenic host/bone marrow combinations were 
also produced as control lines and these are summarised in Table 5.1. Animals were 
used in experiments at 100 d post bone-marrow reconstitution to allow for efficient 
replacement of host bone-marrow derived cells with donor counterparts. Mice from 
each group were then injected ip with 20 μl of a 1% (wt/vol) scrapie brain 
homogenate.  Animals were then culled at 35, 70 and 105 days post-inoculation (dpi) 
and tissues were collected to assess the cellular sites of PrPSc accumulation in the 
spleen.  As animals have no PrPC expression in the CNS, no animals were expected to 
develop clinical disease. For this reason, no animals were left beyond the 105 dpi time 
point. However, to determine if this was true, some CD21-crePrPstop/- animals were 
infected with scrapie directly into the CNS via  ic injection alongside 129/Ola WT 
controls. A summary of experimental design can be found in Figure 7.1.  
 
The cellular sites of PrPSc accumulation in the spleen were determined by 
immunolabelling for PrP.  Immunohistochemical analysis was carried out using the 
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Host Genotype Donor Genotype PrPC switched on Nomenclature 
 
CD21-crePrPstop/- PrPstop/- FDCs only Cre-ve  → 
CD21-crePrPstop/- 
CD21-crePrPstop/- CD21-crePrPstop/- FDCs and B 
lymphocytes 
Cre+ve  → 
CD21-crePrP stop/- 
PrPstop/- CD21-crePrPstop/- B lymphocytes only Cre+ve  → PrPstop/-
 













































rabbit anti-PrP PAb antibody 1B3 and confirmed using the mouse anti-PrP MAb 6H4.  
As both antibodies gave similar results, only immunohistochemistry images from 1B3 
immunolabelling are shown. Treatment with PK digests the cellular PrPC leaving the 
PK-resistant core of PrPSc intact (Manson, Clarke et al. 1994b).  This property of 
PrPSc can be used to distinguish PrPC and PrPSc on histological specimens by using 
the paraffin-embedded tissue (PET) blot method.  This method was used to confirm if 
the disease specific PrP (PrPd) detected by immunohistochemistry were scrapie-
associated PrPSc.  Detection of PrPd and PrPSc have been confirmed by many studies 
to be reliable markers of the ME7 scrapie agent and in most cases correlate closely 
with presence of TSE agent infectivity (Bolton, McKinley et al. 1982; McBride, 
Eikelenboom et al. 1992; Brown, Stewart et al. 1999; Mabbott, Mackay et al. 2000b; 
Mabbott, Young et al. 2003; Glaysher and Mabbott 2007; Raymond, Aucouturier et 
al. 2007; Brown, Wathne et al. 2009). 
 
7.3.2 Pathogenesis of ME7 scrapie at 35 dpi in mice with PrPC expression exclusively 
on FDCs  
 
Animals were culled at 35 dpi with the ME7 scrapie agent and spleens were harvested 
for analysis of the cellular sites of PrPSc accumulation.  In spleens with PrPC 
expression exclusively on Cre-expressing FDCs, and in PrPWT/- control spleens, 
accumulation of the abnormal, disease-associated PrPd occurred in the germinal 
centres of the spleen (Figs 7.2).  This PrPd was located on the FDC network as shown 
by immunolabelling of serial sections for PrPd, FDCs and B lymphocytes (Fig 7.3).  A  





           






























































Figure 7.2 PrPd immunolabelling in the spleen at 35 dpi with the ME7 scrapie 
agent 
Four animals from each experimental line were culled at 35 dpi with the ME7 scrapie 
agent and spleens were immunolabelled to detect PrPd (PAb 1B3, red).  One animal 
was lost to an intrcurrent death. 
All spleens with PrPC expression exclusively in Cre-expressing FDCs (A-G) or 
PrPWT/- mice with PrPC expressing FDCs (L-O), show PrPd immunolabelling at low 
levels on the FDC networks (   ) in the follicles.  However, spleens from animals with 
PrPC-deficient FDCs (H-K) do not show immunolabelling on the FDC network.  In 
these animals, the only positive PrPd immunolabelling is found within the TBMs (*).  
These data demonstrate that the scrapie agent is able to localise to the follicles of the 
spleen independently of PrPC expression as PrPd is present on FDCs of animals 
expressing PrPC exclusively on the FDCs. If FDCs are PrPC deficient, the agent is 
localised to the follicle but is found mainly within the TBMs.  Scale bar on main 
figure100 μm. Scale bar on x 1000 magnification images 20μm. Sections 
counterstained with haematoxylin, blue. 
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Fig 7.3 Immunohistochemical analysis of PrPd, FDC and B lymphocytes in 
spleens of mice taken at 35 dpi with the ME7 scrapie agent 
Serial sections from spleens were immunolabelled for PrPd (PAb 1B3, red), FDCs and 
CD21+ B lymphocytes (MAb 7G6, blue) and B lymphocytes (MAb B220, red) to 
determine if PrPd detected was co-localised to the FDC network. One animal is shown 
from each experimental transgenic line. 
 
In spleens with PrPC expression exclusively on Cre-expressing FDCs (A-F), or with 
PrPC-expressing FDCs in PrPWT/- mice (J-L), PrPd (  ) is localised to the FDC 
networks (    ) as shown in serial sections.  PrPd location in spleens with PrPC 
deficient, FDCs (G-I) PrPd was did not co-localise to the FDC networks but instead 
was found exclusively within TBMs (*) in the follicles.  Scale bar 100 μm.  Sections 
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Figure 7.4 PET blot analysis of PrPSc accumulation in spleens taken at 35 dpi 
with the ME7 scrapie agent 
Paraffin-embedded sections on nitrocellulose membranes were treated with PK to 
remove any native PrPC, then immunolabelled (PAb, 1B3, blue/black) to detect any 
remaining PrPSc. One representative example from each transgenic line is shown. A, 
Cre-ve→CD21-crePrPfl/-; B, Cre+ve→CD21-crePrPfl/-; C, Cre+ve→PrPfl/- ; D, PrPfl/- 
→PrPfl/-).  Scale bar 500 μm. 
 
Due to the low levels of PrPd detected in infected tissue at this stage by 
immunohistochemistry (Fig 7.2), PrPSc is not readily detected after PK treatment in 
any of the transgenic experimental lines, however a few follicles in spleens with 
PrPC-expressing FDCs have a little PrPd labelling present (  ). Therefore PrPd 







little immunolabelling of PrPd was still detected in the follicles after PK treatment, 
however, this was only at very low levels as animals are only expressing half copy 
number levels of Prnp and were culled early  in the incubation period (Fig 7.4).  
These data suggest that in animals with PrPC expression exclusively on FDCs at 35 
dpi with the ME7 scrapie agent, the TSE agent can locate to the follicles of the spleen 
and begin to replicate on the PrPC-expressing FDC networks. 
 
In mice with PrPC deficient FDCs, PrPd was detected in the spleen at 35 dpi (Figs 
7.2).  However, the PrPd detected did not co-localise to the FDC networks.  Instead 
immunolabelling of PrPd was located exclusively within TBMs within the follicle (Fig 
7.3).  Analysis of PET blots of spleens from these animals could not confirm the 
presence of PrPSc (Fig 7.4). 
 
 
7.3.3 Pathogenesis of ME7 scrapie at 70 dpi in mice with PrPC expression exclusively 
on FDCs  
 
At 70 dpi with the ME7 scrapie agent, spleens with PrPC expression exclusively on 
Cre-expressing FDCs, and in PrPWT/- control spleens, accumulation of the abnormal, 
disease-associated PrPd occurred in the germinal centres of the spleen at a greater 
intensity than that seen in spleens from animals culled at 35 dpi (Figs 7.5).  This PrPd 
was located on the FDC network as shown by immunolabelling of serial sections for 
FDCs and B lymphocytes (Fig 7.6).  Furthermore, the PrPd accumulations detected 
upon the FDC networks were confirmed to be PK-resistant, scrapie agent-associated 
PrPSc using the PET blot method (Fig 7.7).    
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Figure 7.5 PrPd immunolabelling in spleen at 70 dpi with the ME7 scrapie agent 
Four animals from each experimental line were culled at 70 dpi with ME7 scrapie and 
spleens were immunolabelled to detect PrPd (PAb 1B3, red). 
All spleens with PrPC expression exclusively in Cre-expressing FDCs (A-G) or 
PrPWT/- mice with PrPC expressing FDCs (L-O), show PrPd immunolabelling on the 
FDC networks (  ) within the follicles at a greater level than that seen in spleens from 
mice culled at 35 dpi.  This indicates the scrapie agent is successfully replicating on 
the PrPC-expressing FDCs despite all other cell types within the animal being Prnp-/-
(A-D) or only CD21+ B lymphocytes also expressing PrPC (E-G). 
 
Spleens from animals with PrPC-deficient FDCs (H-K) do not show any 
immunolabelling of PrPd on the FDC, instead, PrPd is detected only within 
neighbouring TBMs (*). This suggests the scrapie agent is unable to replicate on PrPC 
deficient FDCs and any PrPd from innocula has been cleared from FDC networks and 
sequestered by TBMs in the follicle.  Scale bar on main figure 100 μm.  Scale bar on 
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Fig 7.6 Immunohistochemical analysis of PrPd, FDC and B lymphocytes in 
spleens of mice taken 70 dpi with the ME7 scrapie agent 
Serial sections from spleens were immunolabelled for PrPd (PAb 1B3, red), FDCs and 
CD21+ B lymphocytes (MAb 7G6, red) and B lymphocytes (MAb B220, red) to 
determine if PrPd detected co-localised to the FDC network. One animal is shown 
from each experimental transgenic line. 
 
In spleens with PrPC expression exclusively on Cre-expressing FDCs (A-F), or with 
PrPC-expressing FDCs in PrPWT/- mice (J-L), PrPd (  ) is localised to the FDC 
networks (       ) as shown in serial sections.  PrPd in spleens with PrPC deficient FDCs 
(G-I) was not present on the FDC networks but instead was found exclusively within 
TBMs (*) in the B lymphocyte follicles.  Scale bar 100 μm. Sections counterstained 
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Figure 7.7 PET blot analysis of PrPSc accumulation in spleens taken at 70 dpi 
with the ME7 scrapie agent 
Paraffin-embedded spleens sections on nitrocellulose membranes were treated with 
PK to remove any native PrPC and then immunolabelled (PAb 1B3, blue) to detect 
any remaining PrPSc. One representative example from each transgenic line is shown. 
A, Cre-ve→ CD21-crePrPfl/-; B, Cre+ve→ CD21-crePrPfl/-; C, Cre+ve→ PrPfl/- ; D, 
PrPfl/- → PrPfl/-).  Scale bar 500 μm 
 
 
In spleens with PrPC expression exclusively on Cre-expressing FDCs (A, B), or with 
PrPC-expressing FDCs in PrPWT/- mice (D), PrPd immunolabelling is present in the 
follicles after PK treatment (  ). Therefore PrPd detected in these tissues by 
immunohistochemistry (Fig 7.5) can be confirmed to be the disease-associated PrPSc.  
In contrast, spleens from mice with PrPC deficient FDCs (C) show no PrPSc in the 
follicles.  This confirms that PrPC expressing FDCs actively replicate the TSE agent 
















From these data it can be concluded that PrPC expression exclusively on FDCs is 
sufficient to support replication of the scrapie agent in peripheral lymphoid tissues, 
confirming that the FDCs actively replicate the TSE agent.  Furthermore, no 
significant differences were observed in the levels of deposition of PrPd on Cre-
expressing, PrPC-expressing FDCs in mice that received Cre+ve or Cre-ve bone marrow. 
This suggests that PrPC expression on CD21+ B lymphocytes is irrelevant to 
peripheral disease pathogenesis as previously reported (Klein, Frigg et al. 1998; 
Brown, Stewart et al. 1999; Mohan, Brown et al. 2004). 
 
In spleens from mice with PrPC deficient FDCs, no deposition of PrPd was observed 
on the FDC networks.  Instead, if PrPd was detected at all, it was only found within 
TBMs (Fig 7.5).   Immunolabelling of serial sections for FDCs and B lymphocytes 
confirmed that PrPd immunolabelling did not co-localise with FDC networks (Fig 
7.6).  The levels of PrPd observed within the TBMs were too low to be confirmed by 
the PET blot method as PrPSc (Fig 7.7).  From these data it can be concluded that 
PrPC-expressing FDCs are essential for the scrapie agent to accumulate within the 
lymphoid tissues.  Without active replication of the agent by PrPC expressing FDCs, 
the scrapie agent appears to be scavenged by TBMs in the follicle and possibly 
degraded.  Furthermore, these animals with PrPC deficient FDCs had been given 
Cre+ve bone marrow so have PrPC expression switched on exclusively in CD21+ B 
lymphocytes.  These data also confirm that PrPC expression by mature B 
lymphocytes is not sufficient to support replication of the scrapie agent in the spleen 
as previously reported (Montrasio, Cozzio et al. 2001). 
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7.3.4 Pathogenesis of ME7 scrapie at 105 dpi in mice with PrPC expression 
exclusively on FDCs 
 
At 105 dpi with the ME7 scrapie agent in spleens with PrPC expression exclusively on 
Cre-expressing FDCs, and in PrPWT/- control spleens, accumulation of the abnormal, 
disease-associated PrPd occurred in the germinal centres of the spleen at a greater 
intensity than that seen in spleens from animals culled at 70 dpi (Fig 7.8).  As 
previous, PrPd was co-localised to the FDC network as shown by immunolabelling in 
serial sections for FDCs and B lymphocytes (Fig 7.9).  Furthermore, PrPd 
accumulation within the germinal centres was confirmed to be the PK-resistant, 
scrapie-associated PrPSc using the PET blot method (Fig 7.10).  These results further 
supports data from previous time points showing that the PrPC expression exclusively 
on FDCs is sufficient to support scrapie agent replication in the peripheral lymphoid 
tissues and confirms that PrPC-expressing FDCs actively replicate the TSE agent in 
the lymphoid tissue.  Additionally, no significant differences were seen in deposition 
of PrPd in spleens from mice with PrPC expression exclusively on Cre-expressing 
FDCs that received Cre+ve or Cre-ve bone marrow indicating that PrPC expression on 
CD21+ B lymphocytes is irrelevant to peripheral disease pathogenesis of the scrapie 
agent.   
 
In spleens from mice with Cre-deficient, PrPC deficient FDCs, there was no 
deposition of PrPd on the FDC networks (Fig 7.8).  Furthermore, levels of PrPd 
detected within the TBMs at 105 dpi were greatly reduced in comparison to that seen 
at 35 and 70 dpi (Figs 7.2 and 7.5 respectively).   Immunolabelling of serial sections 
for FDCs and B lymphocytes confirmed that the little PrPd immunolabelling present  
        
171 
        
Infected spleen Uninfected spleen Serum control 
   





























































Figure 7.8 PrPd immunolabelling in the spleen at 105 dpi with the ME7 scrapie 
agent 
Four animals from each experimental line were culled at 105 dpi with the ME7 
scrapie agent and spleens were immunolabelled to detect PrPd (PAb 1B3, red). 
All spleens with PrPC expression exclusively in Cre-expressing FDCs (A-H) or 
PrPWT/- mice with PrPC expressing FDCs (M-P), show PrPd immunolabelling on the 
FDC networks (   ) within the follicles at an increased level than that seen in spleens 
from animals culled at 70 dpi.  This indicates the scrapie agent is continuing to 
replicate on the PrPC-expressing FDCs despite all other cell types within the animal 
being PrPC-deficient (A-D) or only CD21+ B lymphocytes additionally expressing 
PrPC (E-H). 
Spleens from mice with PrPC deficient FDCs (I-L) show little/no immunolabelling of 
PrPd at this time point. PrPd is detected only within TBMs (*) in one animal. This 
suggests the scrapie agent is still unable to replicate on PrPC deficient FDCs and as 
levels of PrPd staining within TBMs are reduced in comparison to earlier time points 
(Fig 7.2 and 7.5), TBMs are most likely degrading the scrapie agent. Scale bar on 
main figure100 μm.  Scale bar on x1000 magnification images 20μm.  Sections 








   
 
         
   
















   






































Fig 7.9 Immunohistochemical analysis of PrPd, FDC and B lymphocytes in 
spleens of mice taken at 105 dpi with the ME7 scrapie agent 
 
Serial sections from spleens were immunolabelled for PrP (PAb 1B3,red), FDCs and 
CD21+ B lymphocytes (MAb 7G6, red) and B lymphocytes (MAb B220, red) to 
determine if PrPd detected was co-localised to the FDC network. One animal is shown 
from each experimental transgenic line. 
 
 In spleens with PrPC expression exclusively on Cre-expressing FDCs (A-F), or with 
PrPC-expressing FDCs in PrPWT/- mice (J-L), PrPd (  ) is localised to the FDC 
networks (      ) as shown by serial sections.  PrPd in spleens with PrPC deficient FDCs 
(G-I), was not present on the FDC networks but instead was found exclusively within 
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Figure 7.10 PET blot analysis of PrPSc accumulation in spleens taken at 105 dpi 
with the ME7 scrapie agent 
Paraffin-embedded sections on nitrocellulose membranes were treated with PK to 
remove any native PrPC, then immunolabelled (PAb 1B3, blue/black) to detect any 
remaining PrPSc. One representative example from each transgenic line is shown A, 
Cre-ve→ CD21-crePrPfl/-; B, Cre+ve→ CD21-crePrPfl/-; C, Cre+ve→ PrPfl/- ; D, PrPfl/- 
→ PrPfl/-).  Scale bar 500 μm. 
 
In spleens with PrPC expression exclusively on Cre-expressing FDCs (A, B), or with 
PrPC-expressing FDCs in PrPWT/- mice (D), PrPd immunolabelling is present in the 
follicles after PK treatment ( ). Therefore PrPd detected in these tissues by 
immunohistochemistry (Fig 7.8) can be confirmed to be the disease-associated PrPSc.  
In contrast, spleens from mice with PrPC deficient FDCs (C) show no PrPSc in the 
follicles.  This confirms that PrPC expressing FDCs actively replicate the TSE agent 
in the lymphoid tissues. 
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did not co-localise with FDC networks (Fig 7.9).  The levels of PrPd accumulation 
observed within the TBMs were too low to be confirmed by the PET blot method as 
PrPSc (Fig 7.10). These data confirm that PrPC-expressing FDCs are essential for the 
scrapie agent to replicate within the lymphoid tissues and without active replication 
by FDCs, the scrapie agent is scavenged by neighbouring TBMs.  As levels of PrPd 
immunolabelling within the TBM are reduced over time it appears that the TBMs 
within the B lymphocyte follicle are degrading the scrapie agent. 
 
  7.3.5 TSE disease in the CNS of mice with PrPC expression exclusively on FDCs 
 
Previous studies have shown that host expression of PrPC is absolutely required for 
TSE disease to occur.  CD21-crePrPstop/- animals only express PrPC on FDCs and 
mature B lymphocytes and are therefore TSE disease should not be able to progress to 
the CNS and develop into clinical disease in these animals.  For this reason, the 105 
dpi time point after ME7 scrapie agent exposure was the final time point included in 
this experiment as no animals were expected to develop clinical disease. However to 
ensure that CD21-crePrPstop/- mice are resistant to TSE disease in the CNS, some 
animals were injected with the ME7 scrapie agent directly into the CNS via ic 
injection alongside 129/Ola WT controls.  WT animals developed TSE clinical 
disease with positive neuropathology in the brain with an average incubation period of 
158 ± 2 dpi (Chapter 5 Fig 5.10).  The classical hallmarks of TSE infection in the 
brain are deposition of abnormal, disease-associated PrPd, gliosis and spongiform 
pathology (vacuolation). TSE disease in the brains of WT animals was confirmed by 
positive immunolabelling of PrPd, activated astrocytes (GFAP+ cells) or microglia 
(IBA-1+ cells) in the brains of transgenic animals in comparison to WT controls 
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(Chapter 5 Fig 5.8).  Furthermore, lesion profiling of the TSE specific vacuolation in 
specific areas of the brain is commonly used to characterise TSE disease in mice. 
Typical neuropathology, characteristic of infection with the ME7 scrapie agent was 
observed in the brains of control mice (Chapter 5 Fig 5.9). In contrast, CD21-
crePrPstop/- mice ic injected with ME7 scrapie are still alive at 313 dpi at point of 
writing.  This exceeds the mean incubation time of 297 ± 4 dpi in CD21-crePrPfl/- 
mice (Chapter 5 Fig 5.10), which have half copy level expression of Prnp.  When 
surviving CD21-crePrPstop/- mice are culled due to clinical disease or aging, brains and 
spleens will be harvested to determine if signs of scrapie pathology are present.  
However, due to lack of PrPC expression in the CNS, it is not anticipated that these 


















The CD21-crePrPstop/- mouse line, with irradiation and reconstitution with non-Cre-
expressing bone marrow, was previously shown to allow PrPC expression to be 
switched on specifically on FDCs without adverse effects on FDC status or the 
lymphoid tissues (Chapter 6).  In this chapter the CD21-crePrPstop/- line was injected  
ip with  the ME7 scrapie agent to determine if PrPC expression exclusively on FDCs 
is sufficient to support scrapie agent replication within the lymphoid tissue and 
conclusively determine whether FDCs themselves actively replicate the scrapie agent.  
If FDCs themselves actively replicate the TSE agent, then PrPC expression 
exclusively on the FDC network should be sufficient to support replication of scrapie 
in the lymphoid tissue.   
 
Immunolabelling of PrPSc in the lymphoid tissue was used to assess the cellular 
localisation of the scrapie agent.  PrPSc has previously been shown to co-purify with 
TSE agent infectivity in tissues from scrapie-affected animals and many studies have 
confirmed this to be a reliable marker of TSE disease (Bolton, McKinley et al. 1982; 
McBride, Eikelenboom et al. 1992; Brown, Stewart et al. 1999; Mabbott, Mackay et 
al. 2000b; Mabbott, Young et al. 2003; Glaysher and Mabbott 2007; Raymond, 
Aucouturier et al. 2007; Brown, Wathne et al. 2009).  PrPSc and infectivity 
accumulates in the lymphoid tissues prior to detection in the CNS and deposition of 
PrPSc on the FDC network can be seen as early as 4 weeks post peripheral inoculation 
(Brown, Stewart et al. 1999).  In this experiment, animals were culled at 35, 70 and 
105 dpi to assess the early pathogenesis of ME7 scrapie in transgenic and control 
lines.  As animals in this study are expressing only half copy number levels of Prnp, 
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less deposition of PrPSc would be expected on the FDC networks than seen in 
previous studies using Prnp+/+ animals.  No animals were left to progress beyond 105 
dpi.  Host expression of PrPC has been shown to be essential for effective 
pathogenesis of the scrapie agent (Büeler, Aguzzi et al. 1993; Blattler, Brandner et al. 
1997).  Therefore, as animals are Prnp-/- except in cells where Cre is expressed (FDCs 
and/or CD21+ B lymphocytes), it is unlikely that CNS disease would ever develop. 
However, to verify this, some CD21-crePrPstop/- animals were also injected ic with the 
ME7 scrapie agent along with 129/Ola WT mice as controls. 
 
Animals with Cre-expressing, Prnp+/- FDCs had detectable PrPSc on the FDCs of the 
spleen at 35 dpi. This accumulation intensified by 70 dpi and 105 dpi suggesting 
active replication of the scrapie agent on the PrPC-expressing FDCs.  This shows that 
PrPC expression on FDCs alone is sufficient to support replication of the scrapie agent 
in the lymphoid tissues. This confirms previous studies which implied that that PrPC-
expressing FDCs actively replicate the scrapie agent in the lymphoid tissue (McBride, 
Eikelenboom et al. 1992; Brown, Stewart et al. 1999; Mabbott, Mackay et al. 2000b; 
Mabbott, McGovern et al. 2002; Mabbott, Young et al. 2003; Glaysher and Mabbott 
2007; Raymond, Aucouturier et al. 2007; Brown, Wathne et al. 2009).  
 
 In animals with PrPC switched on only in CD21+ B lymphocytes, little to no PrPd 
labelling is found in follicle at 35 dpi and by 70 and105 dpi, the only labelling 
detected is within the TBMs in the follicle. Some studies have suggested a role for B 
lymphocytes in replicating the scrapie agent in the lymphoid tissue (Klein, Frigg et al. 
1997).  However, others conclude that B lymphocyte involvement is indirect and is 
due to the dependence of the FDCs on B lymphocyte-derived signals to maintain a 
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mature and functioning FDC network (Klein, Frigg et al. 1998; Brown, Stewart et al. 
1999).  Data from the CD21-crePrPstop/- study shows that PrPC expression on CD21+ 
mature B lymphocytes alone is not sufficient to support scrapie replication. 
Furthermore, no differences were seen in pathogenesis of scrapie when PrPC was 
expressed on FDCs alone or on both FDCs and CD21+ B lymphocytes.  These data 
suggest that CD21+ B lymphocytes do not have an active role in the replication of the 
scrapie agent within the lymphoid tissue. This is in agreement with data from a 
previous study  which found over-expression of PrPC on B-lymphocytes only was not 
sufficient to support scrapie replication in the lymphoid tissue (Montrasio, Cozzio et 
al. 2001).   
 
Transgenic animals that were inoculated ic with the ME7 scrapie agent have still not 
succumbed to clinical TSE disease 313 dpi with the ME7 scrapie agent at time of 
writing.  Previous studies using Prnp+/- mice (Tew and Mandel 1979) and data from 
this thesis using  of CD21-crePrPfl/- animals (Chapter 5) has shown that following ic 
injection with the scrapie agent, the incubation period of Prnp+/- mice is 
approximately 300 dpi (Chapter 5 Fig 5.10).  CD21-crePrPstop/- mice in this study 
have progressed beyond this time point without showing signs of TSE disease so it 
appears that this line will be resistant to disease in the CNS as expected. 
 
These data show that with no PrPC present on the FDCs, the scrapie agent is unable to 
replicate on FDCs after initial localisation and appears to be rapidly cleared from the 
FDC network by TBMs in the follicle.  TBMs are capable of taking up immune-
complex coated portions of FDC membranes and therefore have the potential to 
remove the scrapie agent directly from the FDC surface (Szakal and Tew 1992; 
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Sandberg, Al-Doujaily et al. 2011). Additionally, previous publications have shown 
that depletion of macrophages prior to scrapie infection decreases scrapie incubation 
period and enhances replication in the lymphoid tissues further suggesting a role for 
macrophages in the degradation of the scrapie agent (Beringue, Demoy et al. 2000).  
These data further confirm that PrPC expressing FDCs actively replicate the scrapie 
agent on their surface and without this replication, the scrapie agent is cleared from 
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Accumulation of the TSE agent in the lymphoid tissue occurs in many cases of natural 
TSE disease.  Many natural scrapie infections of sheep have accumulation of PrPSc in 
the spleen and lymphoid tissues of prior to CNS disease (van Keulen, Schreuder et al. 
1996; Andreoletti, Berthon et al. 2000; Heggebo, Press et al. 2000; Heggebo, Press et 
al. 2002) and deer which have been naturally infected with CWD also show PrPd and  
agent infectivity within the lymphoid tissues (Sigurdson, Williams et al. 1999; Fox, 
Jewell et al. 2006). Furthermore, patients with vCJD show PrPd and/or infectivity in 
the appendix and tonsils (Hilton, Fathers et al. 1998; Hill, Butterworth et al. 1999; 
Bruce, McConnell et al. 2001) and recent evidence has shown transmission of vCJD 
from contaminated blood products (Llewelyn, Hewitt et al. 2004; Peden, Head et al. 
2004; Wroe, Pal et al. 2006; Peden, McCardle et al. 2010).  These data, along with the 
current lack of available treatments and invariable fatality of infected patients, 
highlight the need to understand the pathogenesis of TSE disease within the lymphoid 
tissues to determine cellular targets for focused research into prophylactic treatments. 
 
Previous studies investigating the role of the lymphoid tissues in TSE disease have 
highlighted PrPC-expressing FDCs as an essential requirement for successful 
pathogenesis of the TSE agent within peripheral lymphoid tissues (McBride, 
Eikelenboom et al. 1992; Klein, Frigg et al. 1998; Brown, Stewart et al. 1999; 
Mabbott, Mackay et al. 2000b; Kaeser, Klein et al. 2001; Mabbott and Bruce 2002; 
Mabbott, McGovern et al. 2002; Prinz, Montrasio et al. 2002; Mabbott, Young et al. 
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2003; Prinz, Heikenwalder et al. 2003; Glaysher and Mabbott 2007; Raymond and 
Mabbott 2007; von Poser-Klein, Flechsig et al. 2008; Brown, Wathne et al. 2009). 
However, in models used so far, there has been no definitive way to exclusively 
examine the role of PrPC-expressing FDCs in isolation from all other stromal, neural 
and lymphoid cells within the lymphoid tissue. One of the main functions of FDCs is 
to pick up antigenic protein complexes and retain them on their surface for weeks, 
months or even years, which is an essential component in the affinity maturation of B 
lymphocytes and the development of immunological memory (Tew and Mandel 1979; 
Gray and Skarvall 1988; Gray and Matzinger 1991; Ahmed and Gray 1996). 
Therefore, it is possible that the PrPd observed on the FDC networks of TSE-affected 
animals is simply due to accumulation of the TSE agent on the FDC surface after 
replication on another cell type.  An FDC-specific model was required to definitively 
determine whether FDCs themselves actively replicate the TSE agent or if they 
simply accumulate the agent after replication on another cell type. If FDCs are simply 
acquiring the TSE agent after replication on another cell type, investigations into 
which cell is responsible for replicating the TSE agent could provide a new 
therapeutic target for the prevention or prophylactic treatment of TSE disease. 
 
The aims of this thesis were to create and characterise transgenic mouse models that 
allow the manipulation of PrPC expression specifically on FDCs and subsequently to 
infect these animals with scrapie to determine the specific role of the FDCs in TSE 
pathogenesis within the lymphoid tissue. The hypothesis was explored that if FDCs 
are simply accumulating the TSE agent on their surface after replication on another 
cell type, the accumulation of the TSE agent will occur on PrPC deficient FDCs when 
all other cell types within the lymphoid tissue retain PrPC expression.  If however, the 
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FDCs actively replicate the TSE agent in the lymphoid tissue, accumulation of PrPd 
will not occur on the PrPC deficient FDCs. Additionally, if FDCs are responsible for 
replicating the TSE agent within the lymphoid tissue, then PrPC expression 
exclusively on FDCs should be sufficient to allow replication of the TSE agent within 
the lymphoid tissue 
 
8.2 Critical analysis of the transgenic mouse models used in this study 
 
The creation and characterisation of the FDC-specific transgenic mouse models were 
a crucial component of this study.  Transgenic lines were extensively characterised 
before use in ME7 infection studies, however some important points regarding 
conditional gene targeting mice should be noted. The ROSA26 mouse line is a reporter 
strain which is commonly used to characterise Cre-expression under cell specific 
promoters (Mao, Fujiwara et al. 1999).  Promoter specific activation of Cre induces 
expression of β-galactosidase within Cre-expressing cells, which can subsequently be 
detected histologically using an X-gal stain. However, when analysing results 
achieved from such reporter strains, it is important to note that individual alleles may 
have a variable sensitivity to Cre activity as reported by Schmidt-Supprian and 
Rajewsky (Schmidt-Supprian and Rajewsky 2007). Therefore, the pattern of Cre-
mediated DNA recombination will only be identical to that seen in reporter strains if 
the floxed alleles in compound transgenic mice have the same sensitivity to Cre as 
those in the reporter strain.  In this thesis, the ROSA26 reporter strain was used to 
provide an initial indication of the cellular locations of Cre-expression, however 
extensive characterisation was also carried out on the compound transgenic lines 
achieved by crossing CD21-cre mice with the Prnp-floxed mouse lines. 
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  Cre toxicity is a phenomenon where transgenic expression of Cre is lethal to the cell 
due to DNA damage and or chromosomal abnormalities.  This can occur due to the 
presence of cryptic or pseudo LoxP sites that are contained within the mouse genome 
undergoing Cre-mediated DNA recombination (Thyagarajan, Guimarães et al. 2000; 
Schmidt-Supprian and Rajewsky 2007; Semprini, Troup et al. 2007). Characterisation 
of the number of CD21+ B lymphocytes (Chapter 3), the lymphoid tissue composition 
and microarchitecture, and the status and function of the FDCs (Chapters 4 and 6) all 
showed no apparent effects of toxicity in the Cre-expressing cells. 
 
In the transgenic mouse lines used in this thesis, Cre is inserted after the Cr2 
promoter, which encodes CD21.  CD21 was considered to be restricted to FDCs and 
mature B lymphocytes. (Reynes 1985; Liu 1997; Takahashi, Kozono et al. 1997; 
Heggebo, Press et al. 2002).  However, in humans, expression of CD21 has also been 
reported on a subpopulation of immature thymocytes (Tsoukas and Lambris 1988; 
Wagner and Hansch 2006), peripheral T lymphocytes (Fox, Jewell et al. 2006; Peden, 
McCardle et al. 2010) and on human cervical epithelium (Sixbey, Lemon et al. 1986) .  
Within the mouse, expression has also been reported CD4+ T lymphocytes found 
within the MLN, activated granulocytes and mucosal mast cells (Gray and Skarvall 
1988; Gray and Matzinger 1991; Andrasfalvy, Prechl et al. 2002; Heggebo, Gonzalez 
et al. 2003; Llewelyn, Hewitt et al. 2004). These data indicate that expression of 
CD21 is more widespread than previously thought. However, all other cells currently 
reported to express CD21 are derived from the blood.  Therefore lethal γ-irradiation 
and reconstitution with non-Cre expressing bone marrow should still restrict Cre 
expression to the FDC network. 
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The CD21-creROSA26 mouse demonstrated that Cre was efficiently expressed in 
FDCs and mature B lymphocytes and that irradiation and reconstitution with WT 
bone marrow successfully restricted Cre expression to the FDC networks (Chapter 3). 
This was a key factor in using the CD21-cre mouse line for FDC specific 
manipulation of Prnp expression.  Characterisation of both the CD21-crePrPfl/- and 
the CD21-crePrPstop/- lines confirmed the specificity and efficiency of the CD21-cre 
model by demonstrating efficient removal or expression of PrPC specifically on the 
FDC networks (Chapters 4 and 6 respectively) which is in agreement with previous 
data published using this mouse line showing efficient Cre-mediated DNA 
recombination in mature B lymphocytes and FDCs (Kraus, Alimzhanov et al. 2004; 
Victoratos, Lagnel et al. 2006).   Previous studies using the CD21-cre line to restrict 
Cre expression to the FDC network analysed DNA from enriched FDC populations 
from the spleen and used PCR to assess the DNA recombination in the FDCs 
(Victoratos, Lagnel et al. 2006).  These experiments were not undertaken in this 
thesis. However, PCR analysis of whole blood, spleen and tail DNA sufficiently 
showed the correct chimerism between donor bone marrow and host Cre expression 
status. 
 
A population of Cre-expressing neuronal or glial cells within the ganglia of both the 
submucosal and myenteric plexi of the intestine and in the brain were also detected 
(Chapter 3). No literature has reported expression of the CD21 protein within cells of 
these tissues as of yet.  Furthermore, data from the bioGPS database which stores 
microarray data of gene expression profiles from various mouse and human tissues 
shows no non-lymphoid expression of Cr2; including samples from intestine and 
brain (Chapter 1, Fig 1.3 http://biogps.gnf.org) . Due to time constraints, it was not 
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possible to further investigate within which cell population Cre was activated in these 
tissues. However, the route of inoculation was adapted from oral to ip to take any Cre-
mediated manipulation of Prnp in the intestine into consideration. In agreement with 
CD21-creROSA26 characterisation studies in this thesis, Cre activation in the 
forebrain of the CD21-cre mouse line has recently been reported (Schmidt-Supprian 
and Rajewsky 2007).  Cre activation in the forebrain has no effect on the early stages 
of disease incubation that were examined in the ME7 infection studies but a possible 
effect of Cre-activation in the brain was considered when analysing clinical animal 
data in this thesis.  
 
The Prnp floxed mouse lines used were created via gene targeting using bacterial 
artificial chromosomes, which helps to prevent the problems of ectopic- and over-
expression of transgenes and disruption to gene function where the transgene has been 
inserted (Tuzi, Clarke et al. 2004).  The PrPfl/- model has been used with previous 
success to switch off PrPC expression exclusively on Schwann cells in the peripheral 
nerves to determine their role in TSE agent neuroinvasion and achieved a 90% 
reduction of PrPC levels (Bradford, Tuzi et al. 2009).  Western blot quantification of 
PrPC levels expressed was not carried out in this thesis.  However, PCR analysis 
confirmed recombination of the floxed DNA and quantification of the co-localisation 
of PrPC on immunohistochemical images showed efficient switching off/on of PrPC 
on FDC in both mouse lines characterised (Chapters 4 and 6).   
 
The compound transgenic mouse lines used in the ME7 scrapie agent infection studies 
only expressed half copy number levels of Prnp due to complications in breeding the 
CD21-crePrPfl/-line and the Prnpstop allele being lethal at homozygosity, as discussed 
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in Chapters 4 and 6, respectively.  Previous studies have shown that expression levels 
of PrPC inversely correlate with incubation periods of TSE infection in mice. Over 
expression of PrPC leads to significantly shorter incubation periods (Fischer, Rulicke 
et al. 1996),  whereas half copy number levels of Prnp expression extend the 
incubation period of disease (Manson, Clarke et al. 1994b).  Therefore in the models 
used in this thesis, although disease incubation period was increased there should be 
no other differences in disease pathogenesis. 
 
In summary, characterisation of the CD21-creROSA26, CD21-crePrPfl/- and CD21-
crePrPstop/- mouse lines used in this thesis has sufficiently demonstrated gene 
manipulation specifically on FDCs after irradiation and transfer of WT bone marrow. 
Furthermore, no adverse effects were observed on the FDC status or general 
microarchitecture of the lymphoid tissue.  Data from characterisation studies 
demonstrate that the CD21-crePrPfl/- and CD21-crePrPstop/- mice are robust in vivo 
models for manipulating expression of Prnp exclusively on FDCs. 
 
8.3 Do FDCs express PrPC? 
 
The presence of PrPC-expressing FDCs has been shown by many studies to be 
necessary for successful replication of the TSE agent (Brown, Stewart et al. 1999; 
Mabbott, Williams et al. 2000a; Mabbott, Mackay et al. 2000b; Mabbott, McGovern 
et al. 2002; Mabbott, Young et al. 2003; Mohan, Brown et al. 2004; Ierna, Farquhar et 
al. 2006; Brown, Wathne et al. 2009).  However, it has not been confirmed that FDCs 
themselves produce the PrPC protein that they express on their surface.  It is important 
to determine if FDCs acquire or produce expression of PrPC as the mechanisms 
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involved in this process could have implications on the deposition of PrPd seen on the 
FDC surface in scrapie-affected animals. 
 
One of the main roles of the FDC is to trap antigenic protein complexes which they 
can retain on their surface for long periods of time via expression of complement and 
Fc receptors (Fang, Xu et al. 1998; Prodeus, Goerg et al. 1998; Wu, Jiang et al. 2000).   
This is considered essential for affinity maturation of B lymphocytes and the 
development of immunological memory (Gray and Skarvall 1988; Gray, Kosco et al. 
1991; Gray and Matzinger 1991).  Furthermore, previous studies have shown that 
FDCs can acquire proteins, such as MHC class II, on their surface that they 
themselves do not express (Gray, Kosco et al. 1991; Thery, Regnault et al. 1999; 
Denzer, van Eijk et al. 2000).  For these reasons, it is possible that FDCs acquire 
expression of PrPC rather than producing this protein themselves.   
 
Exosomal transport of membrane proteins is a mechanism cells can use to acquire 
proteins that they themselves do not express.  Exosomes are membrane vesicles of 40-
100 nm in diameter, which preferentially contain lipid rafts and GPI-anchored 
proteins (Stoorvogel, Kleijmeer et al. 2002). This makes exosomal transport a 
potential mechanism for the transportation of PrPC protein which is also GPI-
anchored.  Neighbouring B lymphocytes in the follicle also express PrPC and are a 
possible candidate for the transfer of PrPC to FDCs (Mabbott, Brown et al. 1997).  
Indeed, previous studies have shown that FDCs can obtain proteins via exosomes 
from B lymphocytes (Denzer, van Eijk et al. 2000) but also from DCs (Thery, 
Regnault et al. 1999) and macrophages (Wang, Zhou et al. 2010).  Furthermore, in 
vitro studies have shown that cells can release both PrPC and PrPSc on exosomes and 
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have implicated this mechanism may be involved in the intracellular transfer of the 
TSE agent (Fevrier, Vilette et al. 2004; Fevrier, Vilette et al. 2005). 
 
However, there is also evidence to support the expression of PrPC by FDCs 
themselves. Studies analysing the development of FDC networks in SCID mice 
(Bruce, Brown et al. 2000) and neonatal mice (Ierna, Farquhar et al. 2006) found that 
PrPC was detectable in the follicle at the same time as the development of mature 
FDC networks, suggesting that FDCs themselves express PrPC.  Additionally, studies 
using bone marrow chimeric mice which had mismatches in PrPC expression between 
stromal and lymphoid components showed that PrPC was detected upon FDCs by 
immunohistochemistry when the donor bone marrow was PrPC deficient.  This 
eliminates the possibility that bone marrow-derived cells are donating PrPC expression 
to the FDCs in this model (Brown, Stewart et al. 1999).  Furthermore, data from the 
microarray analysis of gene expression by enriched splenic FDCs show that Prnp is 
expressed in these cells indicating that they subsequently express the PrPC protein 
(Huber, Thielen et al. 2005; Wilke, Steinhauser et al. 2010).  Data from this thesis 
supports FDCs producing and expressing PrPC protein themselves.  When PrPC was 
switched off exclusively on FDCs, little to no PrPC was detected on the FDC network 
even though all neighbouring cells in the follicle retained PrPC expression (Chapter 4, 
Figs 4.5 and 4.6).  From this evidence, it appears that FDCs actively produce the PrPC 
protein they express. Hypothetically, it may be possible for FDCs to also acquire PrPC 
protein from other cell types.   However the model used in this study where PrPC 
expression is switched off exclusively on FDCs suggest that little to no PrPC is 
acquired by the FDCs from other cell types. 
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8.4 The function of PrPC in the immune sytem 
 
The function of PrPC is as of yet not fully understood, and many possible functions of 
this protein have been suggested.  PrP-/- mice have no overt neurological phenotype 
although small changes in synaptic transmission (Collinge, Whittington et al. 1994; 
Colling, Collinge et al. 1996; Mallucci, Ratte et al. 2002), circadian rhythms (Tobler, 
Gaus et al. 1996), cognition (Coitinho, Roesler et al. 2003) and seizure thresholds 
(Walz, Amaral et al. 1999) have been reported.  Additional suggested functions of 
PrPC in neurones are copper binding (Hornshaw, McDermott et al. 1995; Jackson, 
Murray et al. 2001), cell signalling (Mouillet-Richard, Ermonval et al. 2000; 
Spielhaupter and Schätzl 2001) and both pro- (Paitel, Alves da Costa et al. 2002) and 
anti- (Kuwahara, Takeuchi et al. 1999; Bounhar, Zhang et al. 2001; Chiarini, Freitas 
et al. 2002) apoptotic activity.  However, these proposed functions of PrPC within the 
CNS do not always have bearing on what PrPC function in the immune system, and 
more specifically on the FDCs, truly is. Maturation of DCs and monocytes has been 
reported to up-regulate PrPC expression (Dürig, Giese et al. 2000; Burthem, Urban et 
al. 2001; Ballerini, Gourdain et al. 2006), whereas down-regulation has been reported 
upon activation of B and T lymphocytes in mice (Kubosaki, Yusa et al. 2001; Liu, Li 
et al. 2001). PrPC is up-regulated in some functionally differentiated lymphocytes 
including a population of regulatory T lymphocytes (Huehn, Siegmund et al. 2004)  
and in memory CD8 T cells (Li, Liu et al. 2001; Goldrath, Luckey et al. 2004).  
Immune function in PrP-/- mice has not been addressed to any great extent.  Studies 
carried out so far have shown PrPC deficiency has no impact on expression levels of 
both MHC Class I and II, maturation of DCs, and numbers of CD4+ and CD8+ T 
lymphocytes and B lymphocytes are no different to that seen in WT counterparts 
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(Bueler, Fischer et al. 1992; Kubosaki, Yusa et al. 2001; Ballerini, Gourdain et al. 
2006; Zhang, Steele et al. 2006).  Recent studies have shown that PrPC deficient T 
lymphocytes are more susceptible to oxidative stress (Aude-Garcia, Villiers et al. 
2011) which is in agreement with previous publications demonstrating a 
neuroprotective role against oxidative stress for PrPC expression by neurones 
(Mitteregger, Vosko et al. 2007).  However, there is a lack of in vivo studies 
investigating the role of PrPC during an active immune response, effects of PrPC 
deficiency on the germinal centre or the role PrPC may play specifically on FDCs. If 
PrPC plays a protective role against oxidative stress or anti-apoptotic functions as 
discussed, FDC may express high levels of PrPC due to their functional attributes, for 
example accumulating large amounts of protein on their surface.  
 
Data from this thesis has shown that removing PrPC specifically on FDCs had no 
effect on the area or number of FDC networks in the spleen (Chapter 4, Fig 4.4). In 
mice with PrPC deficient FDCs,  no observed difference was seen in expression of 
common FDC markers such as the complement receptors CD21/35 and bound 
complement C4 (Chapter 4, Fig 4.3) or on the ability of FDCs to capture immune 
complexes (Chapter 4, Fig 4.8) which suggests that PrPC function does not impact on 
these processes.  However, these observations are made during steady state conditions 
where animals are housed in individually ventilated cages in specified pathogen-free 
conditions.  Perhaps an effect of PrPC deficient FDCs would only become apparent 
after immunisation during initiation of a germinal centre response, or during an 
ongoing immune response.  Furthermore, ultrastructural studies of PrPC deficient 
FDCs in comparison to WT controls may also provide indications as to the function of 
PrPC on the FDCs. 
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8.5 The role of FDCs in TSE pathogenesis 
 
It has now been known for some time that many peripherally acquired TSE infections 
have a stage of replication in the lymphoid tissue prior to neuroinvasion and CNS 
disease.  Studies investigating which cell type was responsible for replicating the 
agent have gradually led to the FDC being identified as the main candidate to 
replicate the TSE agent in the lymphoid tissue.  Initial studies identified the stromal 
component of the spleen as having more TSE agent infectivity than that found in the 
pulp (Clarke and Kimberlin 1984).  Subsequently, it was discovered that ionising 
radiation had no effect on scrapie pathogenesis indicating that the cell type 
responsible for replicating the agent was long lived and radio-resistant (Fraser and 
Farquhar 1987).  As investigations into the cell type responsible for replicating the 
TSE agent continued, the involvement of T lymphocytes (Fraser and Dickinson 1978; 
Klein, Frigg et al. 1997), B lymphocytes (Klein, Frigg et al. 1998; Montrasio, Cozzio 
et al. 2001) or macrophages (Carp and Callaghan 1982; Beringue, Demoy et al. 2000) 
in actively replicating the TSE agent became more unlikely.  Many studies showed 
that SCID mice, which lack T and B lymphocytes and FDCs, were resistant to 
peripherally acquired TSE infection (O'Rourke, Huff et al. 1994; Fraser, Brown et al. 
1996; Lasmezas, Cesbron et al. 1996).  As a role for T and B lymphocytes seemed 
unlikely these studies suggested that FDCs may be responsible for replicating the TSE 
agent.   
 
FDCs had been shown to have relatively large quantities of PrPC on their surface.  
Furthermore, immunohistochemical analysis of TSE-infected spleen showed high 
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levels of deposition of PrPd on the FDC surface, which electron microscopy studies 
confirmed to be located to the FDC plasmalemma (Kitamoto, Muramoto et al. 1991; 
McBride, Eikelenboom et al. 1992; Brown, Ritchie et al. 2000; Jeffrey, McGovern et 
al. 2000).  Animals with genetic deficiencies in TNFα (Mabbott, Williams et al. 
2000a) or LTβ (Oldstone, Race et al. 2002), which have no mature FDC networks, 
were resistant to peripherally inoculated scrapie infection. Additionally, studies which 
temporarily dedifferentiated the FDC networks of mice prior to peripheral inoculation 
with the scrapie agent using the TNF-R1 homologue (Mabbott, McGovern et al. 2002)  
the LTβR-Ig fusion protein (Montrasio 2000; Mabbott, Mackay et al. 2000b) 
prevented or delayed clinical scrapie disease.  These studies provided strong evidence 
that FDCs were responsible for replicating the TSE agent.  However, in all of the 
above models, in addition to removing the PrPC expressing FDC networks, more 
general effects on the immune system were also incited, such as impairment of 
macrophage function (Klein, Frigg et al. 1997; Mabbott, Williams et al. 2000a; 
Mabbott, McGovern et al. 2002) or removal of FDC networks resulting in no 
germinal centres (Montrasio 2000; Mabbott, Williams et al. 2000a; Mabbott, 
McGovern et al. 2002; Oldstone, Race et al. 2002) .  Therefore it is possible that the 
effects on TSE pathogenesis could have been due to a more general 
immunodeficiency and not just the lack of FDCs.  Bone marrow chimeric models, 
which used lethal γ- irradiation and reconstitution with donor bone marrow to create 
mismatches in PrPC expression status between stromal and bone marrow-derived 
cells, showed that PrPC expressing FDCs were essential for successful replication of 
scrapie whereas PrPC expression on lymphocytes was irrelevant (Brown, Stewart et al. 
1999). These models did not have a general effect on the immune system as was seen 
in previous models. However, PrPC expression was retained by other neural, stromal 
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and epithelial cell types alongside the FDCs.  For this reason, the possibility still 
remained that FDCs simply acquired the scrapie agent after replication on another cell 
type.  An FDC-specific model, which had no impact on normal immune function, was 
required to definitively determine if FDCs simply acquire the TSE agent rather than 
actively replicate the agent themselves. 
 
In this thesis, mouse models were created where PrPC could be switched off (Chapter 
4) or on (Chapter 6) exclusively on FDCs. Characterisation of these models 
determined the specificity and efficiency of Cre-mediated recombination of the floxed 
Prnp genes. Additionally we showed that there were no observed effects on the status 
or function of the FDC networks and no effects on lymphoid tissue microarchitecture.  
In animals in which PrPC was switched off exclusively on FDCs that were inoculated 
ip with the ME7 scrapie agent, the scrapie agent initially localised to the FDC 
networks, but at later time points was only detectable within the neighbouring TBMs 
(Chapter 5).  This was in contrast to animals which retained PrPC expression on FDCs 
which showed PrPd accumulation on the FDC network increasing over time.  
Furthermore, clinically scrapie-affected animals with PrPC deficient FDC that had 
been injected directly into the CNS also showed no PrPd accumulation on the FDC 
networks.  Again, the only PrPd detected in these animals was found within the 
TBMs. PrPC deficient FDCs remained free of PrPd accumulation, at early time points 
and in clinically scrapie-affected animals, despite all other cell types within the 
lymphoid tissue retaining expression of PrPC and therefore potentially capable of 
replicating the scrapie agent. It can therefore be concluded that FDCs do not acquire 
PrPd on their surface after replication on another cell type. 
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Animals with PrPC expression switched on exclusively in FDCs were also inoculated 
with the ME7 scrapie agent to determine if PrPC expression exclusively on FDCs was 
sufficient to support scrapie replication in the lymphoid tissue and therefore determine 
whether FDCs actively replicate the TSE agent (Chapter 7).  Animals with PrPC 
expression exclusively on FDCs showed deposition of PrPd on the FDC network 
which increased over time at a comparable level to that observed in PrP+/- hemizygous 
controls. Whereas control animals with PrPC expression switched on only in B 
lymphocytes had little/no detectable PrPd labelling and again any labelling present 
was only found within the TBMs.  These data show that PrPC expression exclusively 
on FDCs is sufficient to support TSE agent replication in the lymphoid tissue. 
 
Taken together, data from these studies shows that FDCs do not acquire PrPd from 
other cell types within the lymphoid tissue and instead actively replicate the TSE 
agent.  FDCs appear to be responsible for replicating the TSE agent to sufficient 
levels that allow neuroinvasion and CNS disease.  However are the FDCs themselves 
actually infected with the scrapie agent?  Data from this thesis has shown that FDCs 
do not accumulate PrPd from other cells in the lymphoid tissues and instead actively 
replicate the scrapie agent themselves.  However, ultrastructural analysis shows PrPd 
accumulations on the FDCs have only ever been observed on the plasmalemma, not 
within the cytoplasm (Jeffrey, McGovern et al. 2000; McGovern, Mabbott et al. 
2009). Furthermore, there is a general belief that although PrPd accumulation on 
neurones causes cell death by an unknown mechanism, PrPd accumulation on the 
FDCs does not have an obvious toxic effect.  As the scrapie agent is not replicating 
within the cell itself and replication does not appear to have a pathological effect on 
196 
the FDCs, one could argue that FDCs merely provide a platform for replication prior 
to neuroinvasion and infection of cells within the CNS. 
 
Recent studies investigating the effects of scrapie infection on cells of the immune 
system have shown that replication of the TSE agent does effect the morphology of 
the FDCs and therefore may have a subtle effect on immune function that as of yet 
has not been investigated closely.  Studies looking at PrPd accumulation on the FDCs 
of sheep noted abnormal convolutions in the plasmalemma and abnormal clustering of 
immune complexes which co-localised with areas of PrPd accumulation on the FDC 
surface. An increased number of exosomes was also observed around FDCs showing 
morphological changes due to PrPd accumulation, some of which contained PrPd 
(McGovern and Jeffrey 2007).  Morphological changes to the FDCs leading to the 
shedding of the PrPd in exosomes may be one possible mechanism of neuroinvasion 
of the scrapie agent.  These observations were confirmed in the FDCs of scrapie-
affected mice, however the increased number of exosomes in the follicle was not 
observed in these models (Jeffrey, McGovern et al. 2000; McGovern, Brown et al. 
2004).  More recent studies showed that accumulation of PrPd in scrapie-affected 
mice led to disruptions in the FDC maturation cycle, abnormal ubiquitin in cell 
membranes and an excessive accumulation of Igs which could therefore impact on 
immune function (McGovern, Mabbott et al. 2009a). The transfer of PrPd to mature 
Ab-producing B lymphocytes has also been noted in the follicles of scrapie-affected 
sheep (McGovern and Jeffrey 2007).  Additional studies have reported changes in B 
lymphocyte subsets in response to scrapie infection in sheep, which again could 
impact on immune function (Eaton, Rocchi et al. 2007; Eaton, Anderson et al. 2009).  
Although PrPd does not appear to be internalised within the FDCs, FDCs actively 
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replicate the TSE agent and show pathological changes in response to accumulation of 
the agent on their surface, which in turn may impact on immune function.  For this 
reason, FDCs could be considered to be infected with the TSE agent as they are 
adversely affected as a consequence. 
 
8.6 FDC-independent TSE pathogenesis  
 
Although data from this thesis and many previous studies show that FDCs have an 
important role in replicating the TSE agent in the lymphoid tissue, in some cases TSE 
infections appear to be able to bypass the need for replication upon FDCs.  Some 
naturally acquired infections, for example BSE in cattle and atypical BSE and scrapie, 
develop clinical disease in the CNS without any apparent replication in the lymphoid 
tissue (Somerville, Birkett et al. 1997; Buschmann, Biacabe et al. 2004; Benestad, 
Arsac et al. 2008). Recent experimental studies created granulomas in the skin of 
mice prior to inoculation with scrapie (Heikenwalder, Kurrer et al. 2008).  
Accumulation of PrPSc and infectivity occurred within the granulomas in association 
with stromal cells.  These stromal cells did not express the characteristic FDC markers 
such as C1q, CD35, FDC-M1, FDC-M2 or mRNA for Mfge8 and therefore this study 
was used as an example of FDC-independent replication of the scrapie agent. 
However, stromal cells within the granuloma were dependent on LT signalling, 
expressed high levels of PrPC and organised B lymphocytes within the granuloma into 
follicle type structures.  Therefore although the commonly used FDC markers were 
not present, these cells demonstrated many of the functional abilities FDCs have 
within the lymphoid tissue.  If these cells were characterised by function they would 
possibly be described as FDCs.  The lack of FDC markers in an artificially induced 
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tertiary lymphoid tissue is possibly not a great example of non-FDC associated 
replication of the scrapie agent as natural disease-induced chronic inflammation with 
formation of ectopic lymphoid follicles have shown development of PrPC expressing 
FDCs which are capable of replicating PrPSc agent upon co-infection with the scrapie 
agent (Heikenwalder, Zeller et al. 2005; Ligios, Sigurdson et al. 2005). 
 
Evidence from other studies has implied that there may be variations between TSE 
agent strains regarding whether replication on the FDCs is required prior to 
neuroinvasion.  Studies described previously in this chapter (and thesis) demonstrated 
that expression of PrPC by the FDCs is essential for successful pathogenesis of the 
ME7 scrapie agent in mice, whereas PrPC expression on lymphocytes was irrelevant 
(Brown, Stewart et al. 1999).  However, similar studies using the RML scrapie isolate 
inoculated into Prnp-/- mice reconstituted with Prnp+/+ haematopoietic stem cells 
showed successful neuroinvasion of the scrapie agent despite the FDCs lacking PrPC 
expression in this model (Blattler, Brandner et al. 1997).  This study may demonstrate 
that different strains of TSE agent have different requirements for replication in the 
periphery prior to neuroinvasion.  However, an important factor to consider is that this 
study used a high TSE agent dose for inoculation, 100 μl of a 1% brain homogenate 
(Blattler, Brandner et al. 1997) in comparison to 20 μl of a 1% brain homogenate used 
in the ME7 study (Brown, Stewart et al. 1999).  Previous experiment using SCID 
mice have shown that the need for TSE agent replication in the periphery can be 
overcome by inoculating with a high dose of the TSE agent (Fraser, Brown et al. 
1996).  Therefore it may be that levels of infectivity in the innocula used in the RML 
experiments were sufficient to allow neuroinvasion without further replication in the 
periphery. 
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With the exception of some natural disease models, such as BSE in cattle, the 
majority of experimental evidence suggests that FDCs provide a crucial site for 
peripheral replication of the TSE agent until sufficient levels of infectivity are reached 
that allow neuroinvasion.  Data in this thesis shows, the ME7 scrapie agent, cannot 
replicate in lymphoid tissues containing PrPC deficient FDC despite all other cell 
types retaining PrPC expression.  However, other TSE strains have not been tested in 
this thesis, so the prospect of strain differences cannot be completely discounted.    
 
8.7 Localisation of the TSE agent to the follicle 
 
Another uncertainty in TSE disease pathogenesis is how the TSE agent localises to 
the FDC network prior to replication and subsequent neuroinvasion.  Data from this 
thesis has shown that the scrapie agent can localise to PrPC deficient FDCs in the 
follicles at the same time points as that seen in PrPC expressing FDCs (Chapter 5).  
This demonstrates that PrPC expression by FDCs is not required for the scrapie agent 
to initially localise to the FDC network.  Furthermore, when PrPC was expressed 
exclusively on the FDC network, the scrapie agent could again localise to the follicle 
at the same time points as Prnp+/- controls (Chapter 7).  This shows that PrPC 
expression by other cell types is not required for the transport of the agent to the FDC 
network.  These data suggest that PrPC is neither required as a ligand for the 
transportation of the scrapie agent to the follicle nor for initial uptake by the FDCs.  
This is in agreement with previous studies which showed that localisation of the 
scrapie agent to the follicle was dependent on CD21/35 expression on the stromal 
compartment of the spleen, whereas expression status of PrPC was irrelevant (Zabel, 
Heikenwalder et al. 2007). 
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Some experimental evidence suggests that the TSE agent may use cell-mediated 
transport to localise to the follicle.  Macrophages have been shown to have the ability 
to take up the PrPd and after peripheral inoculation with scrapie are also capable of 
harbouring infectivity (Jeffrey, McGovern et al. 2000; Manuelidis, Zaitsev et al. 
2000).  However, most studies agree that rather than transporting the agent, PrPd is 
taken up into lysosomes and partially degraded (Jeffrey, Martin et al. 2003; 
McGovern, Mabbott et al. 2009a). Removal of macrophages leads to increased 
replication of the TSE agent suggesting they are involved in clearing the agent 
(Beringue, Demoy et al. 2000; Maignien, Shakweh et al. 2005).  DCs are another 
possible candidate for transport of the TSE agent to the lymphoid tissues.  Previous 
studies have indicated that after oral exposure DCs take up the scrapie agent and 
transport it to the draining lymphoid tissues (Huang, Farquhar et al. 2002; Huang and 
MacPherson 2004; Mohan, Hopkins et al. 2005; Raymond, Aucouturier et al. 2007).  
Recent studies have shown that uptake of the scrapie agent by DCs is facilitated by 
complement components (Flores-Langarica, Sebti et al. 2009).    However, even after 
the temporary depletion of DCs at the time of exposure, some animals eventually 
succumbed to disease, therefore it is possible that cell-free transport of the TSE agent 
to the follicle is also possible (Raymond, Aucouturier et al. 2007). 
 
After peripheral inoculation, the TSE agent may be transported via the blood directly 
to the spleen, by cell-free mechanisms.  Studies investigating which size of PrPd 
aggregates are most infectious discovered that particles of 300-600 KDa in size 
contained the most infectivity.  Therefore it is likely that infectivity and the TSE agent 
itself is associated with PrPd fragment of this size.  The pathway of protein/antigen 
processing by the spleen varies in accordance with the size of the antigen.  Small 
201 
soluble protein antigens, less than 70 KDa, are transported through the spleen via the 
conduits to the follicle (Pape, Catron et al. 2007; Roozendaal, Mempel et al. 2009).  
Whereas large antigen, greater than 70KDa, is trapped by sub-capsular sinus (SCS) 
macrophages in the lymph nodes or marginal zone (MZ) macrophages in the spleen.  
Antigen is then removed from the SCS/ MZ macrophages by follicular B lymphocytes 
which then traffic to the follicle where antigen is taken up by FDCs (Carrasco and 
Batista 2007; Phan, Grigorova et al. 2007; Phan, Green et al. 2009; Roozendaal, 
Mempel et al. 2009).  Therefore, it is likely that cell free infective scrapie agent is 
taken up by SCS macrophages and trafficked via B lymphocytes to the FDCs.  This 
mechanism of antigen transport has been shown to be dependent on complement 
receptors (Phan, Grigorova et al. 2007).  In agreement with the scrapie agent using 
this mechanism of transport to locate to the follicle, previous studies have shown that 
complement components aid scrapie agent localisation to the follicle and that 
depletion of these factors or their receptors can delay neuroinvasion and clinical 
disease (Klein, Kaeser et al. 2001; Mabbott, Bruce et al. 2001). 
 
In all of these studies examining the trafficking of the TSE agent to the FDCs, 
impairment in various mechanisms causes a delay in neuroinvasion but not a 
prevention of disease.  It appears that the TSE agent can use various mechanisms to 
get to the follicle and replicate on the FDCs and no one mechanism is solely 






8.8 The role of B lymphocytes in TSE pathogenesis 
 
Experimental evidence from previous studies indicated that B lymphocytes may have 
a role in replicating the scrapie agent in the lymphoid tissue prior to neuroinvasion 
(Klein, Frigg et al. 1997).  However, it was subsequently determined that effects of B 
cell deficiency on pathogenesis in this model was due to the indirect effect of having a 
lack of B lymphocyte-derived LTs to maintain mature FDC networks.   Subsequent 
studies have shown that PrPC expressing B lymphocytes are not essential for effective 
pathogenesis of the scrapie agent (Brown, Stewart et al. 1999; Montrasio, Cozzio et 
al. 2001).  This is in agreement with data from this thesis which found that switching 
off PrPC exclusively on CD21+ B lymphocytes had no effect on PrPd deposition in the 
spleen after inoculation with the ME7 scrapie agent (Chapter 5).  Furthermore, PrPC 
expression exclusively by CD21+ B lymphocytes did not allow replication of the 
scrapie agent in the spleen (Chapter 7).   Data from previous studies and this thesis 
imply that B lymphocytes do not have a role in replicating the TSE agent in peripheral 
lymphoid tissue.  However, this does not mean that they have no involvement in TSE 
disease.  As discussed in Section 8.7, B lymphocytes may be involved in the initial 
transportation of the TSE agent from SCS macrophages to the FDC networks via 
complement-dependent mechanisms (Carrasco and Batista 2007; Phan, Grigorova et 
al. 2007; Phan, Green et al. 2009; Roozendaal, Mempel et al. 2009).  Furthermore, 
experiments have shown that PrPd is transferred from FDCs to the surface membranes 
of B lymphocytes in the germinal centres of scrapie-affected mice (McGovern and 
Jeffrey 2007),    In addition PrPd was found associated with CD21+ B lymphocytes in 
the blood of scrapie-affected sheep.  Therefore it is possible that B lymphocytes are 
involved in trafficking the scrapie agent before or after replication on the lymphoid 
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tissues.  One experiment that could have been carried out in the studies in this thesis 
would be to isolate CD21+ B lymphocytes from the blood and spleen of scrapie 
affected animals and measure the levels of PrP labelling by FACS analysis.  This 
could provide data on whether switching PrPC expression on or off specifically on 
CD21+ B lymphocytes, or on CD21+ B lymphocytes and FDCs, had any effect on the 
accumulation of PrPd on the CD21+ B lymphocytes. It could be used as one possible 
method to determine if CD21+ B lymphocytes were responsible for trafficking the 
agent after replication on the FDC networks.  Unfortunately there was not sufficient 
time to carry out these experiments in this thesis, but it may provide a method for 
addressing this question in future studies. 
 
8.9 The role of tingible body macrophages in TSE pathogenesis 
 
TBMs are large phagocytic cells found in the germinal centres of secondary lymphoid 
tissues which contain phagocytosed, apoptotic cells known as tingible bodies 
(Swartzendruber and Congdon 1963).  Labelling of PrPd has been found within TBMs 
after inoculation with scrapie in mice (Jeffrey, McGovern et al. 2000) and sheep 
(Jeffrey, Martin et al. 2001) and also in lymphoid tissues taken from individuals who 
have died from vCJD infection (Hilton, Ghani et al. 2004).  In this thesis, PrPd was 
found in association with TBMs when PrPC was switched off on the FDCs after ip 
inoculation with the ME7 scrapie agent (Chapter 5).  In addition, when PrPC was 
switched on exclusively on CD21+ B lymphocytes, PrPd was only found in association 
with TBMs in the lymphoid tissue (Chapter 7).  These data suggest that in the absence 
of TSE agent replication by the FDC network, TBMs scavenge the PrPd that has 
located to the FDC network probably via complement dependent mechanisms (See 
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Section 8.6).  Indeed, previous studies have shown that TBMs are capable of taking 
up portions of immune complex coated membrane from the FDCs (Tew, Kosco et al. 
1989; Szakal and Tew 1992).  In this thesis, it is not certain whether the PrPd labelling 
found within the TBMs will act as a reservoir of infection, harbouring the scrapie 
agent and allowing a delayed neuroinvasion, or whether PrPd within the TBMs is 
degraded and infectivity is destroyed.  Cre+ve →CD21-crePrPfl/- mice, which have 
PrPC switched off exclusively in FDCs, have been ip inoculated with the ME7 scrapie 
agent and left until clinical disease develops or animals need to be culled due to old 
age.  However, at the time of writing, these animals have not succumbed to clinical 
disease or age, so as of yet no conclusions can be drawn from these experiments.  
However, previous studies have shown that PrPd found within the TBMs is truncated 
with a loss of 23-90 aa from the N-terminal region (Jeffrey, Martin et al. 2003; 
McGovern, Mabbott et al. 2009a).  This suggests that the TBMs are degrading the 
scrapie agent after uptake from the FDCs.  In scrapie infections, an initial exponential 
growth of PrPd deposition and infectivity occurs initially in the spleen which is then 
followed by a plateau.  Many suggestions have been made as to why this effect is 
seen.  If TBMs in the follicle are responsible for degrading the scrapie agent, it may 
be that a balance is eventually reached between replication of the scrapie agent on the 




In conclusion, data from this thesis have confirmed that FDCs play a crucial role in 
replicating the scrapie agent prior to neuroinvasion. The CD21-crePrPfl/- transgenic 
mouse line enabled PrPC expression to be switched off exclusively on the FDC 
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network after irradiation and transfer of non-Cre-expressing bone marrow. This model 
was used to determine whether FDCs simply acquire the TSE agent on their surface 
after accumulation on another cell type. Characterisation of this model showed 
efficient removal of PrPC specifically on the FDCs with no additional effects on FDC 
status or function, or on the general microarchitecture of the lymphoid tissue. These 
animals were infected with the ME7 scrapie agent via ip inoculation.  In these 
animals, PrPd initially located to the FDC networks, however the TSE agent was 
unable to replicate on the PrPC deficient FDCs and the agent was taken up by 
neighbouring TBMs and possibly degraded (Chapter 5).  These animals were also 
infected directly into the CNS via ic injection and developed clinical TSE disease 
with positive neuropathology in the brain. This demonstrated that the transgenic 
animals were equally susceptible to TSE disease as their WT counterparts and that 
any effect on disease pathogenesis in the lymphoid tissue was due to PrPC deficient 
FDCs and not a general resistance to TSE disease. As PrPC deficient FDCs did not 
show deposition of the TSE agent on their surface which increased as disease 
progressed, it was concluded that FDCs do not acquire the TSE agent from other 
stromal, neural or lymphoid cells within the lymphoid tissue which retained PrPC 
expression in the CD21-crePrPfl/- transgenic mouse model.  PrPC-expressing FDCs are 
essential for replicating the scrapie agent in the lymphoid tissue. 
 
Following on from these studies, it was determined whether PrPC expression 
exclusively on FDCs was sufficient to support replication of the scrapie agent in the 
lymphoid tissue. The CD21-crePrPstop/- transgenic mouse line enabled PrPC to be 
expressed exclusively on the FDC network after irradiation and transfer of non-Cre-
expressing bone marrow.  Characterisation of this model demonstrated that PrPC was 
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efficiently and specifically expressed on the FDC networks and again no additional 
effects were observed on FDC status or general microarchitecture of the lymphoid 
tissue.  After infection of these animals with the ME7 scrapie agent via ip inoculation, 
accumulation of PrPd occurred on FDCs when PrPC was restricted to the FDC 
network. Furthermore, this accumulation increased over time suggesting active 
replication of the scrapie agent by the FDCs.  Taken together, data from both of these 
transgenic mouse models shows that FDCs do not acquire PrPd and infectivity from 
other cells within the lymphoid tissue.  Furthermore, PrPC expression exclusively on 
FDCs is sufficient to support replication of the scrapie agent in the lymphoid tissue. 
From these data we can conclude that PrPC expressing FDCs actively replicate the 
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ImageJ macro- Multiple colour backgrounds 
 
 
This macro was used to determine background levels of immunolabelling in 
fluorescently labelled images and to determine threshold levels to use in further image 
analysis.  A line is drawn through the image using ImageJ software, ensuring that line 
passes through areas of positive bright immunolabelling, areas of positive lower level 
immunolabelling and background levels of colour present.  The intensity of colour for 
all plots along that line is then plotted out on a graph.  This graph allows the 
determination of a threshold of colour intensity to eliminate background staining from 
further analysis of images. 
 
 
// Generic multiple colour macro for assisting setting of thresholds 
// Analyses pixel intensities along a line selection 
// for a series of greyscale slices in a stack, each corresponding to a colour channel 
// Expandable to any number of colour channels (slices) 
 
// Check for RGB image and convert to greyscale stack 
// Breaks if image name includes "(RGB)" 
image = getImageID(); selectImage(image); info = getInfo();  
if (indexOf(info, "(RGB)") >1) { 
 getLine(x1,y1,x2,y2,width); 
 run("RGB Split"); 
 run("Convert Images to Stack"); 
 makeLine(x1,y1,x2,y2);} 
 
Greyscales = 255; if (indexOf(info, "pixel: 16")>1) {Greyscales = 6553) 
 
setLineWidth(1); 
getLine(startx, starty, endx, endy, temp); 
stack = getImageID(); 
 
selectImage(stack); slices = nSlices(); 
 
 
for (i =0; i<slices; i++) { 
 selectImage(stack); 
 
slice = "slice="+(i+1); 
 run("Set Slice...", slice); 
 ydata = getProfile(); 
         Plot.create(slice, "pixels", "intensity"); 
         Plot.setLimits(0, ydata.length, 0, Greyscales); 
         Plot.setLineWidth(1); 
 Plot.setColor("red"); 





ImageJ macro- Multiple colour analysis 
 
 
This macro was used to measure co-localisation of proteins in immunolabelled 
fluorescent images.  Background levels on immunolabelling were excluded from 
measurements using the multiple colour backgrounds macro (Appendix I) to set a 
threshold for positive labelling.  Each pixel in the image is counted and recorded as 
black (no labelling), red, green, blue, yellow (red and green together), magenta (red 
and blue together), cyan (green and blue together) or white (red, green and blue).  
Quantification of area of image single or double immunolabelled for each protein can 




// Generic multiple colour co-localisation analysis macro 
// Analyses a series of greyscale slices in a stack, each corresponding to a colour 
channel 
// Expandable to any number of colour channels (slices) 
// Provides number of pixels above threshold for each combination of colour channels 
// Data provided is in bins corresponding to (for three channels): 
//  
// Bin Ch 1 Ch 2 Ch 3 
// 0 - - - 
// 1 + - -  
// 2 - + - 
// 3 + + - 
// 4 - - + 
// 5 + - + 
// 6 - + + 
// 7 + + + 
 
// Set threshold values for each colour channel (each slice) 
// Add extra thresholds for more than 5 channels 
Threshold = newArray(6); 
 
Threshold[1] = 10; 
Threshold[2] = 40; 
Threshold[3] = 50; 
Threshold[4] = 50 
Threshold[5] = 50; 
// Check for RGB image and convert to greyscale stack 
// Where Ch 1 = red, Ch 2 = green, Ch 3 = blue 
v // Breaks if image name includes "(RGB)" 
image = getImageID(); selectImage(image); info = getInfo();  
if (indexOf(info, "(RGB)") >1) { 
 run("RGB Split"); 
 run("Convert Images to Stack"); 
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 exit("Draw your ROI and rerun the macro");} 
 
stack = getImageID(); selectImage(stack); slices = nSlices(); 
results = newArray(pow(2, slices)); 





for (i =0; i<slices; i++) { 
 selectImage(stack); 
 slice = "slice="+(i+1); 









run("Histogram", "bins=" + pow(2,slices) + "  x_min=0 x_max=" + pow(2,slices)); 
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